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ABSTRACT 
 
Staphylococcus aureus is known for its extraordinary capacity of colonizing 
asymptomatically the anterior nares of humans. A high versatility allied to the 
successive accumulation of resistance to almost all clinically available antibiotics, 
made S. aureus a major human pathogen worldwide. Soon after the introduction of 
methicillin into clinical practice, methicillin resistant S. aureus (MRSA) emerged as 
a major pathogen in hospitals worldwide, and more recently in the community as 
well. Methicillin susceptible S. aureus (MSSA) are also an important problem. 
MSSA is responsible from mild to severe invasive infections, commonly due to 
enhanced virulence content, rather than accumulation of resistance determinates. 
However, many gaps in the knowledge of the epidemiology of MSSA remain to be 
clarified. 
 
The aim of the work presented in this Thesis was to obtain new insights 
into different S. aureus populations, assessing the genetic background of MSSA 
and MRSA populations, from colonization and infection, recovered from both 
hospital and community settings using well established techniques and a new 
typing method.  
 
The comparison of the genetic background of two MSSA collections (from 
Portuguese nosocomial and community settings and Cape Verde hospitals) with 
contemporary nosocomial MRSA populations, revealed new trends on the origins 
of the dominant MRSA lineages. Except for the MRSA Pediatric clone that might 
have originated in Portugal by the introduction of SCCmec type VI into the 
previously existing MSSA ST5 lineage, the non-overlapping of the remaining 
MSSA and MRSA genetic backgrounds suggested that the major MRSA clones 
identified in Portuguese hospitals were imported from abroad. Moreover, the fact 
that no MRSA coexisted with the MSSA population in Cape Verde further supports 
the evidence that the introduction of SCCmec into sensitive clones is most likely a 
relatively infrequent event that seems to depend not exclusively on the presence 
of a successful MSSA lineage. 
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In parallel to the burden of MRSA in the hospitals, CA-MRSA, first 
described in the early 1990’s, became dispersed worldwide through few major 
pandemic lineages. In contrast to other countries, the CA-MRSA prevalence in 
Portugal, estimated by previous studies of nasal carriage, was very low. The 
screening of skin and soft tissue infections in a pediatric community, presented in 
this Thesis, confirmed these rates. Moreover, we reported the first isolate in 
Portugal belonging to ST80-IV, the major CA-MRSA lineage found in Europe and 
usually associated to the production of the Panton-Valentine leukocidine (PVL). 
An unusual high toxin content was found in the Cape Verde MSSA 
collection, with 35% of the isolates producing PVL and 8% harboring the 
exfoliative toxin D gene, which seems an epidemic advantage in an environment 
with very low antimicrobial pressure, driven by the restricted use of antibiotics. 
By contrast to the low prevalence of CA-MRSA, the MRSA prevalence in 
Portuguese hospitals is one of the highest in Europe, reaching 53% in 2008. 
Whereas the epidemiology of nosocomial MRSA had been very well characterized 
in continental Portugal, there was no information concerning the clonal nature of 
MRSA in the Portuguese islands, namely in the Azores archipelago. To fill this 
gap, a collection of MRSA recovered in an Azorean hospital was studied and 
showed the presence of the EMRSA-15 clone (ST22-IVh), followed by the 
Pediatric clone (ST5-VI), which is in part, in agreement with the continental 
Portugal scenario. Moreover, PVL was described for the first time in association 
with the Pediatric clone.  
To understand the MRSA clonal evolution in Hungary, we performed a 10-
year surveillance study, which revealed a clonal replacement during this period. 
The Hungarian clone (ST239-III), predominant in hospitals in 1994-1998, was 
gradually replaced by the Southern German clone (ST228-I) and the New York/ 
Japan epidemic clone (ST5-II), representing 85% of the 2001–2004 isolates. This 
study described, for the first time, the co-dominance and extensive spread of the 
New York/ Japan clone in a European country. 
 
The definition of clonal lineages and the clarification of their evolution in the 
hospital and in the community, require the use of up-to-date molecular typing 
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methods such as pulsed-field gel electrophoresis (PFGE), spa typing, multilocus 
sequence typing (MLST) and the determination of the SCCmec type in MRSA 
isolates, which are valuable tools for S. aureus characterization. In addition to 
these well-established methods used for the characterization of the collections 
studied in this Thesis, we validated a new typing method: the staphylococcal 
interspersed repeat analysis (SIRUs). It is a multilocus variable number of tandem 
repeats (VNTR) analysis (MLVA) based methodology that we applied to a 
temporal and geographical diverse S. aureus collection. The observed high 
discriminatory power of the SIRU method, along with its apparent concordance 
with MLST, makes it potentially valuable not only for S. aureus short-term 
epidemiological investigations, but for population dynamics as well. 
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RESUMO 
 
Staphylococcus aureus é conhecido pela sua extraordinária capacidade de 
colonização assintomática das narinas no ser humano. A sua versatilidade aliada 
à sucessiva acumulação de resistência à grande maioria dos antibióticos 
disponíveis clinicamente, faz de S. aureus um dos principais agentes patogénicos 
em todo o mundo. Logo após a introdução da meticilina na prática clínica, S. 
aureus resistente à meticilina (MRSA, do inglês “methicillin-resistant 
Staphylococcus aureus”) surgiu como um importante agente patogénico nos 
hospitais, e mais recentemente também na comunidade. No entanto, alterações 
na epidemiologia de S. aureus não estão restritas a MRSA, uma vez que S. 
aureus susceptíveis (MSSA, do inglês “methicillin-susceptible Staphylococcus 
aureus”) são também um problema crescente. MSSA tornou-se responsável por 
uma grande variedade de infecções invasivas com maior ou menor gravidade, 
geralmente devido ao elevado potencial de virulência, e não à acumulação de 
determinantes de resistência. Contudo, muito do conhecimento da epidemiologia 
de MSSA continua por esclarecer. 
 
Pretendeu-se com o trabalho apresentado nesta Tese obter novos dados 
sobre diferentes populações de S. aureus através da utilização de técnicas de 
tipagem bem estabelecidas e de um método de tipagem descrito recentemente. 
Procurámos determinar o perfil genético de populações de MRSA e MSSA, tanto 
de colonização como de infecção, e isoladas não só de ambiente hospitalar como 
também da comunidade. 
 
A comparação entre a componente genética de duas colecções de MSSA, 
isoladas em hospitais e na comunidade Portuguesa e em hospitais de Cabo 
Verde, com as populações de MRSA hospitalares contemporâneas, revelou novas 
pistas sobre as origens das maiores linhagens de MRSA. Foi-nos possível 
demonstrar que os principais clones de MRSA identificados nos hospitais 
Portugueses foram provavelmente importados do estrangeiro. Esta conclusão 
baseou-se na não existência de sobreposição das características genéticas entre 
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os clones de MSSA e MRSA. A única excepção é o clone Pediátrico que poderá 
ter tido a sua origem em Portugal através da introdução do elemento móvel 
transportador do gene mec (SCCmec, do inglês “staphylococcal chromosomal 
cassette mec”) tipo VI na linhagem de MSSA ST5 existente anteriormente, Por 
outro lado, a não existência de MRSA em Cabo Verde no mesmo período 
temporal em que se isolou a colecção de MSSA reforça a evidência de que a 
introdução do SCCmec em clones sensíveis é provavelmente um acontecimento  
pouco frequente que parece não depender apenas da presença de uma linhagem 
de MSSA bem sucedida. 
 
No início dos anos 90 começaram a ser descritas linhagens de MRSA 
isoladas na comunidade (CA-MRSA, do inglês “community-acquired methicillin-
resistant Staphylococcus aureus”), e que actualmente se encontram dispersas por 
todo o mundo. Em contraste com outros países, a prevalência de CA-MRSA em 
Portugal, estimada por estudos anteriores de colonização nasal, parece ser ainda  
reduzida. O rastreio de infecções da pele e tecidos moles numa comunidade 
pediátrica, apresentado nesta Tese, confirmou estas taxas. Além disso, 
descrevemos o primeiro isolado ST80-IV em Portugal, pertencente a uma das 
principais linhagens de CA-MRSA encontradas na Europa e, geralmente, 
associada à produção da leucocidina de Panton-Valentine (PVL do inglês 
“Panton-Valentine leukocidine”). 
 
Na colecção de MSSA de Cabo Verde foi encontrado um elevado número 
de isolados produtores de toxinas, nomeadamente PVL (35%) e toxina esfoliativa 
D (8%). A produção de toxinas por estirpes sensíveis parece ser uma vantagem 
num ambiente onde o uso restrito de antibióticos conduz a uma reduzida pressão 
antimicrobiana. 
 
Em contraste com a baixa prevalência de CA-MRSA, a prevalência de 
MRSA nos hospitais Portugueses é uma das mais elevadas da Europa, tendo 
atingido os 53% em 2008. Apesar da epidemiologia de MRSA em ambiente 
hospitalar estar bem caracterizada em Portugal continental, até à data não existia 
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qualquer informação sobre a natureza clonal dos MRSA nas ilhas Portuguesas, 
nomeadamente no arquipélago dos Açores. Para preencher esta lacuna, estudou-
se uma colecção de MRSA de um hospital Açoriano tendo-se observado uma 
predominância do clone EMRSA-15 (ST22-IV), seguida do clone Pediátrico (ST5-
VI). Este cenário é, em parte, concordante com o de Portugal continental. Além 
disso, neste estudo, a toxina PVL foi descrita pela primeira vez em associação 
com o clone Pediátrico. 
 
Para compreender a evolução clonal dos MRSA nos hospitais na Hungria, 
foi realizado um estudo de vigilância ao longo de 10 anos, que revelou um 
processo de substituição clonal. O clone Húngaro (ST239-III), predominante entre 
1994-1998, foi gradualmente substituído pelos clones Southern German (ST228-I) 
e New York/ Japan (ST5-II), que representam 85% dos isolados no período de 
2001-2004. Este estudo descreve, pela primeira vez, a co-dominância e 
disseminação global do clone New York/ Japan num país Europeu. 
 
A definição de linhagens clonais no hospital e na comunidade e a 
determinação da sua história evolutiva, requerem a utilização de métodos de 
tipagem molecular actualizados, que são ferramentas valiosas na caracterização 
de S. aureus. Os métodos principais no estudo de S. aureus são: a electroforese 
em gel de campo pulsado (PFGE do inglês “pulsed-field gel electrophoresis"), a 
sequenciação do gene que codifica a proteína A (“spa typing”), a sequenciação de 
regiões internas de sete genes essenciais ao metabolismo bacteriano (MLST, do 
inglês “multi-locus sequence typing”), ou a determinação do tipo estrutural do 
SCCmec em isolados de MRSA. Além destes métodos bem estabelecidos e 
utilizados na caracterização das colecções estudadas nesta Tese, procedemos 
também à validação de um novo método de tipagem: a análise de regiões 
repetitivas intercaladas no genoma de Staphylococcus (SIRU do inglês 
“staphylococcal interspersed repeat units”). Esta metodologia é baseada na 
análise do número variável de repetições adjacentes em diferentes locus no 
genoma (MLVA do inglês “multilocus variable number of tandem repeats (VNTR) 
analysis”), que foi aplicada a uma colecção de S. aureus muito diversa tanto 
  xviii
temporal como geograficamente. O elevado poder discriminatório do método 
SIRU, juntamente com a sua aparente concordância com os resultados de MLST, 
torna o método potencialmente valioso, não só para estudos epidemiológicos a 
curto prazo, mas também para estudos de dinâmica populacional de S. aureus.
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Thesis Outline 
 
The present Thesis describes the genetic backgrounds of methicillin-susceptible 
and methicillin-resistant Staphylococcus aureus populations involved in 
colonization and infection, using a combination of well established molecular 
typing methods as well as the validation of a new typing strategy. 
 
Relevant aspects of the biology of S. aureus and an overview of the most used 
typing methods for strain characterization are presented in Chapter I, General 
introduction. Insights into the actual molecular epidemiology of S. aureus as well 
as the role of selected virulence factors in pathogenicity are also reviewed. 
 
The subsequent chapters have been assembled into three main sections: 
 
Methicillin-susceptible S. aureus (MSSA): a colonizer but a clinical threat  
In Chapter II, the genetic background of a collection of MSSA isolates recovered 
from both hospital and community settings in Portugal, is characterized and 
compared with the dominant MRSA clones circulating, during the same period, in 
the same geographical areas.  
S. aureus isolates from skin and soft tissue infections in children attending a 
pediatric emergency unit in a Portuguese hospital are presented in Chapter III. 
The high virulence gene content and the clonal structure of the bacterial isolates 
are compared with the European scenario. 
Chapter IV describes a collection of MSSA colonization isolates recovered in two 
African hospitals in Cape Verde islands showing a high prevalence of the Panton-
Valentine leukocidin virulence determinant. 
 
Methicillin-resistant S. aureus (MRSA): the still most frequent resistant 
pathogen in the nosocomial setting 
Chapters V and VI describe the molecular characterization of nosocomial MRSA 
collections.  
  xx 
Chapter V describes the current MRSA population structure in a Portuguese 
central hospital located in a geographically restricted insular territory (the Azores 
islands). 
In Chapter VI, two temporally separated (1994-1998 and 2001-2004) collections of 
MRSA from different Hungarian hospitals allowed the establishment of the 
temporal evolution of the epidemic clones in Central Europe. 
 
Typing methods: a constant need of improvement 
In Chapter VII, a new multilocus variable tandem repeated based method is 
validated against a temporally and geographically diverse collection of S. aureus, 
previously characterized by well established molecular typing methods. 
 
 
The main achievements of this work are summarized and discussed in Chapter 
VIII. 
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 3  
1. Staphylococcus aureus bacterial portrait 
 
Staphylococcus aureus is the most significant human pathogen among the 
genus Staphylococcus. Its colonizing ability frequently allied to its extraordinary 
pathogenic power includes it amongst the best well characterized microorganisms. 
 
1.1. S. aureus, historical perspective 
After Robert Koch in 1878 recognized that different diseases were 
produced by distinct Gram-positive cocci with diverse bacterial arrangements 
(pairs, chains or clusters), Louis Pasteur and Alexander Ogston, a Scottish 
surgeon, described in 1880 the “small spherical bacteria” as a cause of pus from 
furuncles and abscesses and called them micrococci. However, it was Alexander 
Ogston, who demonstrated that the small spherical bacteria produced 
inflammation and suppuration and in 1882, named the clustered micrococci as 
“staphylococci” from the Greek staphyle, meaning bunch of grapes. In 1884, Anton 
J. Rosenbach, a German surgeon, provided the first taxonomic description of the 
genus Staphylococcus after the isolation of two species with different pigment 
appearance of the colonies: Staphylococcus aureus, from the Latin aurum for gold, 
and Staphylococcus albus (later named Staphylococcus epidermidis) from the 
Latin albus for white (163, 231).  
 
1.2. Culturing and identifying staphylococci and S. aureus  
The genus Staphylococcus is currently composed of 44 species and 24 
subspecies (84), sharing common features: Gram-positive cocci with 0.5 to 1.5 m 
in diameter, characteristically dividing in three successive perpendicular planes to 
form grape-like clusters, and having a unique cell wall peptidoglycan with multiple 
glycine residues in the interpeptide bridge, which renders them susceptible to 
lysostaphin. Staphylococci are nonflagellated, facultative anaerobes, glucose 
fermenting, catalase positive, oxidase negative, and tolerant to high saline 
concentrations with most species able to grow in the presence of 1.7 M of NaCl 
(231). These microorganisms are the hardiest of all non-spore-forming bacteria 
capable to grow in a range of temperature from 10º to 45ºC, with some strains 
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showing resistance to heat (withstanding 60ºC for 30 min) as well as to most 
disinfectants (231). The G+C content of Staphylococcus DNA is within the range 
of 30 to 38 mol percent, which makes the genus one of the members of the low 
G+C Gram-positive bacterial phylogenetic group (231). 
The production of the enzyme coagulase remains one of the main tests to 
identify S. aureus, although two animal-specific coagulase-variable species have 
been described, Staphylococcus intermedius and Staphylococcus hyicus (163, 
231). S. aureus forms typical golden yellow colonies, smooth, slightly risen and 
hemolytic on 5% sheep blood agar. S. aureus is the only Staphylococcus species 
that ferments mannitol anaerobically, and in complex media grows over a wide 
range of pH (4.8 to 9.4) and temperature (25 to 43ºC), showing a minimum 
doubling time of 30 to 40 minutes (231). 
 
1.3. S. aureus as a human colonizer 
S. aureus is a ubiquitous commensal and colonizer of the skin and mucosa 
of humans and animals that may turn into an important pathogen (188, 340). In 
humans, the primary ecological niche of S. aureus are the anterior nares (i.e, the 
vestibulum nasi), although multiple body sites can be colonized, such as the skin, 
perineum, pharynx and less frequently the gastrointestinal tract, vagina and axillae 
(254, 340).  
In 1915, during the treatment of bacterial wound infections of soldiers from 
the World War I, Sir Almroth Wright, a British bacteriologist and immunologist, 
reported that bacterial wound infections probably had an endogenous source. 
However, it was Niels Danbolt, a Norwegian dermatologist and professor of 
medicine, who first reported, in 1931, the association between S. aureus nasal 
carriage and staphylococcal disease during the study of furunculosis (293, 349). 
Later, typing of S. aureus isolates brought additional evidence for the causal 
relation between S. aureus nasal carriage and infection, since nasal carriage 
strains showed the same genotype as infectious isolates. Nasal carriers have a 
three times increased risk of being infected with an endogenous S. aureus than 
non-carriers (340), and therefore decolonization attempts have been carried out in 
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order to reduce infection, cross-transmission and eradication of S. aureus 
reservoirs in nosocomial settings (5, 169).  
 Decolonization of the nostrils with mupirocin ointment and the skin with 
chlorohexidine gluconate soap has shown to be effective in preventing hospital 
associated S. aureus infections (28, 96). Nowadays, nasal mupirocin ointment is 
the first option for nasal carriage eradication.  
Longitudinal studies distinguish three S. aureus nasal carriage patterns in 
healthy individuals: ~20% (range 12-30%) of individuals are persistent carriers, 
~60% (range 16-70%) are intermittent carriers and ~20% (range 16-69%) are non-
carriers (254, 340). However, a recent study stated that apparently, there are only 
two types of nasal carriers: persistent carriers and others, since intermittent 
carriers and non-carriers share similar S. aureus nasal elimination kinetics and 
antistaphylococcal antibody profiles (321). Persistent carriage seems to have a 
protective effect on the acquisition of other strains due to bacterial competition, is 
more common in children than in adults and many individuals change their pattern 
of carriage between the age of 10 to 20 years (164, 340). In contrast to intermittent 
carriers who usually carry different strains over time, persistent carriers are often 
colonized with a single strain over extended periods and with higher S. aureus 
loads that contribute to the enhanced risk of autoinfection and ease of dispersal in 
the environment (169, 327, 340). Cross sectional surveys of general healthy adult 
populations reported a total S. aureus nasal carriage rates ranging from 25-38%, 
depending on the study population, and  usually rates of methicillin-resistant S. 
aureus (MRSA) carriage lower than 1.5% (164, 201, 302, 340). 
Nasal colonization by S. aureus follows four main prerequisites: (i) contact 
of S. aureus with the anterior nares; (ii) S. aureus adherence to specific receptors 
in the nasal mucosa; (iii) overcome of host defenses and competition with the 
other resident microorganisms; and (iv) ability to propagate in the nose (340). 
Although the mechanisms leading to S. aureus nasal carriage are known to be 
multifactorial, including bacterial factors and interactions between bacterial 
organism and host, it seems that host characteristics substantially co-determine 
the S. aureus carrier state (183, 340).  
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Bacterial factors such as the wall teichoic acid (WTA), clumping factor B 
(clfB), the capsular polysaccharide (cap), the iron-regulated surface determinant 
IsdA, the surface protein SasG, autolysins and other virulence and adherence 
factors are thought to be inherent to the biological fitness and involved in the 
bacterial competition process that define which strain is able to colonize the host 
(254, 338, 341).  
On the other hand, host factors are probably involved in the definition of 
carrier or non-carrier status, including the persistent or intermittent carriage. 
Studies on artificial colonization of individuals with known carriage status showed 
that intermittent carriers or non-carriers eliminate the colonizing strains whereas 
persistent carries maintain their original resident strain (230, 321). Inherent host 
factors such as race, sex, age, hormonal status in woman, physiological 
parameters as the glucose concentration in blood, anatomic alterations of the 
nares including the number and nature of bacterial adherence receptors, specific 
anti-staphylococcal components in the nasal secretions (e.g. lysozyme, lactoferrin, 
secretory leukocyte protease inhibitor, neutrophil alpha-defensins, beta-defensins 
or cathelicidins), certain types of histocompatibility antigens (e.g. HLA-DR3), 
polymorphism in genes codifying for glucocorticoid receptors, vitamin D receptor, 
Fc fragment of IgG, interleukine-4, C-reactive protein, the human complement 
cascade activator serine protease C1 inhibitor (C1INH V480M), and some 
additional acquired defects in immunity are potential determinants in carriage (34, 
292, 317, 327, 340). However, S. aureus has proven to be able to specifically 
adapt to different niches in the human host (34). 
Increased S. aureus carriage rates have been reported in certain patient 
groups: patients with diabetes mellitus (both insulin dependent and non-
dependent), undergoing hemodialysis or continuous ambulatory peritoneal 
dialyses, rheumatoid arthritis, human immunodeficiency virus (HIV) infection or 
viral infectious of the upper respiratory tract, intravenous drugs addicts, patients 
with skin infectious and skin disease, obesity, and patients receiving repeated 
injections for allergies. Repetitive or long-term injury to the skin due to needle 
punctures seems to be a common risk factor for colonization in these patient 
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groups (254). Moreover, nasal screening in health care workers (HCW) revealed 
S. aureus carriage rates ranging from 25.7% to 67.2% (179, 288). 
In addition to the enhanced carriage rates of hospitalized patients and 
HCW, veterinary staff, pet owners and farmers that have contact with pigs and 
poultry have been pointed recently as new risk groups for colonization, with rates 
of 5.6 to 12.3% of MRSA carriage (5, 184, 322).  
 
1.4. S. aureus as a human pathogen 
S. aureus is the most significant human pathogen in the genus 
Staphylococcus, capable of promoting disease when the natural skin barrier and 
mucous membranes are disrupted (183, 188). Of the approximately 2 million 
patients who acquire a health-care associated infection annually in the United 
States, around 292,000 have an infection associated to S. aureus, and of these, 
about 126,000 acquire an MRSA infection (172, 306).  
S. aureus is responsible for a wide variety of infections, such as: (i) 
superficial lesions and skin infections (e. g. impetigo, folliculitis, carbuncles, 
mastitis, cellulitis); (ii) life threatening conditions (e. g. bacteremia, endocarditis, 
pneumoniae, meningitis, septicemia and osteomyelitis); and (iii) toxin-mediated 
diseases (e. g. scalded skin syndrome, toxic shock syndrome and food poisoning) 
(188, 306).  
The success of the organism as a pathogen and its ability to cause such a 
wide range of infections depends on a complex interplay between S. aureus 
virulence determinants and the host defense mechanisms (10, 188).  
 
1.4.1. Virulence determinants: structural key factors 
 S. aureus contains an extensive variety of virulence factors, including both 
structural and secreted products, that can be divided into functional categories 
according to its main role in the pathogenesis process: (i) attachment: factors 
involved in the adhesion of the bacteria to cells or extracellular matrices; (ii) 
evasion of host defenses: factors that prevent or reduce phagocytosis or that 
interfere with the function of specific antistaphylococcal antibodies or other 
particular host defense mechanisms; (iii) invasion or tissue penetration: factors 
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that specifically attack host cells and/ or degrade components of extracellular 
matrices; and (iv) maintenance in the host: proteins for utilization of host nutrients 
by the bacteria (13, 233).  
S. aureus has numerous surface proteins, called “microbial surface 
components recognizing adhesive matrix molecules” (MSCRAMMs) that mediate 
adhesion to host tissue to initiate the infectious processes (108, 252).  
S. aureus can form biofilms (slime) that are complex bacterial populations 
surface-attached and enclosed in a poly-N-acetylglucosamine matrix, enabling it to 
persist by evading host defenses and antibiotics (77). Furthermore, staphylococci 
avidly enter into the intracellular environment of endothelial cells, a protected 
milieu that promotes the formation of small-colony variants (SCVs) (188, 331). 
SCVs are sub-populations of S. aureus that exhibit a slow growth, distinct 
phenotype and pathogenic features that allow them to be hidden in host cells 
avoiding host defenses and antibiotics (331). 
One of the S. aureus main defenses in evading the host immune system is 
the production of an antiphagocytic microcapsule, namely types 5 and 8 in clinical 
isolates, staphylokinase, staphylococcal complement inhibitor (SCIN) and S. 
aureus chemotaxis inhibitory protein (CHIPS) which are modulators of the immune 
system (93, 188, 274).  
-type phenol-soluble modulins (PSM) are a recently described group of 
secreted staphylococcal peptides that have a remarkable ability to recruit, activate 
and subsequently lyse human neutrophils, thus eliminating the main cellular 
defense against S. aureus infection. A higher expression of PSM was observed 
in S. aureus infections in the community (335). 
Another two potential S. aureus virulence factors are a cluster of arginine 
catabolism (arc) genes that encode an arginine deiminase pathway, and opp3, 
which encodes an oligopeptide permease, both included in the arginine catabolic 
mobile element (ACME). While ACME is highly common in S. epidermidis (210), in 
S. aureus is almost exclusively found in a particular community associated lineage 
(USA300) (71).  
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1.4.2. Staphylococcal toxin determinants 
Once the infection is established, S. aureus secretes a high number of 
toxins, including cytolysins, exfoliatins and superantigenic toxins (SAgs) that 
enable invasion, destruction of host tissues and spread to other sites (194, 258).  
Cytolytic toxins, include -, -, - and -hemolysins, leukocidins (LukD-
LukE and Luk M) and the Panton-Valentine leukocidin (PVL) that form beta-barrel 
pores in the cytoplasmatic membrane of cells of the host immune system, namely 
erythrocytes and leukocytes, promoting lysis (93, 194). While -hemolysin was 
found to play a role in community acquired pneumonia, other cytolysins were 
found in a high percentage of S. aureus nosocomial isolates (32, 259). Due to its 
actual particular relevance, PVL will be described in more detail below.  
Staphylococcal epidermolysins or exfoliative toxins, (ETA, ETB, ETD and 
ETC) are the major causative toxins of bullous impetigo and staphylococcal 
scalded skin syndrome (SSSS) (258). 
Superantigen toxins are powerful immuno-stimulatory proteins that activate 
T-cells through the cross-linking of the T-cell receptor with the major 
histocompatibility complex (MHC) class II, inducing T-cell proliferation and 
massive cytokine production (14). These toxins include the staphylococcal 
enterotoxins (SEs), toxic shock syndrome toxin (TSST) and exfoliative toxins 
involved in SSSS (73). Staphylococcal enterotoxins have a notorious role in S. 
aureus food poisoning (177). Multiple superantigenic toxin genes are commonly 
found among S. aureus, namely associated with mobile genetic elements such as 
pathogenicity islands, prophages and plasmids (232). Recently, two studies on 
nasal and invasive S. aureus showed that the presence of different superantigenic 
and exfoliative toxin genes is strongly associated to S. aureus clonal lineages, 
rather than to invasiveness (136, 326). 
 
1.4.3. Panton-Valentine leukocidin, a special role in infection? 
PVL belongs to the family of “bicomponent synergohymenotropic toxins”, 
comprising two-component pore-forming toxins that act in synergy to lyse host cell 
membranes, namely mononuclear and polymorphonuclear cells (180). The two 
active proteins are designated S (from slow-eluted) and F (from fast-eluted) and 
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are encoded by two contiguous and co-transcribed genes, lukF-PV and lukS-PV 
(348), which are carried on temperate bacteriophages (153). PVL contributes to 
pathogenesis by promoting an exaggerated inflammatory response and injury to 
the host.  The formation of pores on the cell membranes results in cell lysis and 
activation of neutrophils to release potent mediators of inflammation such as 
enzymes and cytokines (168, 202). PVL also appears to induce neutrophil 
apoptosis (101). 
Although the role of PVL in dermonecrosis was established (58, 337), 
several studies comparing the virulence of PVL-positive and PVL-negative strains 
in animal infection models gave conflicting results about the exact function of PVL 
in pathogenesis (33, 72, 175, 332). Löffler et al. recently demonstrated that PVL 
acts differentially on neutrophils of various species, namely inducing rapid 
activation and cell death in human and rabbit neutrophils, but not in murine or 
simian cells, which could explain the controversial results (185). Diep et al. 
confirmed the role of PVL by postulating a model for the PVL-induced acute lung 
injury and lung inflammation based in a rabbit model of necrotizing pneumonia 
(70). 
 
1.4.4. Virulence regulatory systems 
Regulation of expression of the staphylococcal virulence factors plays a 
central role in pathogenesis, and at least, three major operons are involved: the 
agr (accessory gene regulator) (264, 312), the sar (staphylococcal accessory 
regulator) (44) and the sae (staphylococcal accessory element) loci (1). Additional 
regulatory systems also affecting virulence genes expression include: arlR and 
arlS (autolysis-related locus sensor) (94), rot (repressor of toxins) (280), mgr 
(multiple gene regulator) (189) and the staphylococcal alternative sigma factor, 
sigB (228).  
To reduce undue metabolic demands, expression of virulence factors 
occurs in a coordinated mode: genes coding for surface proteins involved in 
adhesion and defense against the host immune system are down regulated during 
early stages of growth, whereas genes that encode secreted proteins are up 
regulated in the exponential phase. This shift in expression patterns is effected by 
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the agr system and translates a strategic switch from an early establishment 
phase to a late attack phase (234). The staphylococcal agr locus encodes a 
quorum-sensing (QS) system that works as a classical two-component signaling 
module (234). Allelic variations in the agr B–D–C region have resulted in at least 
four agr specificity groups in S. aureus (148).  
 
It is important to note that not all S. aureus stains produce the same 
virulence factors, which in some cases could be clonally related (108). Although no 
evidence for hypervirulence was found (90), basically any S. aureus genotype can 
become a life-threatening human pathogen (197). 
 
1.5. Has the era of S. aureus untreatable infections arrived? 
Resistance to antibiotics arises either by mutation in chromosomal genes 
or by acquisition of foreign genes through horizontal gene transfer of mobile 
genetic elements (e.g. plasmids, transposons, insertion sequences, chromosomal 
cassettes) (20, 145, 261). Resistance can further spread vertically by 
dissemination of resistant clones (20). 
Before the “antibiotic era”, approximately 90% of the S. aureus 
bacteremias were fatal (17, 261). In the early 1940s, with the introduction into 
clinical practice of the beta-lactam antibiotic penicillin G, the mortality rates 
decreased considerably (187). However, the increased use of penicillin resulted a 
few years later in the emergence of the first penicillin resistant S. aureus strains. 
Penicillin resistant strains produce a plasmid-encoded penicillinase that hydrolyses 
the beta-lactam ring of penicillin and by 1946 about 60% of the nosocomial 
isolates of S. aureus in the United Kingdom and United States were resistant to 
penicillin (6, 17, 145). 
Records of the Danish Health Board registered the sequential introduction 
of several antimicrobial agents into clinical practice from 1945 to 1953 [penicillin, 
streptomycin, tetracycline and erythromycin] and reported a consecutive 
appearance of resistant S. aureus bloodstream isolates. By the late 1960s, the 
prevalence of penicillin resistance in the Danish nosocomial setting reached 85% 
to 90% (146). 
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In 1959, methicillin, a semi-synthetic beta-lactamase-resistant penicillin, 
initially called celbenine, was successfully introduced into clinical practice. Within 
two years, the first reports of methicillin resistant S. aureus strains were published 
(16, 147). By the end of the 1960s, multidrug-resistant MRSA became endemic in 
hospitals throughout Europe, Australia and India (59, 247, 276) and during the 
1980s in the United States as well. Subsequently, MRSA isolates disseminated 
worldwide, becoming a major cause of infections in hospitals and the community 
(18, 60, 67, 162, 212, 226) 
The hallmark of S. aureus as a pathogen is its capacity to acquire 
resistance mechanisms to virtually all antibiotics introduced into clinical practice 
(Table 1) (261). The increased use of vancomycin, a glycopeptide antibiotic to 
which MRSA were consistently susceptible, resulted in the emergence in 1996 of 
vancomycin intermediate S. aureus (VISA) and in 2002 of vancomycin resistant S. 
aureus (VRSA) strains (37, 132). Although initially VRSA were exclusively 
confined to the United States,  two VRSA were later reported in the 2008 
European Antimicrobial Resistance Surveillance System (EARSS) annual report 
(83). 
Consequently, the launching of new antibiotics, such as quinopristin-
dalfopristin, linezolid, daptomycin, tigecycline and telavancin was of great 
importance. However, resistance to most of these alternative antibiotics has 
already been reported (127, 129, 131, 314). Other vancomycin derivatives 
(dalbavancin, telavancin and oritavancin) as well as a modified carbapenem 
(razupenem), a novel fluoroquinolone (delafloxacin), oxazolidinone (radezolid) and 
cephalosporins (ceftobiprole and ceftaroline) seem to be valuable candidates to 
treat MRSA (24, 49, 57, 78, 239, 354). 
Alternative approaches to the use of antibiotics have been proposed to 
treat MRSA infections: (i) modification of S. aureus genes associated to virulence 
to reduce infectivity; (ii) topical eradication of nasal carriage; (iii) strict infection 
control measures; and (iv) development of S. aureus vaccines (28, 75, 286, 325). 
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1.5.1. Resistance to topical antibiotics 
Fusidic acid has been effectively used as a topical agent in S. aureus skin 
and soft tissue infections (282). However, long-term therapy is suspected to be 
responsible for increasing resistance (263). Fusidic acid resistance genes (fusB, 
fusC and fusD) were prevalent among European staphylococcal isolates in 2008 
(36). The possible emergence of fusA and fusE mutations by extensive and 
continuous use of this antibiotic is of major concern in the current “era” of CA-
MRSA, therefore the combination with other agents, such as rifampin is strongly 
recommended (76). 
Mupirocin has been employed successfully as a topic nasal ointment to 
decolonize MRSA carriers and to treat superficial skin infections. While both high-
level (generally plasmid mediated and encoded by the mupA gene) (134) and low-
level (associated to point mutations in the chromosomal ileS gene) (9) mupirocin 
resistance was reported, the prevalence of resistant isolates is widely variable 
among different populations, but remains generally low (150). However, 
institutions that are considering the implementation of widespread mupirocin use 
for nasal decolonization are encouraged to reflect on the resistance issues so as 
not to compromise the management of MRSA carriers (251). 
 
1.5.2. Resistance to methicillin: mecA gene and SCCmec 
The central element of methicillin resistance is the mecA gene that 
encodes a unique penicillin binding protein PBP2a (or PBP2’) which has low 
affinity for beta-lactam antibiotics and can function as a substitute of the native 
staphylococcal PBPs that could be inactivated by beta-lactams (62). Besides the 
undoubted role of mecA as the primary determinant of methicillin resistance, 
mutations in additional genes termed fem (factors essential for expression of 
methicillin resistance) or aux (for auxiliary) can also affect the expression of 
resistance (21). 
The mecA gene has been found as part of a large mobile genetic element, 
the Staphylococcal Cassette Chromosome mec (SCCmec) which may contain 
additional resistance genes (143, 157). 
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The SCCmec elements are characterized by the presence of (i) terminal 
inverted and direct repeats; (ii) site-specific recombinases designated as cassette 
chromosome recombinases (ccr) that allow the mobilization of the cassette; (iii) a 
mecA gene complex; and (iv) a specific integration site sequence (ISS) (141). 
SCCmec integrates in the chromosome of susceptible strains at a site specific 
location near the origin of replication, the orfX, a gene of unknown function (157). 
The classification of SCCmec is based on binary combinations of the mec complex 
and the ccr allotype (Figure 1). The mec complex is composed of the mecA gene, 
its regulatory genes (mecR1 and mecI) and associated insertion sequences. The 
ccr complex is composed of the ccr gene(s) and surrounding open reading frames 
(ORFs). So far, four classes of mec complex (A, B, C [C1 and C2] and E) and five 
ccr gene complexes (types 1 to 4, carrying two genes, ccrA and ccrB with four 
allotypes: ccrAB1, ccrAB2, ccrAB3, ccrAB4, and type 5 carrying a single allotype, 
ccrC with five alleles: ccrC1 allele 1 to 4 and ccrC1 allele 8) have been described 
in S. aureus, corresponding to eight SCCmec types (I to VIII) (Figure 1): SCCmec 
type I (class B mec complex, ccrAB1), SCCmec type II (class A mec complex, 
ccrAB2), SCCmec type III (class A mec complex, ccrAB3), SCCmec type IV (class 
B mec complex, ccrAB2), SCCmec type V (class C2 mec complex, ccrC), 
SCCmec type VI (class B mec complex, ccrAB4), SCCmec type VII (class C1 mec 
complex, ccrC), and SCCmec type VIII (class A mec complex, ccrAB4) (22, 121, 
141-144, 178, 190, 242, 355). An additional mec complex class D was described 
in Staphylococcus caprae but so far not found in S. aureus (156). 
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Figure 1. Genetic organization of SCCmec types I–VIII. Figure is not to scale. Reprinted with 
permission from (87). 
 
In addition to the mec and ccr complexes, SCCmec elements contain three 
J regions (J1, J2 and J3) that stand for “junkyard” or “joining regions” (Figure 1), 
composed by non-essential components and in some cases additional 
antimicrobial resistance determinants. These J regions may include 
polymorphisms or variations within the same combination of the mec and ccr 
complexes, which is used to define SCCmec subtypes (141). So far, 26 subtypes 
of SCCmec have been described among the eight major types. Of major interest is 
the subtyping of SCCmec type IV, the smallest, most mobile and most variable 
structural type of SCCmec, present not only in the overwhelming majority of 
emergent community-acquired MRSA (CA-MRSA), but also in some international 
nosocomial clones (64, 344). Ten SCCmec type IV subtypes have been described 
so far with variations in the J1 region (Figure 2), which allows a more specific 
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epidemiological characterization of MRSA collections with high percentage of 
isolates carrying a type IV cassette (23, 141, 203). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A recent standardization of the SCCmec classification and nomenclature, 
is available at http://www.sccmec.org, and has been proposed to accommodate 
the increasing number of types, subtypes and variants (47, 141). 
The origin of the mecA and SCCmec is still a matter of debate. No 
homologue of the mecA has been found in MSSA strains and it has been assumed 
that it is an exogenous gene that originated in coagulase-negative staphylococci 
(CoNS) (11, 63). Couto et al. evidenced that the mecA determinant may be a 
housekeeping gene in a fully beta-lactam susceptible Staphylococcus sciuri (56) 
which is a frequent colonizer of the skin of many domestic and wild animals and is 
one of the most abundant staphylococcal species on Earth (163). The mecA found 
Figure 2. Genetic organization of the subtypes of SCCmec type IV. Adapted from (23, 203). 
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in S. sciuri has 88% homology on the amino acid level to the MRSA gene (350). 
Moreover, introduction of the S. sciuri mecA into an MSSA resulted in increased 
resistance to methicillin together with the detection of a protein homolog to PBP2a 
(351). SCCmec elements are widely found among CoNS which constitute another 
line of evidence of the role of CoNS as reservoirs for the mecA acquisition by S. 
aureus (100, 158, 213). A recent study suggests Staphylococcus fleurettii, a 
commensal bacterium of animals, as a probable intermediary in the evolution of 
the mecA gene. Although the mecA in S. fleurettii was not associated to SCCmec, 
it is located in a chromosome locus with an identical sequence to that of the mecA-
containing region of SCCmec and therefore is speculated that SCCmec was 
assembled by adopting the S. fleurettii mecA gene and its surrounding 
chromosomal region (315). 
 
1.6. S. aureus costs to individuals and society 
S. aureus infections present financial issues not only for the individual, but 
for the society as well, due to prolonged hospital stays, costly medical procedures, 
and medications. S. aureus infection was reported for 0.8% of all hospital 
inpatients, and was associated to 292,045 days of hospital stay per year in the 
United States hospitals in 2000-2001. Inpatients with S. aureus infection present, 
on average, a length of hospital stay three times higher (14.3 vs. 4.5 days; 
P<0.001), total charges three times higher ($48,824 vs. $14,141; P<0.001), and 
the risk of in-hospital death five times higher (11.2% vs. 2.3%; P<0.001) than non-
infected inpatients (229).  
Moreover, various studies showed that, compared to MSSA, MRSA 
infections cause longer hospital stays, higher costs and higher mortality (19, 53, 
55). It has been estimated that MRSA hospital costs in the United States range 
between $1.5 and $4.2 billion at the national level, and the costs to society 
between $17 and $30 billion (109). In a recent study in Northern Europe, the total 
additional costs due to an MRSA outbreak in surgical and internal medicine units 
were calculated in €386,062 (70% for screening and 25% for contact isolation) 
(154). 
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The increasing burden of S. aureus infections worldwide conducted to the 
development of infection control strategies such as the “Search and Destroy 
policy” in countries of Northern Europe (The Scandinavian countries and The 
Netherlands). Controlling MRSA is expensive, even though recent studies 
provided evidence that the strict application of these “Search and Destroy” 
measures can effectively control an epidemic of MRSA colonization and infection, 
preventing 36 cases of MRSA bacteremia per year, which resulted in annual 
savings of €427,356 for the hospital and ten lives per year (237, 325).  
 
 
2. Bacterial typing: tools for fighting S. aureus 
 
2.1. Why typing of S. aureus? 
Typing is roughly defined as the attribution of labels to bacterial isolates, 
and is greatly facilitated by the increasing variability of typing methods currently 
available (319). The identification of the pathogen distribution and strain 
relatedness is essential for the determination of the epidemiology of nosocomial 
infections. Therefore, S. aureus typing is of major importance in: (i) outbreak 
situations, where the identification of the causative agent, the identification of 
bacterial reservoirs and transmission routes, increase the efficacy of control; (ii) 
surveillance studies, allowing an early warning of potential outbreaks by the 
detection of bacterial clusters, and determination of the clonal nature of bacterial 
populations; (iii) evolutionary studies, determining the S. aureus population 
structure and genetics, providing important clues about evolutionary trends of the 
bacterial pathogen as well as the emergence of clinically relevant strains with 
increased resistance or virulent content (290, 319, 339). 
In addition to the critical role of typing in outbreak investigations and 
epidemiological surveillance of S. aureus infections, it also contributes to elucidate 
the progress of infection in single patients or even identifies the exogenous or 
endogenous microflora origin of the infection causative agent (290, 319). 
Typing could be considered as comparative, usually used in outbreaks 
situations, or definitive including the creation of strain collections available for 
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comparative assessment between laboratories (319). S. aureus typing can be 
undertaken at different levels: (i) locally, usually for outbreak investigations in a 
hospital laboratory; (ii) regionally or nationally, in reference laboratories for more 
robust surveillance studies; (iii) internationally, through collaborative networks, to 
define or survey the worldwide dissemination of epidemic clones (319).  
Different typing methods have been used at each level, based on S. 
aureus phenotypic and/ or genotypic features. However, no single typing method 
has proven to be solely sufficient to characterize a collection of isolates (299, 339).  
 
2.2. The value of a typing method 
Every typing method should meet performance and convenience criteria 
(319). Performance criteria include: (i) stability, meaning that the method should 
assess a marker that remains constant during the study period; (ii) typeability, 
translating the ability of a method to assign a type to all the isolates tested; (iii) 
discriminatory power, referring to the ability of the method to differentiate two 
epidemiologically unrelated isolates from the population; (iv) epidemiological 
concordance, i.e. the agreement between the typing results and the 
epidemiological information of the isolates; (v) and reproducibility, meaning that a 
typing result for an isolate should be identical in a different temporal and/ or spatial 
occasion. Convenience criteria should also be taken into account, namely 
feasibility, flexibility, rapidity and ease of use, highly related with the accessibility 
and cost inherent to the equipment and reagents used. The choice of a typing 
method depends not only in performance and convenience criteria, but also on the 
question to be addressed, the specific epidemiological situation and the resources 
available (290).  
Recently, with the study of large collections of isolates, the amenability to 
computerized analysis as well as an easy incorporation of typing results into 
electronic databases are key points for choosing a typing method (319). Moreover, 
new S. aureus typing methods, making use of new technologies, or variation of 
well established methods, have been developed in order to meet these requisites. 
However, such methods require validation in terms of sensitivity and specificity, 
which is usually accomplished by comparison with well established methods (267). 
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The best approach is to evaluate the congruence in a quantitative way. Recently, 
Carriço and coworkers proposed a framework of measures for the quantitative 
assessment of correspondences between different typing methods for 
Streptococcus pyogenes (35), which were already applied to S. aureus and S. 
epidermidis data (88, 209). This Comparing Partitions framework included the 
Simpson’s index of diversity, the adjusted Rand’s index and the Wallace 
coefficients which could be assessed online 
(http://darwin.phyloviz.net/ComparingPartitions). The Simpson’s index of diversity 
(289) associated to confidence intervals measures the probability of two isolates, 
randomly sampled from the population, to belong to two different types (115, 139). 
The adjusted Rand’s index (138) quantifies the global agreement between two 
methods, whereas the Wallace coefficient (334) indicates the probability that two 
isolates classified as the same type by one method are also classified as the same 
type by another method. The use and interpretation of the congruence measures 
may be improved by the estimation of suitable confidence intervals. Therefore, the 
Comparing Partitions web-tool was updated with 95% confidence intervals for 
Wallace and adjusted Rand coefficients, reinforcing the role of these coefficients in 
generating maps of type or subtype equivalence and allowing an objective 
comparison between typing methods (285). 
 
2.3. Phenotypic based methods 
The earliest methods used to identify and type bacterial pathogens were 
based upon their phenotypic characteristics. Biotyping, antimicrobial susceptibility 
testing, phage typing, whole-cell protein electrophoresis, zymotyping, multilocus 
enzyme electrophoresis (MLEE), capsule typing and serotyping are some of the 
methods used in phenotypic characterization of S. aureus (290, 296). However, 
since phenotypic expression depends on environmental conditions, some of the 
performance criteria are not always full field. Therefore, only a small set of 
phenotypic methods are still currently used.  
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Phage typing 
Phage typing classifies the strains based on the pattern of resistance or 
susceptibility to an approved set of bacteriophages by the International 
Subcommittee on Phage Typing of Staphylococci (26, 250). Currently 23 standard 
phages are applied to an agar plate covered with the test isolate, at the Routine 
Test Dilution (RTD), the highest dilution giving confluent lysis of the propagating 
strain, or at a 100 times concentration (100XRTD) when the isolates are 
nontypeable with RTD, in order to produce areas of lysis (i. e. plaques) (265). 
Since not all S. aureus isolates are lysed by the same phages, typical phage types 
could be defined. Some additional locally isolated phages are usually added to the 
approved international set to increase the discrimination of isolates (61).   
For decades, phage typing was the standard method for S. aureus typing. 
However, some drawbacks such as limited typeability and reproducibility, variable 
discrimination, and technically demanding laboratorial efforts (preservation of 
stocks of phages and propagating strains) limited its use in routine (339). 
Therefore, phage typing is nowadays rarely used and in complement to other 
molecular methods in epidemiological studies (61, 343).  
 
Antimicrobial susceptibility testing 
The antimicrobial susceptibility testing, or antibiogram, determines the 
pattern of resistance or susceptibility of an isolate, in vitro, to a panel of 
antimicrobial agents. This method is routinely performed in clinical laboratories 
using either disk diffusion methods or broth microdilution in an automated way 
(290). Microdilution testing provides a quantitative measure of the minimal 
inhibitory concentration (MIC) defined as the lowest concentration of the 
antimicrobial agent that inhibits the growth of the microorganism, while the disk 
diffusion provides a measure of the growth inhibition halo from a defined 
concentration of antibiotic diffused in the media by a paper disk. Both methods 
follow well defined guidelines essential for standardization and interlaboratory 
reproducibility, such as the ones of the Clinical Laboratory Standards Institute 
(CLSI) (50).  
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Clinically, the antibiogram has immediate usefulness to guide 
antibiotherapy (319). In epidemiological studies, it has limited value, since isolates 
that are not genetically and epidemiologically related may have the same 
susceptibility pattern due to the acquisition or loss of mobile genetic elements 
carrying the same resistance genes, or even spontaneous point mutations driven 
by the high antibiotic pressure found in health care settings (290, 347). In contrast, 
the pattern of susceptibility was shown to be an excellent phenotypic marker for 
the identification of two distinct clones of MRSA in a Portuguese hospital (7). 
 
2.4. Genotypic based methods 
The introduction of molecular typing in epidemiological hospital 
surveillance is well-established and is proven to be cost-effective (8, 290).  
Genotypic or molecular typing is a means of sampling the bacterial 
genome by assessing its variability in terms of composition, overall structure or 
precise nucleotide sequence. Basic genetic analysis of molecular events 
associated with pattern variation (e.g. deletions, insertions and mutations) is 
usually the best approach for the determination of strain relatedness. Molecular 
typing presumes that: (i) isolates from an outbreak have the same or highly related 
genotype and derive from a common ancestor or clone; and (ii) epidemiologically 
unrelated isolates have different genotypes (290).  
DNA-based typing methods have significant advantages over phenotypic 
methods concerning typeability, discrimination, reproducibility, rapidity and ease of 
use. A wide variability of genotypic methods have been used for S. aureus typing 
(290, 296), fundamentally based on: (i) the Polymerase Chain Reaction (PCR) 
technique, (ii) endonuclease restriction to create band pattern fingerprints, (iii) 
arrays technology, and (iv) DNA sequencing.  
(i) Despite automation attempts, traditional PCR-based strategies such as 
repetitive sequence based (rep-) PCR (323), random-amplified polymorphic 
DNA (RAPD) (4, 318) or single locus amplification of the coagulase gene 
(165), have been dumped for the identification and comparison of S. aureus 
isolates mainly due to lack of reproducibility, standardization and portability of 
results (65, 279). Other PCR based methods have been developed, such as 
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the restriction-modification (RM) test, based on three PCRs targeting the SauI 
RM system specificity subunit genes (sau1hsdS1 and sau1hsdS2), which 
coupled to the rapidity of real time PCR, was reported as a simple, inexpensive 
and accurate method to identify S. aureus lineages (51). Also, Loughman et al. 
used a real-time reverse transcriptase PCR to detect the expression of 
virulence genes directly from S. aureus cells (186). 
(ii) The endonuclease fragment restriction followed by hybridization with DNA 
probes was the basis for ribotyping (27), binary typing (324) and the study of 
polymorphisms using gene specific probes for mecA and Tn554 (4, 171) 
effectively applied to the epidemiological study of S. aureus collections, but 
currently almost dismissed.  
Methods such as the amplified fragment length polymorphism (AFLP) or the 
recent high-throughput modification (ht-AFLP) combine PCR with fragment 
restriction analysis to produce fingerprints for both MRSA and MSSA typing 
and population structure definition (197, 281). 
(iii) Techniques such as microarray technology have been widely used in the 
evaluation of genetic variation of S. aureus lineages (174, 181, 216), 
characterization of community and hospital MRSA clones (166, 215), and 
detection of resistance, virulence and epidemicity markers (173, 214, 357).  
(iv) Although full genome sequencing is still laborious, time demanding and 
expensive, low cost high throughput sequencing technologies have been 
developed. New comparative genomic approaches have been used to assess 
single nucleotide polymorphisms (SNP) and compare significant fragment 
mutations in relatively large collections of S. aureus isolates for evolutionary 
studies and geographical spread of specific clonal populations (128, 235, 236). 
Moreover, the tracking of in vivo evolution of multidrug-resistance in S. aureus 
isolates recovered periodically from the bloodstream of a patient undergoing 
chemotherapy with vancomycin and other antibiotics was assessed by whole-
genome sequencing (225). A complete genome sequencing and further 
genome comparison was recently performed by Holden el al. for an unusually 
high transmissible MRSA isolate (135). 
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(v) Analytical technologies such as the mass spectrometry (MS) or microfluidics 
have been used as a means of automation, rapidity and throughput increasing 
on S. aureus identification and characterization. Pathogen profiling and 
identification of virulence and resistance genes was carried out coupling PCR 
to electrospray ionization-MS (EIS-MS) (118, 346). Matrix-assisted laser 
desorption ionization time-of-flight MS (MALDI-TOF-MS) or its surface 
enhanced variation (SELDI-TOF-MS) performed well in the identification of 
staphylococci, detection of the staphylococcal PVL gene and discrimination 
between MRSA and MSSA starting in intact cells (25, 79, 353). A new genomic 
typing technology, direct linear analysis (DLA) performed on microfluidic chips, 
was successfully applied to the molecular typing of S. aureus with a high 
discriminatory power, comparable to that of PFGE (342). 
 
Although many molecular methods have been developed for the 
characterization of S. aureus, some were restricted to local or regional studies, 
and only a few are currently well-accepted and generally adopted: (i) pulsed-field 
gel electrophoresis (PFGE); (ii) multilocus sequence typing (MLST) (iii) spa typing; 
(iv) staphylococcal chromosome cassette mec (SCCmec) typing and (v) multilocus 
variable tandem repeats (VNTR) analysis (MLVA). Since these methodologies 
have been extensively used in the present work, a detailed description of each one 
will be provided. 
 
PFGE 
 Pulsed-field gel electrophoresis (PFGE) was first described in 1984 as a 
tool for examining the chromosome of eukaryotic organisms (284). Afterwards, it 
has proven to be a highly effective molecular technique for many bacterial species 
including S. aureus (304). The method is based on the digestion of bacterial DNA 
with restriction endonucleases with relatively few recognition sites, generating 10 
to 30 restriction fragments, which are further resolved as a pattern of distinct 
bands (303). Contrary to conventional electrophoresis, the electric field is applied 
in pulses that alternate in orientation, allowing the separation of the DNA 
fragments that range from 10 to 800 kb in length (284, 303). PFGE is still regarded 
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as the “golden standard” method in S. aureus typing, due to its high discriminatory 
power, reproducibility and high typeability, even for the recent “livestock-
associated” sequence type 398 isolates that due to DNA methylation are 
insensitive to the conventionally used SmaI enzyme, and must be digested with 
the neoschizomer Cfr9I (29, 86). Random genetic events, including point 
mutations, insertions and deletions of DNA, may be detectable in PFGE patterns, 
which made the method suitable for comparisons of highly related isolates and 
hence for local outbreak epidemiologic analysis and for S. aureus surveillance 
studies at regional or national levels (105, 299, 304). However, PFGE requires 
relatively expensive equipment, is time and technically demanding, has some 
limitations in interlaboratory portability and uniform nomenclature (105, 299, 320). 
Consensus guidelines for correlating variations in restriction profiles with 
epidemiological relatedness, as well as harmonization protocols and laboratory 
networks have been proposed to overcome the referred drawbacks (48, 195, 223, 
304).  
 
MLST 
Multilocus sequence typing (MLST) was originally developed to identify 
hypervirulent lineages of Neisseria meningitidis (191) and was then extended to a 
variety of other pathogens, including S. aureus (81). The method is based on the 
sequencing of internal fragments of housekeeping genes. For S. aureus, seven 
housekeeping genes were included in the MLST scheme: arcC, aroE, glpF, gmk, 
pta, tpi and yqiL (81). Fragments of 450-500 bp in size are used since they can be 
accurately sequenced on each strand with a single pair of primers and provide 
sufficient variation in the population (294). For each gene, sequences that differ 
even at a single nucleotide are assigned as different alleles. The combination of 
the allele at each of the seven loci defines the allelic profile, which unambiguously 
identifies the sequence type (ST) of each isolate. In S. aureus new alleles are 
most probably due to point mutations rather than recombination events (90, 294). 
The major advantages of MLST are the portability and reproducibility of the 
sequence data. A freely accessible database is available on the internet 
(http//:www.mlst.net) allowing the assignment of the alleles and STs as well as the 
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deposit and comparison of the DNA sequences. The eBURST algorithm (from 
Based Upon Related Sequence Types) (91) is also freely available 
(http://eburst.mlst.net/), which allows the definition of evolutionary relationships 
between different STs by identifying groups of closely related genotypes, the 
clonal complexes (CC). CC emerges from a founding genotype that increases in 
frequency to become the predominant clone and gradually diversifies into other 
related genotypes (90, 295). If one, two or three of the seven loci are changed, 
single-, double- or triple-locus variants (SLV, DVL, or TLV) are generated, 
respectively.  
MLST shows moderate discriminatory power for local epidemiological 
typing, which associated to the time and cost, compromises its use as a S. aureus 
primary typing tool (299). Since the variation in housekeeping genes indexed by 
MLST accumulates relatively slowly (294), this method is suitable for long-term 
epidemiological and population evolutionary studies (59, 81, 82, 90).  
 
spa typing 
spa typing, a single-locus sequence typing technique developed by Frenay 
et al., relies on the determination of sequence polymorphisms in the variable X 
region of S. aureus protein A gene (spa) (97). The polymorphic X region consists 
of a variable number of tandem short sequence repeats (SSR) located in the 3’ 
coding region of the C-terminal cell wall attachment sequence of protein A (116). 
The SSR are usually 24 bp length, although 21, 27 and 30 bp repeats were also 
described (266). This X region is flanked by well conserved sequences permitting 
the annealing of primers and the subsequent amplification and direct sequencing 
of the entire region (2, 287). The high diversity within the SSR region is attributed 
to point mutations, deletions, duplications and insertions of repetitive units (151).  
To each different repeat is assigned an alpha-numerical code, and the 
order of specific repeats defines the spa type. Two different nomenclature systems 
were developed, which made the comparison of published spa data difficult (126, 
170). A recent software package, StaphType (Ridom GmbH, Wrzburg, Germany) 
appeared as a valuable tool to overcome this drawback using the RIDOM 
nomenclature (126). The resulting sequence chromatograms are analyzed and 
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further synchronized to an online database, the SpaServer 
(http://spaserver2.ridom.de/index.shtml), for the assignment of the spa repeats 
and spa types (126). The SpaServer is one of the largest databases for S. aureus 
typing, curated by the European SeqNet network (http//:www.seqnet.org) that 
includes 50 laboratories from 27 European countries and provides nomenclature 
and epidemiological data (98, 99).  
Despite being a single-locus typing method, spa typing is robust enough to 
cover genetic variations that accumulate at different evolutionary clock speeds 
(micro- and macrovariation) and therefore may be used for outbreaks, local and 
global epidemiological and population based studies (170, 298). It has become 
one of the primary typing methods for S. aureus, mainly due to its high throughput, 
ease of performance, shorter time comparatively to MLST, full portability of the 
data and straightforward interlaboratory comparison and reproducibility (2, 98, 
298). A surveillance method based on spa sequencing and automated alerts, was 
useful as an early warning system to prevent hospital outbreaks (199). 
Coupling the algorithm Based Upon Repeat Pattern (BURP) to the 
StaphType software enabled the grouping of related spa types into clonal lineages 
and the study of long-term evolution of S. aureus populations (200). Several 
studies demonstrated a good correlation between spa type clonal groups of MRSA 
and groups generated by other methods, namely PFGE types and MLST clonal 
complexes generated by eBURST (52, 120, 170).  
However, as a single locus based method, spa typing showed some 
limitations in the differentiation of particular genetic lineages, namely CC1/CC80 
and CC8/CC30/CC45 (298). Combinations of additional genetic markers, such as 
SCCmec for MRSA and lineage specific virulence genes for MSSA, are useful to 
increase the discriminatory power of the method (120, 298).  
Recently, Grundmann et al. used spa typing to map the geographic 
distribution of MRSA and MSSA clones causing invasive infections in Europe and 
made available an online mapping platform for geographic tracking of 
strains/clones with particular public health importance 
(http://www.spatialepidemiology.net/SRL-Maps/) (113). 
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SCCmec typing 
SCCmec typing has been recognized as an addendum to the MRSA clonal 
characterization, which is currently defined by the combination of the MLST 
sequence type (ST) and the SCCmec type (82, 272). 
Since 2002, that a variety of PCR based methods have been described to 
determine the structure of the different SCCmec types harbored by MRSA. The 
SCCmec typing methodology inquires specific loci in the mobile genetic element 
by conventional or multiplex PCR. Oliveira et al. developed the first multiplex PCR 
assay that detects the mecA gene and eight loci scattered trough the entire 
cassette, resulting in specific band patterns for SCCmec types I-IV (241). This 
strategy misclassifies SCCmec types V/ VI and types III/ IV, respectively, since the 
former types were not described at the time of this multiplex design. In order to 
overcome the drawback, an update of the method was later published, allowing 
the association of SCCmec types I-VI to specific amplification patterns of 2-5 
bands (204). 
Alongside to the Oliveira et al. PCR multiplex, Okuma et al. developed a 
strategy that uses conventional PCR assays to determine the mec complex and 
ccr genes structure, where different combinations correspond to different SCCmec 
types (240). 
Although several other multiplex strategies were proposed to overcome the 
limitation of these first strategies in the non identification of the new types V-VIII 
and subtypes (31, 167, 356), they were not extensively adopted since they lack 
discriminatory power, are laborious, time consuming and not practicable for routine 
typing. 
In 2006, a different approach was proposed based on the sequencing of an 
internal fragment of the ccrB gene using a single pair of degenerated primers 
(243). An online database (http//:ccrbtyping.net) permits the user to query his own 
sequences, assign a ccrB allele and determine the most probable SCCmec type, 
as well as tracing the SCCmec elements within the MRSA population based on the 
stored sequence data (244). This tool has the advantage of being easily integrated 
into the spa typing or MLST protocols for routine typing.  
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The increasing number of MRSA infections in the community made the 
typing of SCCmec IV and its variants a major concern. Therefore, Milheiriço et al. 
developed a multiplex PCR assay based on the detection of polymorphisms in the 
J1 region to identify SCCmec type IV subtypes (IVa to IVh) (203). 
The best SCCmec typing strategy depends on the purpose of the study. In 
this context, de Lencastre et al. (62) proposed a flexible and feasible SCCmec 
typing scheme including three sequential steps: 1) ccrB typing (243, 244); 2) 
SCCmec multiplex PCR, updated version (204); and in the cases of type IV 
cassettes 3) SCCmec IV multiplex PCR (203). In addition, a recent report of the 
International Working Group on the Classification of Staphylococcal Cassette 
Chromosome Elements (IWG-SCC) proposed some guidelines for the 
classification, nomenclature and definition of new SCCmec types (141).  
So far, no single multiplex PCR strategy can include the 22 out of 34 binary 
targets necessary to properly genotype all 46 SCCmec variants described by 
Stephens et al. (297). The continuous emergence of new SCCmec structures and 
variants requires a permanent update of the existing schemes or the design of 
new ones. 
 
MLVA 
The genome of S. aureus harbors a variety of loci of repetitive DNA, which 
may contain variable repeated units among strains and in many occasions 
constitutes a strain-defining parameter (182). Analysis of variable number of 
tandem repeats (VNTR) has been extensively used for typing clinical isolates of 
several bacterial species, including S. aureus, since a limited number of loci 
provides an overview of diversity within a bacterial population (182, 329). For this 
purpose the study of VNTRs was based in two interrelated basic methodologies: i) 
the production of multiple band patterns by multilocus VNTR fingerprint (MLVF) 
assays and ii) the determination of the number of DNA repeats per loci forming a 
string of numbers that characterizes each strain, the multilocus VNTR analysis 
(MLVA) (257, 279, 329).  
Sabat et al. in 2003, proposed an MLVF method that discriminates different 
S. aureus clinical isolates based on the analysis of five (sdr, clfA, clfB, ssp, and 
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spa) tandem repeat loci (278, 279). The method has been extensively used as 
initially described or with slight variations such as the addition of virulence genes 
containing repeated units such as fnbA, fnbB and can (95, 103, 193, 198, 222, 
255, 268, 279, 307). The discriminatory power and clustering capability similar to 
PFGE, made the MLVF method reliable for short-term epidemiological studies 
(193, 307). However, the fact that the data are interpreted by band patterns 
comparison in agarose gels makes the results inaccurate, not easily comparable 
between laboratories and not prone to be introduced in international databases 
(257, 279).  
MLVA was first applied for S. aureus genotyping by Hardy et al. (123, 125). 
The method, designated staphylococcal interspersed repeat unit (SIRU) typing, 
relies on PCR amplification of seven loci of repetitive DNA and on the 
determination of the size of each amplicon. To each of the seven loci is attributed 
the respective number of DNA repeats, generating a code of seven numbers that 
characterizes each strain and corresponds to the allelic profile. This numerical 
allelic profile makes the SIRU data amenable to interlaboratory comparisons and 
database management, comparable to MLST. The strict methodology and slight 
modifications have been applied to nosocomial outbreaks and to a restricted 
European collection of contemporary S. aureus isolates (102, 122-124, 140). 
Recently, two additional MLVA schemes were published, including new 
VNTR markers as well as some of the loci included in the previous referred assays 
(257, 283). Schouls et al. described a robust and portable MLVA system including 
eight loci amplified in two multiplex PCR reactions, followed by an accurate sizing 
of fluorescently labeled amplicons on an automated DNA sequencer. The 
validation of the method showed 100% typeability and the clustering was similar to 
spa typing or PFGE grouping (283). The MLVA-14 proposed by Pourcel el al. 
included two complementary panels totaling 14 VNTRs providing an easy and 
extremely informative genotyping assay with strong phylogenetic content and high 
congruence with MLST and spa typing (257). This method was successfully used 
in a longitudinal survey of S. aureus infections in 143 cystic fibrosis patients (333).  
As a PCR based technique, MLVA is neither expensive nor time 
consuming, and is open to automation and portability of the data, which makes it 
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amenable for routine laboratories (95, 198). The adoption of capillary 
electrophoresis equipment, DNA sequencers and automated DNA sizing systems 
may improve the accuracy of the method (196, 329).  
The major drawbacks of the MLVA methodology are the lack of 
standardization, since no consensus is achieved about the most informative 
VNTRs to be used. In order to overcome this disadvantage two MLVA databases 
are nowadays freely available.  
Pourcel et al. created an online database based on its own MLVA scheme 
(http//:mlva.u-psud.fr) that allows users to create their own account to manage 
personal data. Different VNTR markers could be selected by the users to query 
the stored database, which may be seen as a repository of MLVA data (329). 
Shouls et al. created a reference online database hosted at the Dutch 
National Institute for Public Health and the Environment (RIVM) and available at 
http://www.mlva.net. The database includes over 2550 different MLVA profiles and 
23 MLVA complexes obtained from over 11000 Dutch S. aureus isolates and 
additional 2500 isolates from 23 other European countries. This database 
constitutes a MLVA typing tool that allows interrogation of MLVA types by the 
users.  
 
2.5. Translating typing results into useful information for infection control 
Microbial typing is widely applied, directly or indirectly, in clinical practice. 
Reports of typing results are important in outbreak situations and in long term 
surveillance, to decide on infection control measures (319). However, the 
application and interpretation of molecular typing in clinical and epidemiological 
contexts requires, not only the understanding of the typing results, but also the 
inclusion of epidemiological data concerning the patients (291, 319). The 
introduction of the concept of pathogen profile, which integrates phenotypic and 
genotypic typing results with additional clinical and epidemiological data, 
constitutes a valuable tool of communicable disease control (291). Therefore, the 
mutual contribution of the laboratory and the clinical practitioners is of major 
importance. 
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Moreover, the feedback following typing is essential and must include all 
those involved, not only to translate the results into practice, but also to guarantee 
continued motivation in maintaining the infection control measures and 
surveillance screenings (319). 
 
 
3. Epidemiology of S. aureus: contemporary scenario 
 
3.1. Evolution and global dissemination of MRSA clonal lineages 
Two theories addressed the origins of the major contemporary MRSA 
clones: (i) the single-clone theory proposes that all MRSA were descendent from a 
single ancestral and that the SCCmec was introduced only once into this S. 
aureus strain (171); (ii) the more recent multi-clone theory suggests that SCCmec 
has been introduced several times into various S. aureus lineages (82, 106, 224). 
In order to clarify the origins and spread of MRSA, Crisóstomo et al. 
studied a collection of MSSA and early MRSA strains isolated in the 1950/60s in 
Denmark and UK, where the first MRSA were identified and preserved (59). The 
authors noticed a gradual accumulation of resistance traits in MSSA paralleling the 
antimicrobial introduction in therapeutics, and suggested that these MSSA 
presenting a genetic background similar to the early and contemporary MRSA, 
represented the progeny of an S. aureus strain that must have been one of the 
first recipients of the mec element in the evolutionary history of MRSA (59). These 
findings were further confirmed by another study of Danish S. aureus isolates 
recovered in the 1960s from blood infections (106). The early MRSA, 
characterized by ST250 and SCCmec type I, was named “Archaic” clone (59, 
245).  
The characterization of more than 3,000 MRSA isolates from surveillance 
and outbreak studies in Southern and Eastern Europe, North and Latin America 
and Asia, by the CEM/NET initiative between 1994 and 2000 evidenced the 
spread of six major clones (310). Each clonal lineage was defined by a specific 
genetic background: the Iberian (ST247-IIA), Brazilian (ST239-IIIA), Hungarian 
(ST239-III), New York/ Japan (ST5-II), Pediatric (ST5-VI) and EMRSA-16 (ST36-II) 
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MRSA clones (3, 63). Two additional clones, the EMRSA-15 (ST22-IV) and Berlin 
(ST45-IV) showed epidemic potential, namely in the United Kingdom and 
Germany (149, 220, 336, 345). 
Enright et al. characterized by MLST and SCCmec typing a wide collection 
of MRSA and MSSA isolated in 20 countries between 1961 and 1999, and defined 
that the major MRSA clones were associated to five clonal lineages: CC5, 8, 22, 
30 and 45. Moreover, the study has shown that the successful ST8-MSSA lineage, 
in CC8 was the ancestor of the Archaic clone (ST250-MRSA-I), since ST250 
differs from ST8 by a single point mutation in the yqiL locus (82). Evolutionary 
schemes were drawn for each of the five major CC, based on point mutations in 
housekeeping genes, recombination events and acquisition of SCCmec (Figure 3) 
(82, 106, 272).  
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Figure 3. Evolutionary origins of the main MRSA clones belonging to each major clonal complex 
(CC), CC8, CC5, CC22, CC30 and CC45. Adapted from (82, 106, 272, 273). 
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In addition to ST250-MRSA-I, CC8 included the genetic background for 
other successful MRSA lineages such as the ST247-MRSA I (Iberian clone), the 
ST239-MRSA-III (Brazilian and Hungarian clone), ST254-MRSA-IV (Hannover 
clone), ST8-MRSA-II (Irish-1 clone) and one of the most virulent and widespread 
community acquired clones, the ST8-MRSA-IV PVL positive USA300 (82, 272, 
Figure 3. Continued. 
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305). ST239-MRSA-III is a pathogenically distinct and clinically important branch 
of CC8 that arose by the exchange of a ~557kb chromosomal fragment of the 
ST30 into the ST8 genetic background (271).  
CC5 originated from an ancestral ST5-MSSA that diverged into major 
actual clonal lineages, as the ST5-MRSA-II (New York/ Japan clone), the ST5-
MRSA-IV (Pediatric clone) and ST228-MRSA-I (Southern German clone). 
Moreover, the first VISA and VRSA isolates reported evolved from the ST5-MRSA-
II genetic background (37, 132). A recent study on the CC5 evolution showed that 
variations of this successful lineage emerged by temporal and geographic 
independent SCCmec acquisitions (236). 
In CC22 lineage, an ST22-MSSA was the predicted precursor of ST22-
MRSA-IV known as the Barnim or EMRSA-15 clone, depending of the geographic 
origin of the isolates. In CC45, the ancestor ST45-MSSA precedes the ST45-
MRSA-IV background of the Berlin clone.  
In CC30, the ST30-MSSA was thought to be the ancestral of two currently 
distinct clonal types: the ST36-MRSA-II, the hospital acquired EMRSA-16, and the 
community acquired ST30-MRSA-IV PVL positive Southwest Pacific clone (272, 
273).  
SCCmec seems to be a driving force for evolution, hence MRSA has 
emerged at least 20 times upon SCCmec acquisition, which is four times more 
common than the replacement of one SCCmec cassette by another, and the 
smallest cassette type, type IV, was found in twice as many clones as any other 
SCCmec (272).  
 
3.2. Methicillin-resistant S. aureus (MRSA) in the nosocomial setting 
Defined risk factors for hospital acquired (HA-) MRSA infection include 
prolonged hospitalization or residence in a nursing home, patients undergoing 
dialysis, indwelling catheters, ICU exposure, prior antimicrobial therapy, surgical 
procedures, history of anterior MRSA infection or colonization, and close proximity 
to an inpatient colonized with MRSA (162). Moreover, the overwhelming majority 
of HA-MRSA infections are associated with invasive disease, namely pneumonia, 
blood stream, surgical wound and urinary tract infections (43). The growing impact 
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of antibiotic use in addition to more invasive medical interventions and 
comorbidities of the patients seems to add to the burden of MRSA infections (30). 
HA-MRSA are usually multiresistant, harbor SCCmec cassette types I, II, 
III and IV, which include plasmids and transposons carrying additional antibiotics 
and heavy metals resistance genes (66, 92). 
Several epidemiologic studies, including the SENTRY Antimicrobial 
Surveillance Program determined that between 1997 and 2003 the global MRSA 
prevalence in hospitals was 23% in Australia, 67% in Japan, 40% in South 
America, 36% in the United States and 23% in Europe (18, 67, 114, 308). 
Additional SENTRY data reveal the increasing trend in the proportion of MRSA in 
Latin America from 33.8% in 1997 to 40.2% in 2006 (256). Moreover, the Pan-
American Association of Infectious Diseases reported for the same year of 2006 
rates of HA-MRSA ranging from 25% in Ecuador to more than 50% in Argentina, 
Bolívia and Brazil (117). 
In the Unites States’ nosocomial setting, the proportion of HA-MRSA has 
been increasing over time, from 2% of the total S. aureus isolates in 1974, to 22% 
in 1995, 60% in 2003 and 64% in 2004 (160, 227). However, between 2005 and 
2008, a population-based surveillance study reported a 9.4% and a 5.7% yearly 
decrease amongst hospital-onset invasive infections and heath-care associated 
community-onset infections, respectively. In the same study, a decrease of the 
hospital-onset infections (from 26% to 23%) was paralleled by an increase of the 
community-associated infections (from 17% to 19%) (152). 
In Europe, the 2008 report from the European Antimicrobial Resistance 
Surveillance System (EARSS) stated that 21% of the invasive S. aureus were 
identified as MRSA and the geographic prevalence varied considerably, from less 
than 1% in the north to over 50% in southern nations. While several countries from 
Central and Eastern Europe have been showing a decreasing trend in MRSA 
occurrence, Malta and Portugal reported still rising MRSA proportions of 56% and 
53%, respectively (83). Currently, a few highly epidemic MRSA clones are spread 
worldwide (Table 2). 
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3.3. Methicillin-resistant S. aureus (MRSA) in the community  
The notion that MRSA infections are confined to the nosocomial setting 
changed in the early 1990s with the increasing number of MRSA infections in the 
community, reported in otherwise healthy persons without established health care 
risk factors for MRSA. These infections were apparently acquired in the 
community and have been referred to as community acquired or community 
associated MRSA (CA-MRSA) infections (60). The first truly cases of CA-MRSA 
infection were reported among Aboriginal patients in remote communities in 
Western Australia during 1993 (316). Afterwards, in 1997-1999, four otherwise 
healthy children died from sepsis and necrotizing pneumonia due to CA-MRSA in 
Minnesota and North Dakota (39). Since then, CA-MRSA was recognized as a 
new public health treat.  
 
3.3.1. CA-MRSA definition and predisposing risks for infection 
The Center for Disease Control and Prevention (CDC) defined CA-MRSA 
infection as “any MRSA infection diagnosed for an outpatient or within 48 h of 
hospital admission”. The patient’s medical history cannot contain MRSA infection 
or colonization, hospitalization or residence in a long-term care facility during the 
previous year, hemodialysis or surgery. Furthermore, the patient should not carry 
indwelling catheters or percutaneous medical devices (74, 221). However, the 
previous criteria were not always met and a clear delineation between CA-MRSA 
and HA-MRSA is not straightforward and the CDC proposed the definition of 
“health care associated, community-onset” MRSA for infections in patients with 
history of health care exposure but originated in the community (161). Additionally, 
recent reports of CA-MRSA infections in health care settings have been bluring the 
boundaries of CA-MRSA definition (160, 162).    
Although skin and soft tissue infections (SSTI) such as furuncles, boils and 
abscesses are the most common clinical manifestations of CA-MRSA infections 
(39), some CA-MRSA have been associated to more invasive disease as 
folliculitis, cellulites, impetigo, pyomyositis and myositis, septic arthritis, 
osteomyelitis, sepsis, endocarditis, necrotizing pneumonia and necrotizing fasciitis 
(12, 205, 208, 249, 269).  
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Specific population groups are at higher risk of infection, namely children 
and young people (130), injecting and intranasal drug users (137), people of low 
socioeconomic status (42), athletic and competitive sport players (40), prison 
inmates and soldiers (41, 80), men who have sex with men (69), ethnically closed 
or semi-closed communities such as Pacific Islanders (38), rural American Indian 
and Southwester Alaska populations (112) and remote Aboriginal communities 
(316).  
CA-MRSA is highly transmitted by direct contact, usually skin-to-skin or to 
contaminated fomites (40, 206), therefore the CDC proposed the six C’s that 
promote CA-MRSA transmission: crowding, contact, cleanliness, compromised 
skin integrity, contaminated objects and exposure to antibiotic capsules (206).  
 
3.3.2. CA-MRSA genetic markers 
CA-MRSA isolates show some specific phenotypic and genotypic traits 
producing infections clinically and epidemiologically different from HA-MRSA. CA-
MRSA strains are mainly susceptible to non-beta-lactam antibiotics and have a 
faster growth rate (92, 240). In addition, these isolates frequently produce the PVL 
leukotoxin, carry SCCmec types IV, V or VII, and the accessory gene regulator 
genotype I or III (66, 246, 300, 313). The association of CA-MRSA to smaller 
SCCmec cassettes seems to offer fitness advantage in the community setting 
(240).  
PVL has been considered a genetic marker for CA-MRSA PVL-positive 
CA-MRSA isolates have been epidemiologically linked to recurrent and severe 
skin infections and necrotizing pneumonia (104, 180). However, reports of 
successful CA-MRSA PVL-negative clonal lineages have raised some controversy 
about the effective role of this leukotoxin gene as a specific marker for CA-MRSA 
(64, 238). 
In fact, some studies suggested that other factors than PVL are enrolled in 
pathogenicity (68, 111). Sequencing of the successful CA-MRSA USA300 genome 
revealed the presence of the mobile genetic element ACME that is believed to 
confer fitness advantage and enhanced transmissibility (71). Moreover, recently, 
Wang et al. identified -type phenol-soluble modulins (PSM) that contribute 
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significantly to the CA-MRSA ability to cause disease, associated to the production 
of gama-hemolysin (335). Bubeck Wardenburg at al. also showed that -toxin (or 
-hemolysin), a pore forming toxin that lyses many types of host cells (including 
leukocytes, but not neutrophils) is also involved in CA-MRSA disease and 
pathogenesis (32). 
 
3.3.3. Geographic distribution and clonal dynamics of CA-MRSA 
Successful PVL-positive CA-MRSA clones were initially associated to a 
continent specific geographic location (328). The European clone, ST80-IV was 
spread in Europe (328) while in the United States predominated the USA300 clone 
(ST8-IV), in addition to USA400 (ST1-IV) and USA1000 (ST59-IV) (248, 270). The 
Southwest Pacific clone (ST30-IV) was found in Asia and Oceania, and the 
Queensland clone (ST93-IV) existed in Oceania only (133, 330). However, this 
picture is smearing since nowadays five major PVL-positive CA-MRSA clones 
have disseminated worldwide (Figure 4) (313). 
While the European clone is currently found in Europe, North Africa, 
Singapore and in the Middle-East, USA300 became widely dispersed in the United 
States and Europe. In Japan, ST8-IV is the prevalent CA-MRSA clone, but is 
distinct from USA300 since it does not contain PVL or ACME. USA400, beyond 
the United States, is found in Europe, Australia and Asia. The Southwest Pacific 
clone is found in Australia, Europe, South America and South East Asia (China 
and Japan). USA1000 spread from the United States to the Asiatic continent, 
namely to Taiwan and China (60, 64, 313, 352).  
Notwithstanding the major CA-MRSA clonal lineages, some PVL-positive 
minor clones emerged in more restricted geographic areas, despite the 
Queensland clone (ST93-IV) that migrated from Oceania to Europe and clone 
ST377-V currently disseminated in Australia, France, Greece, Switzerland and 
The Netherlands (Figure 4) (66). Moreover, in Taiwan the prevalent ST59 clone is 
usually found associated to two SCCmec cassettes: types IV and V, but only 
ST59-V is mostly PVL positive (300). 
On the other hand, PVL-negative CA-MRSA are prevalent among the 
Australian ST1, the Japanese ST8-IV and the Korean ST72 clonal lineages, but 
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also found in minor clonal backgrounds as ST5 and ST129 in Australia and ST88 
in Africa (Figure 4) (64, 159, 238, 301).  
 
 
In the Northern European countries, were the prevalence of HA-MRSA is 
very low, CA-MRSA accounts for the increasing incidence of MRSA infections in 
both the nosocomial and community settings (89, 176). The emergence of CA-
MRSA infections among hospitalized patients with risk factors for MRSA infection 
suggests that the distinction between CA- and HA-MRSA is blurring (160, 162). 
 
3.4. Methicillin-susceptible S. aureus (MSSA) 
Until recently, MSSA was mostly regarded as the receptor of the SCCmec 
and predictive ancestor of epidemic MRSA lineages, which allied to the increased 
burden produced by the MRSA infections in nosocomial and community settings, 
relegated to a secondary plan the MSSA importance as a human pathogen.  
Global assessment of S. aureus carriage rates in different populations 
showed that the overwhelming majority of the isolates (ranging from 97% to 100%) 
are MSSA (28, 46, 192, 302). Moreover, recent studies report the increasing 
number of invasive disease caused by MSSA, often resulting in a fatal outcome, 
Figure 4. Global distribution and routes of dissemination of CA-MRSA lineages. Dotted lines 
indicate possible route of strains dissemination and color areas identify the extent of spread of 
major CA-MRSA clonal lineages infections, ST1 (green), ST8 (red), ST30 (blue), and ST80 (grey 
hatched). +, PVL-positive strains; −, PVL-negative strains; ±, combination of PVL-positive and 
PVL-negative strains. Reprinted with permission from (64). 
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namely in children (110, 207, 219, 253, 275). Data also showed that MSSA can 
persist for long periods in the ICUs (107).  
Community acquired MSSA (CA-MSSA) infections associated to SSTI 
have been also reported (218, 309). In two pediatric hospitals in the United States, 
the number of cases of CA-MSSA ranged from 25% to 45% of the total CA-S. 
aureus infections and CA-MSSA were more likely to be associated with invasive 
infections than CA-MRSA (211, 218). 
Although methicillin resistance was associated to high mortality rates, 
increased length of hospitalization and hospital costs (54, 260), several studies 
showed an identical outcome for MSSA infections and therefore virulence was not 
correlated with resistance (207, 219, 311). In addition, to date, there is no 
compelling evidence that MRSA are more virulent than MSSA isolates (277).  
The pathogenicity of MSSA strains is believed to be associated to the 
presence of a variety of virulence factors often also carried by MRSA (155). Of 
major interest is the increasing prevalence of MSSA isolates carrying PVL (217, 
262). A recent study on the global distribution of MSSA isolates showed that most 
predominant genetic backgrounds of PVL-positive MSSA are pandemic and are 
phylogenetically related to CA-MRSA (262). In addition, infections caused by CA-
MRSA or CA-MSSA present similar epidemiologic and clinical characteristics (130, 
311) reinforcing the idea of MSSA as a genetic reservoir of MRSA.  
Despite the wide genetic diversity among the MSSA population, some 
major lineages corresponding to the genetic background of the major MRSA 
clones were described worldwide, and in certain cases co-existed in the hospital 
and community (81, 113, 119). Some S. aureus lineages were found to be 
associated specifically to methicillin susceptibility, as the case of the successful 
ST121. ST121 frequently carries PVL and was already present in the early MSSA 
isolates from Denmark (106, 217). This MSSA lineage has been isolated in 
geographic distinct locations associated to both nasal carriage and disease, 
namely SSTI in children (15, 262). Of major concern was the recent report of 
methicillin resistance in three ST121 isolates in pediatric communities in China 
and Cambodia: one isolate, PVL negative responsible for staphylococcal scalded 
skin syndrome and two PVL positive, SCCmec type V isolates responsible for 
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osteomyelitis and soft tissue abscess (45, 85). Moreover, additional ST121 MRSA 
isolates were reported in the United States (248), which means that the S. aureus 
epidemiology is dynamic and under continuous evolution. 
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ABSTRACT 
 
In order to understand the origins of the dominant methicillin-resistant 
Staphylococcus aureus (MRSA) clones in Portuguese hospitals, we compared the 
genetic backgrounds of nosocomial MRSA with methicillin-susceptible S. aureus 
(MSSA) isolates from the same hospitals (n = 155) and from the community (n = 
157) where they were located. Pulsed-field gel electrophoresis, spa typing, 
multilocus sequence typing, and agr type analysis revealed that the genetic 
backgrounds correspondent to the dominant MRSA clones in Portuguese hospitals 
during the last 15 years (Iberian ST247, Brazilian ST239, and EMRSA-15 ST22) 
were scarcely or not found among the present MSSA collection. The four major 
MSSA clones encountered (A-ST30, B-ST34, C-ST5, and H-ST45) correspond, or 
are very similar, to the background of other international MRSA pandemic clones, 
i.e., EMRSA-16, New York/Japan, Pediatric, and Berlin clones. However, with the 
exception of the Pediatric clone, none of these MRSA clones has been detected in 
Portugal. Our findings suggest the three major MRSA clones identified in 
Portuguese hospitals have not originated from the introduction of SCCmec into 
dominant MSSA backgrounds present in the Portuguese nosocomial or community 
environment but were probably imported from abroad. In contrast, the MRSA 
Pediatric clone might have originated in our country by the acquisition of SCCmec 
type IV into MSSA clone C. Furthermore, we provide evidence that the introduction 
of SCCmec into sensitive clones is most likely a relatively infrequent event that 
seems to depend not exclusively on the presence of a successful MSSA lineage. 
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INTRODUCTION 
 
Staphylococcus aureus is a major human pathogen capable of causing a 
wide range of infections of different severity, such as skin abscesses and wound 
infections, osteomyelitis, endocarditis, pneumonia, meningitis, bacteremia, and 
toxic shock syndrome. Gradually, S. aureus has evolved resistance to all classes 
of antibiotics (35). Methicillin-resistant S. aureus (MRSA) strains have emerged by 
acquisition of a mobile genetic element called staphylococcal chromosomal 
cassette (SCC) mec, which carries the mecA gene. Five different types of 
SCCmec (types I to V), which differ in size and structure, have been described for 
S. aureus (11, 12, 17). 
It is now clear that methicillin resistance has emerged by the introduction of 
SCCmec into at least five phylogenetically distinct successful methicillin-
susceptible S. aureus (MSSA) lineages (5, 27) resulting in a relatively small 
number of pandemic MRSA clones spread worldwide, namely the Iberian (ST247-
SCCmec IA), Brazilian (ST239-III), New York/ Japan (ST5-II), Pediatric (ST5-IV), 
EMRSA-16 (ST36-II), EMRSA-15 (ST22-IV), and Berlin (ST45-IV) clones (1, 7, 
26). On the other hand, there is evidence that resistance has been transferred to 
S. aureus on more than five occasions, as some lineages have acquired different 
structural types of SCCmec (7, 27). 
The nosocomial prevalence of MRSA in Portugal was estimated as close to 
50% between 1993 and 1997 (19, 20) and 47.5% in 2003 (J. Melo-Cristino, 
personal communication). The European Antimicrobial Resistance Surveillance 
System reported an MRSA prevalence in Portugal in blood isolates of around 39% 
in 2002, which is one of the highest in Europe (32). During the last 15 years there 
were successive waves of dominant MRSA clones in Portuguese hospitals: (i) in 
1992 and 1993, the Iberian clone replaced the Portuguese clone (ST239-III 
variant) widely spread in the country in the mid-1980s and early 1990s; (ii) in 1994 
and 1995, the Brazilian clone was introduced, and its representation has rapidly 
increased since then; and (iii) in 2001, clone EMRSA-15 emerged and is 
nowadays becoming the dominant clone in the hospital setting (1). In addition, the 
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Pediatric clone was described for the first time in a pediatric hospital in Lisbon in 
coexistence with the Iberian clone between 1992 and 1996 (30). 
Although reports of community-acquired MRSA (CA-MRSA) are increasing 
worldwide, the single study evaluating the prevalence of MRSA among the 
Portuguese community revealed a low carriage rate (<1%) (29). In that study, the 
two out of seven CA-MRSA isolates not health-care associated produced 
enterotoxins A and B and were both ST82. 
In order to understand the origins of the nosocomial major MRSA clones 
present in Portuguese hospitals, we compared the genetic background of MRSA 
collected in different periods from three hospitals located in Lisbon and Oporto 
with MSSA isolates from those hospitals and from the community where they were 
located. 
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MATERIAL and METHODS 
 
Bacterial strains 
A total of 312 MSSA isolates divided into nosocomial (n = 155) and 
community (n = 157) collections were included in the present study. 
Nosocomial isolates were collected from single patients at three 
Portuguese hospitals: Hospital Geral de Santo António (49 HSA isolates) and 
Instituto Português de Oncologia do Porto (39 IPOP isolates), both located in 
Oporto, and Hospital de São José (53 HSJ isolates) located in Lisbon. The three 
nosocomial subcollections included invasive and carriage isolates that were 
recovered in different periods corresponding to the successive waves of dominant 
MRSA clones in Portuguese hospitals, namely, 1992–1993 (introduction of the 
Iberian clone), 1995 (introduction of the Brazilian clone), and 2001 (emergence of 
clone EMRSA-15). HSA isolates were collected between December 1992 and 
February 1993, the HSJ isolates were collected between September and 
November 1995 (49 isolates), and one isolate in July 1996 and three isolates 
between January and February 1997 and the IPOP isolates were collected 
between January and December 2001. Also included in the nosocomial collection 
were 14 carriage isolates obtained between June and September 2003 from 
health care workers at Hospital São Francisco Xavier (Lisbon) (BOH isolates). 
Community isolates were obtained from different subcollections. One 
collection originated from a community-based study on the prevalence of S. 
aureus colonizing healthy young Portuguese populations including children 
attending day care centers and draftees (29). From 1,331 children aged 0 to 5 
years old attending 16 day care centers located in different geographical areas of 
Lisbon, nasopharyngeal samples were obtained between February and March 
1996 and 1997. S. aureus was isolated from 210 children, from which 64 MSSA 
(DCC isolates) representing several day care centers were randomly selected. 
From 823 draftees, males and females aged 17 to 22 years old, nasal swab 
cultures were obtained between May and June 1996 and between October and 
November 1997. S. aureus was isolated from 280 draftees, out of which 77 were 
originally from Lisbon or Oporto and were all included in the present study 
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(draftees isolates). Finally, 16 isolates were obtained from nasal, pharyngeal, or 
nasopharyngeal swabs of children and adult patients who attended an outpatient 
clinic in Oporto, Instituto Nacional Ricardo Jorge (RJ isolates) (1992 and 1993). 
 
DNA isolation, detection of mecA and PVL genes, and determination of agr 
type 
Chromosomal DNA was extracted by incubating cells grown overnight in a 
solid medium in 20 µl of TE 1x (10 mM Tris, 1 mM EDTA, pH 8) with lysostaphin at 
0.5 mg/ml for the lysis step for 30 min, followed by a denaturation step of 15 min at 
95°C. The mixture was harvested at 13,000 rpm for 5  min, and 2 µl of the 
supernatant was used as DNA template in the PCRs. The presence of the mecA 
and Panton-Valentine leukocidin (PVL) genes was determined by PCR as 
described previously (16, 22). The accessory gene regulator (agr) group was 
determined by a multiplex PCR according to the methods of Jarraud et al. (13). 
 
Molecular typing  
Pulsed-field gel electrophoresis (PFGE) was performed as described by 
Chung et al. (3) on all 312 isolates. The resulting band patterns were analyzed by 
visual inspection followed by the analysis with the Bionumerics software (version 
4.0; Applied Maths, Gent, Belgium) for relatedness evaluation. Dendrograms were 
generated from similarity matrixes calculated with the Jaccard coefficient, and 
patterns were clustered by unweighted pair group method with averages using an 
optimization of 0.25% and a tolerance of 1.0%. 
Nosocomial IPOP and HSA isolates, community DCC isolates, and all 
remaining isolates that presented a PFGE pattern not observed among the 
previous collections were further characterized by spa typing (14, 31) (total, 171 
isolates). As done previously (14, 31), spa types with similar repeat profiles were 
grouped together as part of a same lineage (spa lineage), which was identified in 
the present study by capital letters. Multilocus sequence typing (MLST) was 
performed in representatives of each PFGE type/spa lineage as described 
previously (6), with the exception that primer arcCF2 (5’-CCT TTA TTT GAT TCA 
CCA GCG-3’) (4) was used. For spa typing and MLST, PCR products were 
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purified with a Wizard PCR Preps purification system (Promega, Madison, WI) and 
used as templates for sequencing of both strands at Macrogen, Seoul, South 
Korea. MLST alleles and sequence types (STs) were identified using the MLST 
database (http://www.mlst.net) hosted by Imperial College. 
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RESULTS 
 
Genetic diversity 
A total of 20 different PFGE patterns were found among the 312 MSSA 
isolates. Further characterization by spa typing distributed the isolates into 72 spa 
types. Isolates showing related spa types could be grouped in 19 spa lineages 
showing congruence between clustering by PFGE and spa typing, with the 
exception of spa lineages B and P, which were associated with two PFGE patterns 
each, B and Q and P and L, respectively. PFGE analysis versus spa typing 
analysis is depicted in Figure 1. MLST performed on representatives of each 
PFGE pattern and/or spa lineage identified 20 STs, confirming the existence of 20 
distinct clones among the 312 MSSA isolates. Application of the eBURST 
algorithm to the 20 STs recognized 17 groups, which were defined as clusters of 
closely related STs in which a single difference in the allelic profile was tolerated 
and therefore considered to belong to 17 clonal complexes (CCs) (8). Figure 2 
illustrates the molecular characterization of strains representing the 20 clonal 
types defined by PFGE, spa typing, and MLST as well as the CC assignment 
generated by eBURST. Interestingly, some clones belonging to different CCs 
presented a higher PFGE similarity than clones included in the same CC. For 
instance, clone PFGE L-ST188 showed a PFGE similarity of 63.2% with clone 
PFGE Y-ST106 but only 55.3% with clone PFGE M-ST573 (Figure 2). These 
discrepancies may be due to the different spectra of changes detected by the two 
typing methods. PFGE examines both nucleotide changes that are in specific 
restriction sites and changes that involve large insertions or deletions of DNA in 
the whole genome, while MLST detects nucleotide changes only within the seven 
amplified housekeeping gene fragments. Moreover, to complicate the 
interpretation, bands of the same size are assumed to be identical in PFGE and 
unrelated fragments that are indistinguishable by size can occur by chance, 
especially as the genetic distance between strains increases. Despite the fact that 
in one case in the present study the PFGE and allelic profile similarities were not 
connected, it did not constitute an issue for typing, since the isolates were 
sufficiently unrelated and classified into different clones. 
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Despite the high genetic variability, over half (61%) of the isolates belonged 
to four major clonal types (represented by more than 10% of the isolates) and 
three CCs: clone A (PFGE type A, spa type 33 or related, ST30, CC30), clone B 
(PFGE type B, spa type 497 or related, ST34, CC30), clone C (PFGE type C, spa 
type 2 or related, ST5, CC5), and clone H (PFGE type H, spa type 136 or related, 
ST45, CC45). 
 
Hospital versus community MSSA isolates 
Sixteen out of 20 clones, including the four major clones, A, B, C, and H, 
were present in both nosocomial and community settings (Figure 1). However, 
some of the major clones were clearly represented by different proportions: clone 
C was overrepresented in the hospital setting (chi homogeneous square test, p = 
0.039), and clone B contained proportionally more isolates from the community 
(chi homogeneous square test, p < 0.0001). 
Among the 155 nosocomial isolates, four major clones could be identified, 
clones A (n = 34, 22%), C (n = 22, 14%), and H and K (n = 17 each, 11%), 
whereas clone B (n = 49, 32%) followed by clone A (n = 37, 24%) embraced 86 
out of the 157 (55%) community isolates (Figure 3). Clone K was characterized by 
PFGE type K, spa type 21 or related, and ST15. The clonal distribution among the 
nosocomial isolates varied according to the hospital: clone A was predominant in 
both hospitals in Oporto, while clones C and K were the principal clones in hospital 
HSJ located in Lisbon. A relatively large number of genetic backgrounds (n = 7) 
was found among the 14 isolates recovered from health care workers from another 
hospital in Lisbon, and the major clones included only three isolates each. 
Although the community isolates belonged to two major clones, the 
different populations were not evenly distributed: children attending day care 
centers more often carried strains from clone B (n = 32, 50%) in comparison with 
draftees (n = 14, 18%) (chi homogeneous square test, p = 0.001). No significant 
difference was found in the clonal distribution of community isolates from Oporto 
versus Lisbon (data not shown). The isolates recovered from patients attending 
the outpatient clinic in Oporto (RJ isolates) were distributed into several clonal 
types, as happened with the nosocomial BOH isolates, rather than showing a 
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significant major clone, probably due to the reduced number of isolates 
representing these subcollections. 
A considerable number of minor clones, each harboring a maximum of 5% 
of all isolates, was found among both the hospital and community isolates. Minor 
clones reached 30 and 21% of all hospital and community isolates, respectively 
(Figure 3). 
 
MSSA versus MRSA background 
Comparing the genetic backgrounds of the major MSSA clones (A, B, C, 
and H) with international pandemic MRSA lineages, including the main MRSA 
clones present in Portugal during the last 15 years, revealed that clones A and B 
correspond to slight variations (MLST single and double locus variants, 
respectively) of the genetic background of MRSA clone EMRSA-16 (ST36, 
SCCmec type II), clone C corresponds to the background of the New York/Japan 
(ST5-II) and Pediatric (ST5-IV) clones, and clone H corresponds to the 
background of the Berlin clone (ST45-IV). In addition, two minor MSSA clones, J 
(6% of all isolates) and T (one isolate), are related to two additional widely spread 
MRSA clones. Clone J (PFGE J, spa type 1 or related, ST8) corresponds to a 
single and a double locus variant of the Brazilian (ST239-III) and Iberian (ST247-
IA) clones, respectively, and clone T corresponds to clone EMRSA-15 (ST22-IV). 
On the other hand, eBURST analysis showed that 67% of all isolates belonged to 
one of the five major CCs described for MRSA, i.e., CC30, CC5, CC45, CC8, and 
CC22 (Figure 1, right panel). 
A dendrogram representing the clustering of the 20 MSSA PFGE types 
together with representatives of the seven major international MRSA clones 
(Iberian, Brazilian, New York/ Japan, Pediatric, EMRSA-15, EMRSA-16, and 
Berlin) confirmed the relatedness between MSSA found in the present study and 
MRSA pandemic clones (Figure 2). 
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Figure 1. PFGE analysis versus spa type analysis of MSSA strains. Distribution of the 312 MSSA 
isolates into 20 PFGE types is shown. The area of each circle is proportional to the number of 
isolates included in the PFGE type, and white and gray areas correspond to nosocomial and 
community isolates, respectively. Subtypes are indicated for each PFGE type as well as the 
corresponding ST. spa type data, including spa type, spa profile, and spa lineage, are shown for 171 
MSSA strains. PFGE types A, B, C, J, H, and T (left side of the figure) correspond to 67% of the total 
MSSA isolates and belong to the five major MRSA CCs 
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mecA and PVL gene amplification and agr specificity group 
The presence of the mecA gene was determined by PCR amplification, and 
only mecA-negative isolates were included in the present study. We have 
assessed the prevalence of the PVL gene in isolates representing all clonal types 
from both the community and hospital populations. Two of 86 isolates tested were 
PVL-positive MSSA strains. These two isolates belonged to clone F (PFGE F, spa 
type 441, ST121). Interestingly, among the 17 strains belonging to clone F (9 from 
the hospital and 8 from the community), only 2 isolates harbored the PVL gene. 
These two isolates were found in the community among carriage isolates from a 
child attending a day care center and an Air Force draftee. 
The determination of the agr specificity group for representatives of the 20 
MSSA clones revealed that half belonged to agr type 1. The remaining clones 
belonged to agr type 2 (seven clones) and type 3 (three clones) (Figure 2). 
Although agr type 3 included three clonal types only, it was associated with the 
major clones A and B as well as clone G and therefore har-bored 44% of all MSSA 
isolates. Interestingly, the three clonal types belonging to CC1 showed three 
different agr types (Figure 2). 
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Figure 3. Clonal type distribution. Numbers underlined represent the major clonal types in each 
collection or subcollection. Minor clones (clones harboring a maximum of 5% of all isolates) were 
classified as “other” clonal types and include STs 1, 9, 10, 12, 20, 22, 25, 97, 106, 121, 188, 573, 
580, and 615 
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DISCUSSION 
 
The incidence of MRSA in Portuguese hospitals is one of the highest in 
Europe. We previously drew a temporal scheme for the evolution of MRSA clonal 
types in Portuguese hospitals (1). In the present study, the population structure of 
Portuguese MSSA, isolated from clinical and nonclinical isolates, has been 
determined. Among the nosocomial isolates four subcollections were used, 
corresponding to different hospitals and periods. The community subcollections 
were obtained from the geographical area served by the hospitals from children 
attending day care centers (<5 years) and Air Force draftees (17 to 22 years) with 
nasal carriage of S. aureus and from a small group of patients attending an 
outpatient clinic. 
PFGE, spa typing, and MLST analysis distributed the 312 isolates into 20 
clonal types. A search in the MLST database (http://www.mlst.net/) revealed that 
15 out of the 20 STs identified in the present study are exclusively or mostly 
associated with MSSA isolates, evidencing a high genetic diversity among the 
MSSA population, as found by others (2, 6). Despite the high diversity, eBURST, a 
computer algorithm used to solve population structures based on MLST data (8), 
grouped 67% of the MSSA isolates, including clinical and carriage isolates, into 
four major clonal complexes (CC30, CC5, CC45, and CC8) corresponding to four 
of the five major MRSA clusters spread worldwide (7, 27, 28, 33). On the other 
hand, the main STs found in the present study have been found in other countries 
showing MSSA geographical spread. These observations support the evidence 
that the same main MSSA lineages seem to be disseminated in different regions 
of the world and that pandemic MRSA originated by the introduction of SCCmec 
into these most successful lineages. The fact that clinical and carriage strains as 
well as MSSA and MRSA isolates fall into the same main clusters is in agreement 
with Melles et al., who proposed that essentially any S. aureus genotype carried 
by humans can transform into a life-threatening human pathogen (18). 
In comparison with the scenario observed for nosocomial Portuguese 
MRSA clones, the representation of the major MSSA clones in Portuguese 
hospitals appears to be more stable over time. Whether the slight differences in 
the clonal distribution between hospitals are due to the different sampling 
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moments or to the different geographic location of the hospitals is currently 
unclear. Comparison of the genetic backgrounds of the MSSA clones found in the 
present study with the backgrounds of the major international pandemic MRSA 
lineages revealed some overlapping. The major MSSA clones, A-ST30, B-ST34, 
C-ST5, and H-ST45, correspond or show a high degree of similarity in PFGE, spa 
type, and MLST to EMRSA-16 (ST36), the New York/ Japan or Pediatric clones 
(ST5), and the Berlin clone (ST45). 
However, to the best of our knowledge, none of these clones with the 
exception of the Pediatric MRSA has been reported among nosocomial 
Portuguese MRSA isolates recovered between 1990 and 2001. The Pediatric 
MRSA clone was first described in a pediatric Portuguese hospital (30) and could 
have originated in our country by the introduction of a variant of SCCmec type IV 
(25) into MSSA clone C. We cannot rule out the hypothesis that the remaining 
main MSSA clones will not become major MRSA clones in Portugal in the future. 
Interestingly, the genetic backgrounds corresponding to the three dominant 
MRSA clones in Portuguese hospitals during the last 15 years (Iberian-ST247, 
Brazilian-ST239, and EMRSA-15-ST22) or their ancestral genotypes were not 
detected or scarcely found among the present MSSA collection, clones J-ST8 
(ancestral of ST239 and ST247) and T-ST22. Moreover, in the present collection 
the prevalence of the MSSA clone J increased between 1992 and 2001, which 
may indicate that most MSSA isolates belonging to this clone were probably 
isolated after the introduction of the Iberian clone (1992 to 1993) in Portuguese 
hospitals. These observations suggest the Iberian, Brazilian, and EMRSA-15 
MRSA clones have not originated from the introduction of SCCmec into dominant 
MSSA backgrounds present in the Portuguese nosocomial or community 
environment but were probably imported from abroad. 
The fact that there is no congruence between the genetic backgrounds of 
the major MSSA and MRSA clones within a population indicates that the presence 
of a successful MSSA lineage is not the sole factor necessary for SCCmec 
acquisition or for the success of an MRSA clone. Moreover, the introduction of 
SCCmec into sensitive clones seems to be a relatively infrequent event compared 
to the geographical spread of MRSA clones. 
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CA-MRSA isolates are reported to differ genetically from hospital-acquired 
MRSA (23). In contrast, community-acquired MSSA isolates are no different than 
hospital-acquired MSSA, as reported by Enright et al. (6). In the present study, 
clone A was overrepresented in the hospital setting, whereas clone B was the 
main clone in the community collection. Nevertheless, clone B was only 
predominant among isolates collected from children attending day care centers 
(50%). The different age categories may be an explanation for the observed 
difference. Moreover, confined environments such as day care centers, where 
children have close contacts, facilitate the easy spread of bacteria and therefore a 
high clonal expansion (15). Nevertheless, we cannot exclude the hypothesis that 
the restricted number of isolates is not a confounding factor. 
PFGE and MLST analysis indicated distinct genetic backgrounds for CA-
MRSA associated with each geographic origin, namely ST80 in Europe, STs 1, 8, 
and 59 in the United States, and ST30 in Oceania (33). Although in the present 
study we have not detected any MSSA sharing the background of the major 
European CA-MRSA clone, ST80, we detected MSSA isolates of STs 1, 8, and 30. 
ST1 and ST8 represented minor clones, but ST30, which was initially described 
among CA-MRSA in Australia and recently reported to have spread in the 
community in Europe both in The Netherlands and in Latvia (21, 34), 
corresponded to the main clone found in the present study. In addition, the 
background of the only two true CA-MRSA strains described so far in Portugal (29) 
was not found among the MSSA nasal carriage population in our work that in part 
overlaps the S. aureus isolates from the Sa-Leao et al. study (29). Apparently, as 
happened with the major hospital-acquired MRSA, we anticipate CA-MRSA ST82 
was probably imported from abroad. 
PVL is a toxin associated with S. aureus strains causing severe skin 
infections (16) and with highly virulent necrotizing pneumonia in young patients 
(9). We assessed the presence of PVL genes in representatives of each MSSA 
clonal type. The two single PVL-positive isolates belonged to clone F and were 
recovered in the community from one child and one draftee. The reason why only 
2 out of the 17 clone F isolates harbored PVL may be due to the fact that PVL 
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determinants are carried by different temperate phages (24) and therefore should 
have integrated independently in the two isolates with background F. 
As a further contribution to the genotypic characterization of the MSSA 
isolates, we determined the agr sequence types for representatives of each MSSA 
clone. The four successive major MRSA clones present in Portuguese hospitals 
during the last 15 years belonged to the same agr group 1 (10). However, the 
major MSSA and MRSA clones coexisting in the same hospital do not belong to 
the same agr type. It would be interesting to clarify the agr-associated interference 
between MSSA and MRSA. In addition, the fact that the three clonal types 
belonging to CC1 showed different agr types is intriguing and needs further 
investigation, since previous studies have linked the genetic background of S. 
aureus isolates to the agr type (10, 13). 
In summary, the major hospital-acquired MRSA clones as well as the rare 
cases of CA-MRSA in Portugal are not related to the MSSA circulating in the 
nosocomial or the community setting in the country, which provides supportive 
evidence that SCCmec moves rarely and that pandemic MRSA spreads in-
dependently of the local MSSA clones. 
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ABSTRACT 
 
In order to evaluate the incidence of community-associated methicillin-
resistant Staphylococcus aureus (CA-MRSA) in Portugal, we analyzed a collection 
of 38 S. aureus isolates recovered from 30 children attending the pediatric 
emergency department of a central hospital in Lisbon due to skin and soft tissue 
infections. Molecular characterization identified seven clonal lineages among the 
35 methicillin-susceptible S. aureus (MSSA) isolates, of which the major lineage 
PFGE A/t159/ST121 included 63% of the isolates. The three MRSA isolates 
belonged to the Pediatric clone PFGE D/t535/ ST5-IV (n = 2) and to the European 
CA-MRSA clone PFGE G/ t044/ ST80-IVc. All isolates harbored several virulence 
factors, namely, leukocidins. Panton-Valentine leukocidin (PVL) was produced by 
isolates from five MSSA lineages and by the ST80 MRSA. Of interest, this is the 
first reported isolation of CA-MRSA ST80 in Portugal. 
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RESULTS and DISCUSSION 
 
Methicillin-resistant Staphylococcus aureus (MRSA) infections in the 
community have been increasing worldwide and are mainly reported as skin and 
soft tissue infections (SSTI) in otherwise healthy young individuals (18, 29, 32). 
The Centers for Disease Control and Prevention (CDC) consider a community- 
associated MRSA (CA-MRSA) infection when the patient has no previous history 
of MRSA infection or colonization, surgery, dialysis, hospitalization, residence in a 
long-term care facility within the year before infection, presence of a percutaneous 
device or indwelling catheter or hospitalization >48 h before MRSA cultures (6, 
13). 
CA-MRSA isolates differ phenotypically and genotypically from hospital-
associated (HA-) MRSA, namely, in its non-multiresistant antibiotic patterns, 
enhanced virulent gene content, including the acquisition of the necrotizing 
Panton-Valentine leukocidin (PVL) genes or the expression of α-type phenol-
soluble modulins (PSMs) (18, 29). The staphylococcal cassette chromosome mec 
(SCCmec) type and the accessory gene regulator (agr) alleles are also 
differentially distributed: SCCmec types IV or V and agr type III are more 
commonly present in CA-MRSA, while SCCmec types I-III and agr type II are more 
typical of HA-MRSA (29). In contrast, community-acquired methicillin-susceptible 
S. aureus (CA-MSSA) isolates, responsible for a significant number of mild SSTI, 
do not differ from HA-MSSA (4, 28).  
Although reports of CA-MRSA prevalence are increasing worldwide, there 
is no description of the actual scenario in Portugal, a country with >50% HA-MRSA 
infection, currently the highest in Europe (14). Previous studies dated from 1996 to 
2009, including isolates from nasal swabs of young healthy individuals and 
nasopharyngeal swabs of children attending day care centers, reported an MRSA 
prevalence lower than 0.25% in the Portuguese healthy community (0.24% in 
1996-1998 and 0.13% in 2006-2009) (4, 34, 37).  
It is conceivable that the incidence of CA-MRSA in Portugal is 
underestimated partially because skin infection samples are not routinely cultured.  
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The aim of the present study was to assess the prevalence and molecular 
characterization of S. aureus in children attending the pediatric emergency 
department of a central hospital due to SSTI. 
 
The pediatric emergency department of Hospital Fernando Fonseca, a 
large tertiary-care hospital (670 beds), is the second largest pediatric urgency unit 
in the urban area of Lisbon, Portugal, and receives approximately 180 children per 
day. Between August 2005 and October 2006, all children attending this unit due 
to SSTI were enrolled in the study. Samples were recovered by swabbing the 
largest area of skin infection or wounds with spontaneous or surgical drainage, or 
in case of severe SSTI from hemoculture. Whenever possible, nasal swabs were 
also performed. A questionnaire was filled in order to collect data on basic socio-
demographic patient information, risk factors associated with skin infection, and 
description of the infection. 
S. aureus isolates were first identified by conventional coagulase and 
catalase tests. Additional identification and susceptibility testing with a panel of 10 
antibiotics (Figure 1) were performed by the semi-automatic VITEK2 system 
(bioMérieux, SA, France) and the disk diffusion method with D-test for clindamycin 
(9). All isolates were tested by polymerase chain reaction (PCR) for the presence 
of mecA (30) and also characterized by pulsed-field gel electrophoresis (PFGE) 
(8). The resulting SmaI patterns were analyzed by both visual inspection and 
automatically with BioNumerics software version 4.61 (Applied Maths, Sint-
Martens-Latem, Belgium) (16, 23). Characterization by spa typing, multilocus 
sequence typing (MLST), and the agr allele type were performed on representative 
isolates of each PFGE type (1, 10, 20). The SCCmec was typed for all MRSA 
isolates (24, 25). Specific staphylococcal virulence determinants, including 
leukocidins, hemolysins, and super-antigenic toxins of each isolate, were 
determined by PCR (27, 38) (Figure 2). Categorical variables were compared 
using the χ2 or Fisher’s exact test when appropriated, considering p values of 
0.05 being statistically significant, and odds ratio (OD) estimates using the SPSS 
software package version 11.5 (SPSS Inc., Chicago, IL, USA). 
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During the 15-month study period, 30 (73.2%) out of the 41 children who 
attended the emergency department due to SSTI were infected by S. aureus. The 
major clinical infection presentations were cutaneous abscesses (n = 12, 40%) 
and cellulitis (n = 10, 33.33%). A total of 38 isolates were recovered, of which 
three (7.9%) were MRSA. Although eight clonal types (Table 1) were identified 
among the isolates, 63% (n = 19) belonged to a single type: PFGE A, spa type 
t159, sequence type (ST) 121, agr type IV. The ST121 lineage was also the 
predominant lineage found in MSSA isolates through Europe and Russia (5, 33, 
39) and an identical scenario has been reported among Asiatic children in both 
carriage and disease isolates, and frequently associated to PVL. Of major concern 
was the local emergence of methicillin resistance in ST121 isolates in these 
pediatric communities: one MRSA isolate, PVL-negative responsible for 
staphylococcal scalded skin syndrome in China and two MRSA, PVL-positive, 
SCCmec type V isolates responsible for osteomyelitis and soft tissue abscess, in 
Cambodia (7, 15). Moreover, single ST121 MRSA isolates were reported in China 
(http://saureus.mlst.net/) and the United States (31).  
Table 1. Molecular characterization and clinical presentation of the clonal lineages found among 
the 38 Staphylococcus aureus isolates recovered during the 15-month study period. 
MLSTb No. of 
isolates 
PFGE 
types     
(no. of 
subtypes) 
spa 
typea 
ST CC 
SCCmec 
type PVL 
agr 
type 
Related 
clonec 
Clinical 
presentation       
(no. of isolates) 
19 A (8) t159 121 121 MSSA - IV  Cellulitis (9), 
cutaneous abscess 
(3), impetigo (1), 
wound (1), nasal 
swab (5) 
6 B (4) t318 30 30 MSSA + III Southwest 
Pacific 
Cutaneous abscess 
(6) 
3 C (3) t576 45 45 MSSA - I Berlin Cutaneous abscess 
(2), cellulitis (1) 
2 D (1)  t535  5 5  IVc - II Pediatric Impetigo (1), 
bacteremia (1) 
1 D (1) t311 5 5 MSSA + II Pediatric Cutaneous abscess 
(1) 
3 E (2) t355 152 152 MSSA + I  Cutaneous abscess 
(1), cellulitis (1), 
adenophlegmon (1) 
2 F (2) t127 1 1 MSSA + III  Cutaneous abscess 
(1), pustule (1) 
1 G t044 80 80 IVc + III European Pustule (1) 
1 H t084 582 15 MSSA - IV  Impetigo (1) 
a Ridom nomenclature (http://spaserver.ridom.de/).  
b MLST – multilocus sequence typing, ST – sequence type; CC – clonal complex, defined by eBURST v3 assessed on 12 
April 2010. 
d Common designation of community - or hospital-associated MRSA or MSSA clones. 
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Retrospectively, all STs found in the present study (with the exception of 
ST152) have already been described in carriage among the Portuguese 
community in 1996, although with a different prevalence (4). Despite the small size 
of the collection, the major CA-MSSA clones described in Europe, ST1, ST5, 
ST30, and ST45 (19) were found in the pediatric Portuguese community (Table 1). 
Moreover, all clonal lineages, with the exception of PFGE H/t084/ST582/agrIV, 
were recently reported among a geographical and temporal diverse collection of 
211 PVL-positive CA-MSSA (33). ST1/t127, the sixth most frequent type among 
MSSA isolates recovered in 26 European countries (19), was also found in the 
present collection. In the same work, Grundmann et al. showed that European 
MSSA isolates belonged to more diverse genetic backgrounds and have a wide 
geographical distribution compared to MRSA, which have a predominantly 
regional spread of a few pandemic clones (19).  
A non-multiresistant antibiotic pattern is common in the present collection 
(Figure 1). Clindamycin and trimethoprim-sulfamethoxazole (SXT) are rational 
empiric choices for mild-to-moderate CA-MRSA infections (36). However, a 
positive D-test result in erythromycin-resistant isolates indicates that clindamycin 
resistance may emerge during therapy and, therefore, should not be prescribed 
(21, 22). The detection of clindamycin inducible resistance in all erythromycin-
resistant isolates (n = 10) raises some concerns about the antibiotherapy available 
for the treatment of children, namely, since resistance to STX was found in three 
isolates from children with no previous hospitalization.  
As far as we know, the single tetracycline-resistant strain, HFF189, was the 
first MRSA ST80 (known as the European CA-MRSA clone), PVL-positive 
described in Portugal. Nevertheless, since it was recovered from a periumbilical 
exudate of a neonate, the connection to the nosocomial setting could not be 
discarded, as ST80 PVL-positive isolates were already described as nosocomial 
isolates in the late 1990s (3). Regular surveillance studies in Portuguese hospitals 
(2), together with the present study seem to indicate that CA-MRSA-ST80 is not 
widely spread in Portugal in contrast to what was described in several other 
European countries (17, 38). 
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Interestingly, the remaining two MRSA isolates, PVL-negative, showed 
ST5-SCCmec type IV typical of the Pediatric clone, described for the first time in a 
Portuguese pediatric hospital (35). The spread in the community of a typical HA-
MRSA lineage raises some concern about the changing epidemiology of MRSA, 
and the blurring of the boundaries between the hospital and the community. 
All of the isolates presented virulence determinants, namely, leukocidins 
(Figure 2). Recently, a mechanism of PVL-induced acute lung injury and lung 
inflammation in rabbit models resolved the controversy about the role of PVL as a 
key factor in S. aureus infection (12). In our study, isolates producing PVL or γ-
hemolysin were mainly associated to cutaneous abscesses (p = 0.003 and p = 
0.000, respectively), as has already been reported in recent studies in children 
infections (11, 40). Conversely, the production of β-hemolysin, ETA, or ETB 
seemed to be associated with cellulitis (p = 0.010, p = 0.003 and p = 0.038, 
respectively) (data not shown). 
No significant positive association was found between socio-demographic 
data or possible risk factors for S. aureus infection, possibly due to the small 
dimension of the collection (data not shown). 
Figure 1. Antimicrobial susceptibility of the 38 S. aureus isolates to a panel of 10 
antibiotics. Abbreviations: S, susceptible; R, resistant; na, not available; OXA, oxacillin; 
PEN, penicillin; AMC, amoxicillin-clavulanic acid, CIP, ciprofloxacin; ERY, erythromycin; 
CLI, clindamycin; TET, tetracycline; GEN, gentamicin; SXT, trimethoprim-
sulfamethoxazole; VAN, vancomycin. All the resistant phenotypes observed for 
clindamycin mean inducible resistance, determined by D-test (9). 
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MSSA infections, independently of the PVL content, frequently show similar 
epidemiological and clinical characteristics to MRSA, but specific PVL-positive 
MSSA lineages are dynamically interrelated and recently reported as reservoirs of 
CA-MRSA (26, 33). Therefore, a regular surveillance of SSTI, namely, in children, 
is critical in order to predict and control the emergence of methicillin resistance 
and spread of staphylococcal infections in the community. 
 
Figure 2. Virulence gene determinants of the eight clonal lineages. The totality of the 
isolates was tested for 11 virulence genes. Abbreviations: PVL, Panton Valentine 
leukocidin; LukM, leukocidin M; LukDE, leukocidins D and E; -hemol, -hemolysin; γ-
hemol, γ-hemolysin; γ-hemol var, γ-hemolysin variant; ETA, ETB, ETD, exfoliative toxins A, 
B and D; SEL, SEP, staphylococcal enterotoxins L and P. 
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ABSTRACT 
 
Characterization of nosocomial methicillin-susceptible Staphylococcus 
aureus isolates from Cape Verde showed that (i) Panton-Valentine leukocidin 
genes were present in 35% of the isolates and (ii) half of the collection had the 
same genetic background as methicillin-resistant pandemic clones. Introduction of 
the staphylococcal chromosome cassette mec (SCCmec) into virulent and 
epidemic isolates could pose serious threats to public health. 
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RESULTS and DISCUSSION 
 
Staphylococcus aureus constitutes a major public health threat, and 
methicillin-resistant S. aureus (MRSA) is currently the most commonly identified 
antibiotic-resistant pathogen in many parts of the world. Concerning the African 
continent, although there is still a lack of epidemiologic data, MRSA was reported 
as a problem in different countries, including South Africa (6), Zimbabwe (16), 
Kenya (13), Ethiopia (29), Egypt (9), Senegal (27), and Ivory Coast (4). In contrast, 
the prevalence of MRSA was very low or nonexistent in Somalia (23), Nigeria (1), 
and Tanzania (30). 
In a previous study we determined the rates of nosocomial colonization by 
staphylococci in Cape Verde islands and the antimicrobial susceptibility profiles 
(3). The S. aureus carriage rates were around 41%, and all isolates were 
susceptible to methicillin (3). The aim of the present study was to obtain insights 
into the methicillin-susceptible S. aureus (MSSA) genetic population, including the 
detection of virulence determinants, in a country where at least in a particular 
period the prevalence of MRSA in colonization samples seemed to be null. 
The MSSA isolates included in this work were collected during a 
surveillance study in two hospitals on the two most populated islands of the Cape 
Verde archipelago (3). Hospital Dr. Agostinho Neto is located in Praia, on São 
Tiago, and Hospital Baptista de Sousa is in Mindelo, on São Vicente. The isolates 
represented colonization samples from patients or health care workers and were 
recovered from nasal or wound swabs. Five isolates from the previous study were 
not viable when cultured from the frozen stocks and could not be included in the 
present work. 
Pulsed-field gel electrophoresis (PFGE) was performed after SmaI 
digestion as described by Chung et al. (7). The resulting band patterns were 
analyzed by visual inspection followed by analysis with BioNumerics software 
(version 4.0; Applied Maths, Gent, Belgium) for relatedness evaluation. 
Dendrograms were generated from similarity matrixes calculated with the Jaccard 
coefficient, and patterns were clustered by the unweighted pair group method with 
arithmetic mean using an optimization of 1.5% and a tolerance of 1.3%. Profiles 
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with more than 70% similarity were considered closely related. spa typing was 
performed as previously described (17, 26). The spa types were assigned through 
the eGenomics and Ridom (http://www.ridom.de/spaserver/) (12) web servers. spa 
types with similar repeat profiles were grouped together as part of the same 
lineage (spa lineage); lineages are identified by the same capital letter. 
Multilocus sequence typing (MLST) was carried out as described by 
Enright et al. (10), with the exception that primer arcCF2 (5’-CCT TTA TTT GAT 
TCA CCA GCG-3’) was used (8). spa typing and MLST PCR products were 
purified with a Wizard PCR Preps purification system (Promega, Madison, WI) and 
used as templates for sequencing of both strands at Macrogen (Seoul, South 
Korea). MLST alleles and sequence types (STs) were identified using the MLST 
database (http://www.mlst.net), which was also used to search for earlier reports 
on the STs identified during the present study. 
The presence of the Panton-Valentine leukocidin (PVL) and the exfoliative 
toxin D (ETD) genes, i.e., lukS-PV and lukF-PV and etd, respectively, was 
determined by PCR as described previously (15, 19). 
The characterization of 63 MSSA strains by PFGE resulted in the definition 
of 13 different genotypes (Figure 1). Representatives of these 13 PFGE patterns 
(17 isolates) were characterized by spa typing and classified into 17 spa types and 
12 spa lineages. MLST was performed on single isolates of each PFGE pattern 
and/or spa lineage identified (13 isolates). All PFGE types belonged to a different 
ST, confirming the existence of 13 distinct clones among the 63 MSSA isolates, 
whose main characteristics are shown in Figure 1. 
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The genetic studies on the clonal population of the MSSA isolates in Cape 
Verde demonstrated that some clones were very successful. Clone U (spa type 
92/ t359 or related, ST669) was represented by 19% of the isolates (n = 12), 
whereas the second and third most prevalent clones, clone J (spa type 651/ t301 
or related, ST683) and clone A (spa type 650/ t942 or related, ST30), had 
incidences of 16% (n = 10) and 14% (n = 9), respectively. In addition, some of 
these clones have the capacity to disseminate between islands: 8 of the 13 clones 
occurred in both hospitals (Figure 2). However, the most successful clone, clone 
U, was identified in HBS only. 
 
Figure 2. Clonal distribution between Hospital Baptista de Sousa (Praia, São Tiago) and Hospital Dr. 
Agostinho Neto (Mindelo, São Vicente). 
 
Although no MRSA strains have been found in Cape Verde, about half of 
the isolates (46%, n = 29) showed a genetic background identical (same ST) or 
very similar (single-locus variant [SLV] or double-locus variant [DLV]) to the 
genotypes of pandemic MRSA clones. For instance, clone J (ST683) is a DLV of 
the Iberian MRSA (ST247), clone A (ST 30) is an SLV of EMRSA-16 (ST36), and 
clone C (ST5) has a background identical to the New York/ Japan and Pediatric 
(ST5) clones. Moreover, clone H (ST508) is an SLV of and clone Z (ST45) shares 
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the same ST as the Berlin clone (ST45) (Figure 1). The fact that some of the major 
MSSA clones established in Cape Verde correspond to internationally successful 
MRSA clones provides evidence that the emergence of MRSA isolates in an 
environment is not exclusively dependent on the presence of successful MSSA 
lineages. A similar observation was recently published from Portugal (2). 
Although most MSSA clones in Cape Verde are recognized as international 
clonal types, three STs found in the present study have not been described before 
(STs 668, 669, and 683). Interestingly, ST398, which was detected in a single 
isolate in the present study, was recently reported to be resistant to digestion with 
SmaI restriction endonuclease (33) and seems to be associated with pigs and pig 
farmers (5, 33). Whether the isolate from Cape Verde was pig related is unknown. 
However, there were no signs of resistance to SmaI digestion, and the isolate was 
classified as PFGE type V. 
A total of 22 (35%) and 5 (8%) isolates tested positive by PCR amplification 
for the PVL and ETD genes, respectively. All but one isolate belonging to STs 30 
(n = 8), 121 (n = 6), 1 (n = 4), and 25 (n = 4) were PVL positive, whereas the five 
ETD-positive isolates belonged to ST25 (n = 4) and ST398 (n = 1). Out of the 22 
PVL-positive isolates that were almost equally distributed among patients and 
health care workers, four were recovered from wound infections, whereas 18 were 
obtained from nasal samples. We found a proportion of PVL-positive MSSA 
isolates that was fairly high (35%) compared with data in studies from other 
countries. Melles et al. (21) found a PVL prevalence of only 0.6% in a large (n = 
829) Dutch collection of carriage isolates, whereas Kuehnert et al. (18) reported 
the presence of PVL in 1% of 297 American MSSA nasal isolates, and Holmes et 
al. (14) found only 8 PVL-positive isolates (1.6%) among 515 isolates of S. aureus 
from different sites of infection. An additional study demonstrated that PVL genes 
were very rare in Germany in both nasal and blood isolates (32). Moreover, the 
PVL gene has been reported to be more common in MRSA isolates than in MSSA 
isolates (18, 20), particularly among community-acquired MRSA strains of STs 1, 
8, 30, 59, 80, and 93 (31). 
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In the present study, the PVL genes were detected in all isolates belonging 
to clones A-ST30 (with the exception of one isolate), F-ST121, G-ST1, and S-
ST25, whereas etd was present in all isolates of clones S and V-ST398. A 
previous study comparing the genetic backgrounds of MSSA and MRSA in 
Portugal showed some MSSA clonal overlapping between Portugal and Cape 
Verde. Although the four PVL-positive clonal types detected in Cape Verde had 
been identified among the Portuguese MSSA nosocomial and/or community 
population, the cytotoxin was found exclusively in clone F-ST121 and in a very 
restricted number of Portuguese isolates (2 out of 19 isolates) (2). Clones ST1 and 
ST30 PVL-positive have been described as the most frequent community-acquired 
MRSA clones in the United States and Oceania, respectively (31). ST121 has 
been detected among isolates carrying PVL genes in England and Wales (14), 
and ST25 was recently reported as a highly transmissible clone associated with 
colonization and infection in the niche of AIDS-infected patients with a history of 
drug use (11). It is known that the genes that encode PVL are carried by different 
temperate phages and that S. aureus strains are usually lysogenized by a 
phage(s) (22). Our results suggest that hospitals in Cape Verde may represent a 
reservoir of PVL-positive clones. However, the reason why MSSA strains from 
Cape Verde seem to be more prone to PVL-converting phage infection is currently 
unclear. This study indicates that the acquisition of virulence might confer a 
greater advantage to S. aureus than antibiotic resistance genes in a country and 
period in which the use of antibiotics is very limited. 
Interestingly, clone A is closely related to phage type 80/81 strains, which 
became pandemic during the 1950s, causing a high frequency of skin lesions, 
sepsis, and pneumonia in children and young adults in hospitals and the 
community (25). The phage type 80/81 clone is ST30, carries the PVL genes, and 
has been suggested to be the ancestor of the community-acquired PVL-positive 
southwest Pacific MRSA clone (ST30, SCCmec IV) (24). On the other hand, 
Taneike et al. recently reported that the MRSA isolates that caused nosocomial 
outbreaks in Japan in the 1980s were ST30 and PVL positive (28). This clone was 
replaced by the PVL-negative New York/ Japan MRSA ST5 clone in the 1990s 
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and now seems to be re-emerging in the community after having lost some 
virulence genes (28). 
In summary, the genetic backgrounds corresponding to five pandemic 
MRSA clones were represented among the MSSA isolates from Cape Verde, and 
the genes that code for PVL were detected in a high proportion of strains with 
different genetic backgrounds. Although a fitness cost associated with the 
maintenance of both SCCmec and the PVL genes may exist, we should be aware 
of the eventual emergence of MRSA strains by the introduction of SCCmec into 
highly virulent and epidemic MSSA backgrounds. This could pose an additional 
threat to public health, warranting continuing surveillance studies, namely in 
African countries. 
 
 
Post publication note of the authors: 
Soon after the publication of the present data, an occasional review of the 
MLST results showed that the single PFGE type V, spa type 208/ t937, ETD 
positive isolate (CV55) was incorrectly assigned to ST398. In fact, the allelic 
sequence of this isolate (3-37-19-2-20-26-32) corresponds to the ST291, a single 
locus variant of ST398 (3-35-19-2-20-26-32). Therefore, in the previous text it 
should be read ST291 instead of ST398, and the clone considered as a singleton 
in the collection. 
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ABSTRACT 
 
In order to obtain insights into the methicillin-resistant Staphylococcus 
aureus (MRSA) population structure in the Azores archipelago, 106 MRSA isolates 
were collected from patients attending an Azorean central hospital between 
January 2007 and February 2008. Antimicrobial resistance was determined for all 
isolates. Molecular typing was performed by pulsed-field gel electrophoresis 
(PFGE), spa typing, multilocus sequence typing (MLST), staphylococcal 
chromosome cassette mec (SCCmec) typing and the presence of Panton–
Valentine leukocidin (PVL). The majority of the isolates (87%, n = 92) belonged to 
the EMRSA-15 clone (ST22, SCCmec-IVh), followed by the Pediatric clone (ST5-
VI/IVc) (11%, n = 12). The Berlin clone (ST45-IVa) and a new clone (spa type 
t1839, ST1339 and SCCmec V variant) were represented by single isolates. All of 
the isolates carried SCCmec types IV, V or VI and a non-multiresistant antibiotic 
profile, resembling the currently emerging community MRSA. Moreover, PVL was 
described for the first time to be associated with the Pediatric clone carrying 
SCCmec type VI. We provided the first description of the population structure of 
MRSA in the Azores islands, which seems to be shaped by genetic events 
occurring locally, as well as by the regular population exchange between the 
islands, continental Portugal, the United Kingdom and the United States. 
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INTRODUCTION 
 
Methicillin-resistant Staphylococcus aureus (MRSA) is a major pathogen 
associated with both nosocomial- and community-acquired infections (hospital-
acquired [HA] MRSA and CA-MRSA, respectively) (14). MRSA are believed to 
have emerged by the acquisition of the staphylococcal cassette chromosome mec 
(SCCmec), the mobile genetic element carrying the determinant of methicillin 
resistance (mecA) into methicillin-susceptible S. aureus (MSSA). Eight different 
SCCmec types (I to VIII) have been described so far in S. aureus, differing in their 
structure and size. Epidemiological studies using molecular typing methods 
showed that the massive geographical spread of MRSA in hospitals results from 
the dissemination of a few highly epidemic clones. These major epidemic clones 
resulted from a limited number of independent acquisitions of SCCmec into well-
defined genetic backgrounds: (i) New York/Japan clone, sequence type (ST) 5, 
SCCmec II; (ii) Pediatric clone, ST5-IV/VI; (iii) Brazilian clone, ST239-III/IIIA; (iv) 
Iberian clone, ST247-IA; (v) EMRSA-15, ST22-IV; (vi) EMRSA-16, ST36-II; and 
(vii) Berlin clone, ST45-IV (12, 29, 34). 
The MRSA prevalence in European hospitals varies from less than 3.0% in 
the Nordic Countries and The Netherlands to over 50% in southern European 
countries and the United Kingdom. Despite the significant decrease in MRSA 
incidence in a few countries (France, Slovenia, Belgium, Cyprus and Turkey) due 
to improved infection control, the incidence has increased in other countries, 
including Portugal, where the MRSA proportion is, nowadays, over 50%, being 
one of the highest in Europe (2, 14). 
Surveillance studies have been conducted in Portugal since the early 
1990s, showing temporal waves of MRSA clonal prevalence. In the most recent 
survey conducted in 2006, EMRSA-15 (ST22-IVh) was found to be the most 
prevalent clone in Portuguese hospitals, followed by the New York/Japan clone 
(ST5-II) (2, 5). 
Information about the epidemiology of CA-MRSA is still scarce and non-
existent in Portugal. Unlike HA-MRSA, CA-MRSA are usually only resistant to 
beta-lactams and one or two additional antimicrobial classes, and carry mainly 
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SCCmec types IV and V, the smallest in size, which are believed to be more 
mobile. CA-MRSA frequently harbour Panton-Valentine leukocidin (PVL), but the 
toxin has also been detected in the hospital environment (16, 42). Similarly to HA-
MRSA, CA-MRSA epidemic clones have been described (7). However, a much 
larger genetic diversity in the genetic backgrounds of CA-MRSA has been 
observed, suggesting a high number of SCCmec acquisitions in the community. 
Recent data indicates that MRSA epidemiology is suffering a new change and that 
the boundaries between the hospital and the community are blurring. As a result, 
clones traditionally linked to the hospital, like the EMRSA-15 clone, were found to 
be aetiologic agents of infection in the community (30) and clones specific to the 
community were observed as causing infections in hospitals, as is the case of the 
USA300 strain (38, 40). A common trait to these clones that can survive in both 
environments appears to be the presence of SCCmec type IV that is, nowadays, 
prevalent among the current overall MRSA population (2, 4, 5, 20, 43). 
Whereas the epidemiology of nosocomial MRSA has been very well 
characterised in the Portuguese continental territory, there is no information 
concerning the prevalence and clonality of MRSA in the Portuguese islands, 
namely in the Azores archipelago. 
The aim of the present study was to identify the MRSA clonal types 
currently circulating in the Azores archipelago and compare them with the major 
MRSA clones described in continental Portugal, Europe and the United States. 
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MATERIAL and METHODS 
 
Hospital setting 
Hospital do Divino Espírito Santo (HDES) is a 390-bed central hospital 
located in Ponta Delgada, São Miguel island, that services an outpatient 
population of 138,000 inhabitants, from the two most populous Azorean islands, S. 
Miguel and Santa Maria. The hospital, the largest in the archipelago, includes 
medicine and surgery as principal wards, and a large outpatient ambulatory unit. 
 
Bacterial isolates 
Between January 2007 and February 2008, a total of 106 MRSA isolates 
were collected from both inpatients (n = 93, 87.7% of the isolates) and outpatients 
(n = 13, 12.3% of the isolates) attending HDES. The collection included single-
patient isolates recovered from several sources, including sputum (n = 35, 33%), 
urine (n = 22, 21%), swabs from various origins (n = 19, 18%), exudates from 
wounds, one abscess and one ear infection (n = 16, 15%), blood (n = 10, 9.5%), 
catheters (n = 2, 1.9%) and auricular and peritoneal fluids (n = 1, 0.9% each). 
Most of the isolates (95%, n = 101) were from infection. The majority of the 
patients (73.5%) were inpatients hospitalised in three wards: medicine (n = 42, 
39.6%), surgery (n = 24, 22.6%) and pneumology (n = 12, 11.3%). Among the 13 
outpatients, three attended the haemodialysis unit. 
 
Antimicrobial susceptibility testing and mecA detection 
Susceptibility testing was performed with the semi-automatic Vitek system 
(bioMérieux, SA, France) according to the manufacturer’s instructions for a panel 
of 12 antibiotics: ciprofloxacin, clindamycin, erythromycin, gentamicin, linezolid, 
oxacillin, penicillin, rifampicin, trimethoprim-sulfamethoxazole, teicoplanin, 
tetracycline and vancomycin. Bacterial isolates were considered to belong to 
different antibiotypes if at least one difference was observed in the antibiotic 
resistance profile. 
The presence of the mecA gene was confirmed in all oxacillin-resistant isolates by 
polymerase chain reaction (PCR) (31). 
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PFGE 
Pulsed-field gel electrophoresis (PFGE) was performed as described by 
Chung et al. (8) on all 106 isolates. The resulting SmaI restriction patterns were 
analysed by both visual inspection using the criteria of McDougal et al. (23) and 
automatically with the BioNumerics software version 4.61 (Applied Maths, Sint-
Martens-Latem, Belgium). Dendrograms were generated as previously described 
(15) using an optimisation of 0.50% and a tolerance of 1.25%. A similarity 
coefficient of 80% was used to define the PFGE type clusters (15). 
 
spa typing and MLST 
spa typing was carried out on at least one representative of each PFGE 
subtype (n = 26) and spa types were assigned through the Ridom web server 
(http://spaserver.ridom.de) (1). Multilocus sequence typing (MLST) was conducted 
as described (10) for selected strains previously typed by PFGE and spa typing. 
The allelic profiles and sequence types (ST) were defined using the MLST 
database (http://www.mlst.net). 
 
SCCmec and ccr typing 
SCCmec was typed by the multiplex PCR strategy described by Milheiriço 
et al. (25). Additionally, all type IV isolates were further subtyped as previously 
described (24). Type VI isolates were confirmed by amplification of the cassette 
chromosome recombinase genes ccrAB4 (32). Type V was confirmed by PCR 
amplification of ccrC and mec complex C, as previously described (19, 31). Non-
typeable isolates by the methods mentioned above were characterised by ccrB 
sequencing (33). 
 
PVL detection 
All 106 MRSA isolates were screened for the presence of PVL lukS/lukF 
genes by PCR, as described previously (22). Positive results were confirmed by 
sequencing of the PCR amplicon. 
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RESULTS 
 
Antimicrobial susceptibility 
The 106 isolates were assigned to eight different antibiotypes (Table 1) 
with a prevalent non-multiresistant pattern. 
The majority of the isolates (n = 91, 85.9%) showed antibiotype 1 (resistance to 
oxacillin, penicillin, ciprofloxacin and erythromycin) or 2 (resistance to oxacillin, 
penicillin and ciprofloxacin). The isolate with antibiotype 7 was unique in showing 
resistance to gentamicin. Antibiotype 8, which showed resistance to six different 
antimicrobials, included a single isolate. 
All 106 isolates harboured the mecA gene and, therefore, were classified 
as MRSA. 
 
Table 1. Resistance profile of the 108 MRSA isolates and associated PFGE types 
Resistance profilea Antibio 
type OXA PEN CIP ERY CLI RIF GEN LZD SXT TEC TET VAN 
Total nº of 
isolates 
(%) 
PFGE types 
(subtypes) 
1 R R R R S S S S S S S S 67 (63.2) A (1-9); B (1, 2); D (1) 
2 R R R S S S S S S S S S 24 (22.7) A (1-6); B (1, 4); C (1) 
3 R R S R S S S S S S S S 7 (6.6) A (1, 2, 5); B (1) 
4 R R R R R S S S S S S S 3 (2.8) A (1) 
5 R R S S S S S S S S S S 2 (1.9) A (4); B (3) 
6 R R R S S R S S S S S S 1 (0.9) A (1) 
7 R R S S I R R S S S S S 1 (0.9) B (1) 
8 R R R R R R S S S S S S 1 (0.9) B (1) 
 
a S, Susceptible; I, intermediate; R, resistant. Antibiotic abbreviations: OXA, oxacillin; PEN, penicillin; CIP, ciprofloxacin; ERY, erythromycin; CLI, 
clindamycin; RIF, rifampicin; GEN, gentamicin; LZD, linezolid; SXT, trimethoprim-sulfamethoxazole; TEC, teicoplanin; TET, tetracycline; VAN, 
vancomycin. 
 
 
Predominance of EMRSA-15 clone 
The characterisation of the 106 MRSA strains by PFGE, spa typing, MLST 
and SCCmec typing clustered the isolates into four clonal types (Figure 1). The 
majority of the isolates (n = 92, 87%) belonged to PFGE type A. PFGE type B 
included 11% (n = 12) of the isolates and types C and D were represented by 
single isolates only (1% each). 
PFGE type A was subdivided into nine subtypes; subtypes A1 (n = 40) and 
A2 (n = 22) represented 67% of all type A isolates. The representative isolate of 
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PFGE type A (subtype A1) showed spa type t032, ST22 and SCCmec type IVh, 
which are characteristics of the internationally disseminated EMRSA-15 clone 
(27). Interestingly, subtype A4 showed the same restriction profile as the EMRSA-
15 clone reference strain, HAR22, but a different spa type (t032), including one 
additional repeat sequence (Figure 1). All representative isolates of type A shared 
the same spa type t032, except one isolate (t910), which differs from t032 by the 
deletion of five repeats. HDES85 was the unique isolate of PFGE type A1 defined 
as non-typeable by spa typing, since no PCR product was obtained. Another 
single type A1 isolate, HDES73, showed a SCCmec cassette type IV non-
subtypeable. PFGE type A included isolates from six out of the eight antibiotypes 
described, but 95% (n = 53) of the isolates belonged to antibiotypes 1 and 2 
(Table 1). 
Evidence of horizontal gene transfer among strains of the Pediatric clone 
PFGE type B was the second most common PFGE type and included three 
subtypes, of which B1 represented 75% (n = 9) of type B isolates (Figure 1). 
Subtypes B1 and B2 showed ST5, SCCmec VI and spa types t062, t2049, t2724 
(B1)/t311 (B2), which are typical of the Pediatric clone. SCCmec type VI was 
confirmed in five isolates by amplification of the characteristic ccrAB4 genes. The 
remaining type VI isolates did not amplify the ccrAB4 genes by uniplex PCR but 
showed a ccrB sequence with 100% homology with the Pediatric clone reference 
strain HDE288 (37). Interestingly, subtype B3 carried SCCmec type IVc instead of 
the SCCmec type VI, which may indicate the occurrence of independent 
acquisition of SCCmec in the Pediatric clone background. 
Moreover, we found that three isolates belonging to PFGE subtype B1 
(ST5-VI) carried the PVL genes. 
The remaining two isolates belonged to PFGE types C and D and were, 
respectively, recovered from an outpatient and an inpatient. PFGE C isolate, spa 
type t004 and ST45-IVa showed a single band difference relative to HAR38, the 
prototype isolate of the Berlin clone (spa type t004, ST45-IVa) (9, 28). PFGE type 
D isolate showed spa type t1839, a novel sequence type (ST1339) not related to 
any major clonal complex (CC) and a variant of SCCmec type V. 
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High genetic diversity and high frequency of SCCmec types IV, V and VI 
SCCmec type IV was found to be the prevalent type (n = 13) among the 24 
isolates tested. Three different SCCmec IV subtypes were found in this collection, 
associated to three unrelated genetic backgrounds (ST5: SCCmec IVc, ST22: 
SCCmec IVh/IVnon-subtypeable, and ST45: SCCmec IVa). SCCmec type VI was 
the second most prevalent cassette type, which appeared to be associated to 
isolates with PFGE types B1 and B2. A variant of SCCmec type V was shown on a 
single isolate that harboured the mec complex C and ccrC genes, but missed the 
specific type V J1 region. No isolates carrying SCCmec types I, II or III were 
identified in this collection. 
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DISCUSSION 
 
In order to describe the MRSA population structure in the Atlantic Azores 
islands, a collection of 106 isolates recovered during a 13-month period was 
characterised by a combination of up-to-date molecular typing methods. The 
analysis showed the predominance of two major international MRSA clones: the 
EMRSA-15 clone and the Pediatric clone. 
 
Massive dominance of the EMRSA-15 clone 
In the present study, 87% of the isolates showed molecular characteristics 
of the highly internationally disseminated EMRSA-15 clone (ST22-IVh) (27), 
including a common spa type t032. In addition, a single PFGE type A2 isolate 
showed t910, a spa type already reported in a CC22 isolate from Germany (41). 
This fact is not surprising, since the spa gene is a variable repeat region prone to 
the introduction or deletion of repeats. Regional spa clusters frequently include 
highly related spa types characterising clonal related isolates, which translates a 
local evolution of the spa locus (16, 17). Unusually, a non-typeable isolate was 
found in the collection, which should be due to a mutation or insertion/deletion in 
spa rather than non-existence of the gene (6).  
Interestingly, the majority of the EMRSA-15 isolates described in this study 
were recovered from sources other than blood (sputum, swabs, exudates and 
urine), corresponding to the major pathologies presented by the patients attending 
HDES (respiratory tract and skin related). The non-multiresistant EMRSA-15 clone 
emerged in the United Kingdom in 1991 and rapidly became a dominant clone 
worldwide, particularly in Europe (16, 21). Recently, an EMRSA-15 variant was 
reported in central United States (48). In the Azores islands, the clear dominance 
of the EMRSA-15 clone is, in part, in agreement with the situation in continental 
Portugal (2, 5). In fact, in a study involving isolates recovered in the same period 
from 11 hospitals scattered over continental Portugal, EMRSA-15 was found to be 
the most prevalent clone. However, and in contrast with the present study, the 
New York/ Japan clone (ST5-II) was shown to represent a new wave of MRSA in 
the country, whereas the Pediatric clone (ST5-VI/IV) was exceedingly rare (2). In 
MRSA clones in Azores islands 
 135 
the Portuguese neighbouring country Spain, EMRSA-15 was found in continental 
territory in co-existence with EMRSA-16 and two CC5 clones (ST125-IV and 
ST146-IV), but not as a major clone as in the Spanish islands (Majorca and 
Canarias) and as in our study (4, 35, 44). The frequent touristic flux from the 
United Kingdom, hypothesised as the cause of the importation of EMRSA-15 to 
the Mediterranean island of Malta (39), could also support, in part, the emergence 
of this clone in the most touristic Azores islands. In parallel, the regular exchange 
of inhabitants between the islands and the continent seem to be an important 
vehicle of clonal importation. 
 
Emergence of PVL and SCCmec variability: evidence for local evolution 
Recent studies revealed that the Pediatric MRSA clone, isolated for the first 
time in 1992 in a Portuguese hospital (37), was no longer present in that hospital 
in 2006 (2). However, it appeared in the present collection as the second major 
clone. 
Interestingly, in this study, we observed that strains of the Pediatric clone 
differing in three to five bands in PFGE pattern, isolated in the same hospital, 
carried either the typical SCCmec types VI or IVc. ST5-VI MRSA isolates, which 
had been restricted to isolates from continental Portugal, were recently found in a 
collection of nosocomial isolates recovered from 23 hospitals located throughout 
France (11, 32). The hypothesis of a recent introduction of this clone from 
continental Portugal seems to be quite remote, since, in a recent national study, 
this clone was isolated from a single patient only in a hospital in the South of 
Portugal (2). On the other hand, the Azores islands have a high emigrant 
community in the United States, who frequently travel to the national territory, 
constituting also possible vehicles of dissemination of the Pediatric clone strains 
already reported in this country. 
ST5 lineage is known to frequently acquire mobile genetic elements, such 
as different SCCmec, antibiotic resistance and toxin genes (13, 29). In a recent 
study, Nübel et al. showed that at least 23 SCCmec acquisitions events have 
occurred within ST5 lineage, on multiple and independent occasions, showing 
evidence that the MRSA emerged in numerous circumstances and in distinct 
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locations rather than by the geographic dispersal of isolates (29). Moreover, 
besides being originally identified in a community-associated USA400 strain, the 
first introduction of SCCmec IV in S. aureus might have occurred in the ST5 
Pediatric clone background that was circulating in hospitals in the 1990s (7). 
Similarly, our results suggest that SCCmec cassettes VI and IVc might have been 
introduced de novo and recently in these ST5 strains and that the Pediatric clone 
may be evolving locally. Another observation that supports the hypothesis of 
recent local evolution of the Pediatric clone is the presence of PVL-positive and 
PVL-negative strains with closely related PFGE profiles. Noteworthy, this is the 
first report of PVL among isolates belonging to the SCCmec type VI Pediatric 
clone. The introduction of the PVL genes in a genetic background with such a high 
epidemic potential is of particular concern. However, we cannot exclude the 
reverse hypothesis of a local evolution through the acquisition of SCCmec type VI 
by a PVL-positive MSSA. Only the analysis of the genetic background of 
susceptible S. aureus in the Azores islands would clarify the chronological 
acquisition of PVL and SCCmec in these Pediatric clone strains. 
The Berlin MRSA clone (ST45-IVa), first observed in Berlin hospitals in 
1993, is currently spread in some European countries (16, 45), showing a high 
epidemic potential not only in the hospital environment but also in the community 
(36, 47). This clone was found in a single MRSA isolate in the Azores island 
collection. The same genetic background (ST45) had been previously described in 
Portuguese hospitals, but exclusively among MSSA isolates (3). The collection of 
a single MRSA isolate carrying SCCmec IVa suggests another de novo SCCmec 
acquisition, probably in an already established MSSA clone.  
Likewise, the introduction of a variant of SCCmec type V seems to have 
occurred in an isolate with spa type t1839 and a novel sequence type (ST1339) 
that is a singleton. This strain is not related to the single SCCmec type V variant 
isolate (ST45) previously reported in Portugal (2). Interestingly, this isolate was 
recovered from a patient within the first 48 h of hospitalisation, from a skin and soft 
tissue infection (erysipelas), the main source of CA-MRSA isolates. However, the 
isolate could not be considered as having a community origin, since no additional 
information regarding patient risk factors was available. 
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Emergence of HA-MRSA isolates with community traits 
SCCmec type IV is one of the most frequent SCCmec types found in the 
community and is, nowadays, becoming the predominant type also in the 
nosocomial setting (2, 4, 5, 7, 20, 43, 46). Moreover, this SCCmec type has been 
usually associated to a pattern of susceptibility to almost all antimicrobial classes. 
These same characteristics were observed in isolates from our study: SCCmec 
type IV was found to be the most frequent SCCmec type and all isolates were 
highly susceptible. At least three different SCCmec subtypes were identified (IVh: 
EMRSA-15, IVc: Pediatric clone, IVa: Berlin clone), showing evidence of a high 
genetic diversity among the pool of SCCmec type IV in the Azores islands. 
Interestingly, the detection of one isolate belonging to the EMRSA-15 clone, 
SCCmec type IV non-subtypeable (only positive for the ccrB2 allele in the 
subtyping multiplex), suggests the presence of a new uncharacterised SCCmec 
type IV subtype in addition to the ones already described (24). 
Besides SCCmec type IV, the only SCCmec types found among the whole 
collection were the small SCCmec V and VI, reflecting the actual tendency for the 
dominance of low resistant and fitness cost clones within the hospital setting, 
which is parallel with what is observed in the community environment (7). The 
introduction of well-established community isolates into the hospital setting is not 
new, as observed in Taiwan, where the ST59 clonal type, highly prevalent in the 
community, emerged in the hospital setting as the second most prevalent clone 
(18, 26, 35). Although ST22-IV EMRSA-15 related isolates as well as ST5-IV were 
already reported in the community (30, 46), no conclusions can be drawn for the 
flow direction in the present study. Even if a high percentage (30%) of the isolates 
studied was recovered within the first 48 h of admission or in an outpatient unit, no 
data of previous hospital contact was available for the patients. 
In the present study, we provided the first description of the population 
structure of MRSA in the Azores islands and showed a prevalence of the epidemic 
EMRSA-15 clone in co-existence with the Pediatric clone. Our findings were in line 
with recent reports from continental Portuguese and European hospitals. The 
horizontal gene transfer and the de novo acquisition of mobile genetic elements 
seem to have contributed to the local genetic diversity and clonal evolution. 
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Moreover, the population exchange between the islands and continental Portugal 
or the United States, in addition to the high flux of tourists, particularly from the 
United Kingdom, may explain the dominance and spread of the EMRSA-15 and 
Pediatric clones. Further surveillance studies concerning both HA-MRSA and 
MSSA populations and CA-MRSA in the geographically restricted Azores islands 
will be fundamental to support the S. aureus localised evolution, as well as to 
understand the links between the hospital and the community. 
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ABSTRACT 
 
The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in 
Hungary has been increasing and is now close to 20% among invasive isolates of 
S. aureus. In order to understand the evolution of MRSA in Hungary, two 
collections of isolates were studied: 22 representatives of a collection of 238 
MRSA isolates recovered between 1994 and 1998, and a collection of 299 MRSA 
isolates recovered between 2001 and 2004. The isolates were first characterised 
by pulsed-field gel electrophoresis (PFGE) and were distributed into 19 different 
PFGE patterns. Representatives of each pattern were further characterised by spa 
typing, multilocus sequence typing (MLST) and staphylococcal cassette 
chromosome mec (SCCmec) typing. The Hungarian clone that was predominant in 
1994-1998 (PFGE E, ST239-III) had almost disappeared in 2003–2004, being 
replaced by the Southern German clone (PFGE B, ST228-I) and the New York/ 
Japan epidemic clone (PFGE A, ST5-II), which represented c. 85% of the 2001–
2004 isolates. Thus, this study describes, for the first time, the co-dominance and 
extensive spread of the New York/ Japan clone in a European country. 
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INTRODUCTION 
 
During the past two decades methicillin-resistant Staphylococcus aureus 
(MRSA) has become the most prevalent and important nosocomial pathogen, 
causing serious infections such as skin abscesses and wound infections, 
osteomyelitis, endocarditis, pneumonia, meningitis, bacteraemia and toxic shock 
syndrome (25). More recently, MRSA infections have been reported in the 
community among patients with and without traditional risk-factors for MRSA 
infection. These latter infections are associated predominantly with skin and soft-
tissue abscesses and cellulitis (39). 
In Europe, the prevalence of MRSA varies widely among nations and is 
consistently higher in southern countries, e.g., Portugal, Spain, Italy, France and 
Greece, which report a prevalence of >30%, as compared with <2% in 
Scandinavian countries, Switzerland and The Netherlands 
(http://www.earss.rivm.nl). In central and eastern Europe, the prevalence of MRSA 
has been estimated at c. 15% in Austria, the Czech Republic and Slovenia, 
between 20% and 37% in Hungary, Slovakia, Poland, Bulgaria and Croatia, and 
>60% in Romania (http://www.earss. rivm.nl) (44). 
Epidemiological studies using molecular typing methods have indicated 
that the massive geographical spread of MRSA results from the dissemination of a 
few highly epidemic clones. These major epidemic clones belong to sequence 
type (ST) 5 (SCCmec II - New York/ Japan, and SCCmec IV - Pediatric), ST239 
(SCCmec III/IIIA - Brazilian), ST247 (SCCmec IA - Iberian), ST22 (SCCmec IV - 
EMRSA-15), ST36 (SCCmec II - EMRSA-16) and ST45 (SCCmec IV - Berlin) (4, 
18, 35). 
Another epidemic MRSA clone, sharing ST239 with the Brazilian clone, 
was described for the first time in Hungary, and was reported to be widely 
dispersed in Hungarian hospitals between 1993 and 1998 (14, 32). Further studies 
reported the local predominance of this clone in other regions of the world, namely 
Taiwan and China (3), and more recently in India (6), Poland (26) and Norway 
(21). Norway has one of the lowest rates of MRSA in Europe, which indicates the 
high capacity for dissemination of this particular clone. 
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Besides the limited number of MRSA clones circulating in Europe, the 
phenomenon of clonal replacement has been observed; i.e., clones that were 
disseminated widely during the beginning of the last decade have become less 
common and have been replaced by other epidemic clones. In Portuguese 
hospitals, the prevalent Portuguese clone (ST239-III variant) in the mid-1980s was 
replaced by the Iberian clone (ST247-IA) in 1992–1993, and later, by the Brazilian 
clone (ST239-III/IIIA) (4). Another example of clone replacement was observed in 
German hospitals between 1994 and 2002. The Northern German (ST247-I) and 
the Hannover (ST254-IV) clones, which were prevalent at the beginning of the 
1990s, were replaced in 2000 by the Berlin (ST45-IV), the Southern German and 
the Barnim (ST22-IV) clones, and 1 year later by the Rhine-Hesse (ST5-II) MRSA 
epidemic clone (43). Also, in the Czech Republic, Melter et al. (30) reported the 
arrival of the epidemic EMRSA-15 (ST22-IV) clone, replacing the previously 
prevalent clones in the country, i.e., the Brazilian or ST239-related clones and the 
Iberian (ST247-IA) clone. 
The incidence of MRSA in Hungary is currently c. 20% among invasive 
isolates of S. aureus (http://www.earss.rivm.nl). However, since the late 1990s, 
there have been no molecular data available from Hungary. Therefore, the aims of 
the present study were, first, to provide an update of the MRSA clonal types 
circulating in Hungary between 2001 and 2004, and second, to trace the temporal 
evolution of the epidemic clones in Hungary during the last decade. 
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MATERIAL and METHODS 
 
Bacteria 
The study investigated two collections of isolates: (i) 299 isolates selected 
from among 3539 MRSA isolates, recovered between 2001 and 2004 from 
different provincial hospitals located in 18 of the 19 Hungarian counties (Figure 1), 
sent to the Hungarian National Center for Epidemiology as part of routine MRSA 
surveillance-the 299 isolates were all single patient invasive isolates (from blood 
cultures or cerebrospinal fluid), with 15 isolates from 2001, 48 isolates from 2002, 
103 isolates from 2003, and 133 isolates from 2004; and (ii) 22 clinical MRSA 
isolates selected from among 238 MRSA isolates recovered between 1994 and 
1998 in six Hungarian counties (Figure 1) (32) - these 22 isolates represented all 
of the pulsed-field gel electrophoresis (PFGE) profiles described by Oliveira et al. 
(32), and were included in the present study to enable a more detailed 
characterisation in order to trace the evolution of the clonal types circulating in 
Hungary between 1994 and 2004. 
 
Antimicrobial susceptibility testing 
Susceptibility to oxacillin, vancomycin, ciprofloxacin, erythromycin, 
clindamycin, gentamicin, trimethoprim–sulphamethoxazole, tetracycline, 
rifampicin, teicoplanin, quinupristin–dalfopristin and linezolid was tested by the 
disk-diffusion method according to CLSI guidelines (9). Antimicrobial susceptibility 
testing for oxacillin and vancomycin was also performed using Etests (AB Biodisk, 
Solna, Sweden) according to the manufacturer’s instructions. S. aureus ATCC 
25923 was used as a quality control strain for antimicrobial susceptibility testing. 
 
Phage typing 
The isolates recovered between 2001 and 2004 were typed using the 
international basic set of phages for S. aureus isolates of human origin, and a set 
of ten phages selected by Richardson et al. (37) that were developed in certain 
countries in response to local problems in typing MRSA strains. All phages were 
used at 100·the routine test dilution. 
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PFGE 
PFGE was performed for all isolates as described by Chung et al. (11). In 
brief, genomic DNA samples immobilised in agarose were digested overnight with 
SmaI (New England BioLabs, Beverly, MA, USA), followed by resolution of the 
restriction fragments in a CHEF-DRIII contour-clamped homogeneous electric field 
apparatus (Bio-Rad, Hemel Hempstead, UK). PFGE patterns were analysed 
visually and interpreted using the criteria of McDougal et al. (29), and were also 
analysed using BioNumerics v.4.0 (Applied Maths, Sint-Mar-tens-Latem, Belgium). 
Concatamerised phage  DNA (New England BioLabs) and a SmaI genomic 
digest of S. aureus NCTC 8325 were used as internal markers to normalise the 
gels. Percentage similarities were determined from a dendrogram that was 
constructed using the unweighted pair group with arithmetic averages (UPGMA) 
method and the Dice coefficient, with band position tolerance and optimisation set 
at 1%. According to Carriço et al. (10), and after reviewing the epidemiological 
data associated with each of the clusters, a similarity coefficient of 80% was used 
to define the PFGE type clusters. 
 
spa typing 
Analysis of polymorphism in the X region of the protein A gene (spa) was 
performed as described previously (41) for at least one representative of each 
PFGE type (n = 40). The spa types were determined by assignment according to 
the Ridom web server (http://www.ridom.de/spaserver/), using Ridom StaphType 
v.1.4.10 software (Ridom GmbH, Wurz-burg, Germany) and the eGenomics web 
server (http:// tools.egenomics.com/). As observed previously (2, 41), spa types 
with similar repeat profiles were grouped together in spa lineages, which were 
identified in the present study by numbers. 
 
Multilocus sequence typing (MLST) 
MLST was performed on at least one representative of each PFGE pattern 
(n = 49) by PCR amplification of internal fragments of seven housekeeping genes 
as described by Enright et al. (19), except that primer arcCF2 (5’-
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CCTTTATTTGATTCACCAGCG) was used (13), or according to van Leeuwen et 
al. (45). The allelic profile, and hence the ST, of each isolate was identified using 
the MLST database (http:// www.mlst.net). 
 
SCCmec and ccrAB typing 
The staphylococcal cassette chromosome mec (SCCmec) type was 
determined for at least one representative of each PFGE pattern/spa lineage (n = 
66) using the multiplex PCR strategy developed by Oliveira and de Lencastre (33), 
which assembles a specific amplification profile for each cassette type. A ccrAB 
(cassette chromosome recombinase)-specific PCR (24) was performed to confirm 
the presence of SCCmec type IV, and also when a non-conclusive result was 
obtained using the multiplex strategy. Amplification of ccrB (34) was also 
performed for one isolate that was not typeable using the above approaches. 
 
Panton-Valentine leukocidin (PVL) gene analysis 
The presence of the PVL lukS/lukF genes was investigated by PCR (27) 
for representatives of each PFGE pattern. 
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RESULTS 
 
Antibiotic profiles and phage typing 
The 321 isolates were assigned to 12 antibiotypes (Table 1). All isolates 
were resistant to oxacillin, and high proportions were resistant to erythromycin 
(95.6%), ciprofloxacin (95.3%), clindamycin (87.9%) and gentamicin (58.9%). 
None of the isolates was resistant to linezolid, teicoplanin, quinupristin–dalfopristin 
or vanco-mycin. 
Among the 299 isolates collected between 2001 and 2004, 193 (64.5%) 
were typeable with both sets of phages: 154 belonged to phage group III, 13 to 
group 83A, ten to group I, nine to group 95, and seven to group 80. The remaining 
106 isolates, which could not be assigned to a defined group, included 58 non-
typeable isolates and 48 belonging to mixed groups. These 48 isolates included 22 
isolates from mixed groups III + 95, nine isolates from groups III + I, six isolates 
from groups III + II, and five isolates from groups III + 94/96. Mixed groups I + 83A, 
I + 94/96 and II + 83A each contained a single isolate, and the remaining three 
isolates belonged to groups 83A + 94/96. 
 
Macrorestriction analysis 
All 321 MRSA isolates were studied by PFGE. Although the isolates were 
distributed into 19 PFGE patterns (types A-C, E-L, P-T, V, X and Z) differing by six 
or more bands, two major clonal groups could be distinguished: pattern B, 
accounting for 141 (44%) of the isolates, and pattern A, accounting for 113 
(35.2%) isolates. With the exception of pattern E (n = 13, 4.5%), all remaining 
clones were represented by <4%of the isolates, and were considered to be minor 
clones (Table 1). 
 
spa typing, MLST and SCCmec typing 
Representatives of the 19 PFGE patterns were characterised further by 
spa typing (n = 40), MLST (n = 49) and SCCmec type (n = 66) (Table 1). 
According to spa typing, the isolates were assigned to seven spa lineages. MLST 
identified 11 different sequence types (ST5, ST228, ST239, ST36, ST254, ST247, 
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ST8, ST1, ST45, ST22 and ST875), which belonged to seven clonal complexes 
(CC5, CC8, CC1, CC30, CC45, CC22 and CC12). 
All four of the typical SCCmec types I-IV, as well as variants IA, IIIA and 
IVA, were detected among the isolates investigated. One isolate, belonging to 
CC12, was mecA-positive, but was not typeable by the PCR multiplex strategy 
(33), or by ccrAB (24) and ccrB (34) typing. In the two predominant clonal 
complexes, CC5 appeared to be associated with both SCCmecI and SCCmecII, 
while SCCmec III and SCCmec IIIA were detected only in CC8, in association with 
ST239. 
Although PFGE patterns A and B, which included most (n = 254) of the 
isolates, were assigned to a specific spa type, i.e., spa type t002/2 or spa type 
t041/388 (RIDOM/eGenomics nomenclature), respectively, they shared the same 
spa motif r20r17r12r17r16 (eGenomics nomenclature: DMGMK) and were both 
associated with spa lineage 1. Lineage 2, motif r16r02r25r17r24 (eGenomics 
nomenclature: KAOMQ), included nine PFGE patterns that, with the exception of 
pattern L, all belonged to ST239-SCCmec type III (or IIIA). 
Of the 11 STs identified, two predominated (>113 isolates each) and 
belonged to CC5: (i) ST5, associated with PFGE patterns A and J, and with 
SCCmecII; and (ii) ST228, a double-locus variant of ST5 in the tpi and yqiL alleles, 
corresponding to PFGE pattern B and SCCmec I. 
 
PVL screening 
Representatives (n = 65) of each PFGE pattern were selected randomly 
and tested for the presence of the PVL determinant. None of the isolates tested 
positive for the genes encoding PVL. 
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Temporal and geographical clonal distribution 
The evolution of MRSA clones in Hungarian hospitals between 1994 and 
2004 is summarised in Figure 2. Previous data (32) and the results obtained for 
the 22 representative isolates by spa typing, MLST and SCCmec typing showed 
that 99% of the isolates (i.e., all except two isolates) from 1994-1996 belonged to 
ST239-III. Several PFGE patterns were associated with the ST239-III isolates, but 
the Hungarian clone (PFGE E) was clearly predominant (74%). Over time, the 
prevalence of ST239-III clones, including the Hungarian clone, decreased 
progressively to a minimum of <0.5% in 2003- 2004. In parallel, two other well-
represented clones emerged in Hungary: (i) PFGE B-ST228-I (the Southern 
German clone) was introduced in 1997-1998, represented by 28% of the isolates; 
and (ii) PFGE A-ST5-II (the New York/ Japan clone) emerged in 2001-2002, with a 
prevalence of 30%. Over time, the prevalence of both clones increased, reaching 
50% and 40%, respectively, in 2003-2004, at which time they became the two 
most prevalent clones isolated in Hungary. The two isolates recovered in 1994-
1996 that did not share ST239 were found to belong to the Hannover clone (PFGE 
F-ST254-IV). This clone, absent during 1997-1998, re-emerged during 2001-2002 
(6%), but remained at a relatively low prevalence (1%) during the following years. 
The MRSA isolates from 1994-1998 were recovered from six of the 19 
Hungarian counties, while the prevalent Hungarian clone ST239-III was found in 
five different counties throughout the country (Figure 1). Despite the fact that the 
county in which the capital was located was over-represented among the 2001-
2004 isolates, all except one of the remaining counties were represented in this 
collection (Figure 1). During this second study period, the Hungarian clone (or 
ST239-related clones) was still present in four counties throughout Hungary, three 
of which were included in the 1994-1998 study, as well as in an additional 
southern county. The Southern German clone ST228-I, which was restricted to 
one county until 1999, was isolated subsequently in nine additional counties 
throughout Hungary. Moreover, the New York/ Japan clone ST5-II, present in 
Hungary only since 2001, was widespread throughout 11 counties. The rapid 
dissemination of these clones might be linked to the transfer of Hungarian patients 
from hospital to hospital, and hence from county to county. 
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Figure 1. Comparison of the geographical distribution of the major methicillin-resistant 
Staphylococcus aureus clones in Hungary during 1994-1998 and 2001-2004. The Hungarian clone 
(ST239-III) is represented by circles, the Southern German clone (ST228-I) by triangles, and the 
New York/ Japan clone (ST5-II) by squares. The counties studied in each period are highlighted in 
grey. 
 
Figure 2. Clonal evolution of methicillin-resistant Staphylococcus aureus over a 10-year period in 
Hungarian hospitals (numbers over each bar indicate the number of isolates). 
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DISCUSSION 
 
Few surveillance studies have described the evolution of MRSA in central 
and eastern Europe. Although there was a gap in the present study between 1999 
and 2000, during which MRSA isolates from Hungary were not obtained, this 
report describes the evolution of the clonal types circulating in Hungary over the 
last decade. 
The predominance of a single clone in Hungarian hospitals between 1993 
and 1994 was reported by de Lencastre et al. (14). This Hungarian clone, 
characterised by ST239-III, was related closely to the epidemic Brazilian clone, 
which is dispersed widely in Europe, South America and Asia (4). Oliveira et al. 
(32) used a combination of spa typing and PFGE typing to reveal a significant 
decrease in the prevalence of the Hungarian clone, from c. 74% in 1994-1996 to 
42% in 1997-1998. Although the Hungarian clone has also been described in 
Poland (26) and Norway (21), the present results show that it is currently almost 
non-existent in Hungary. Two other clones, both belonging to CC5, i.e., the 
Southern German (ST228-I) and the New York/ Japan (ST5-II) clones, are now the 
predominant clones in Hungarian hospitals. 
The Southern German clone was first described in the southern area of 
Germany in 1992, and spread throughout Germany during 1995-1996 (48). About 
1 year later, this clone was detected in Budapest, the Hungarian capital, with a 
prevalence of 28%, and then spread rapidly throughout Hungary, becoming the 
prevalent clone in 2003-2004. ST228-I has also been reported to be the 
predominant clone (86% of MRSA isolates) in a hospital in Slovenia (31). In 
Croatia, which also borders Hungary, Budimir et al. (8) reported that ST111-I, a 
single-locus variant of ST228 with the same SCCmec type, occurred at a 
prevalence of 52% in bloodstream isolates. Moreover, other minor clones 
associated with ST228-I have been reported in Italy (28), Denmark (20), Belgium 
(16) and Switzerland (40) (http://www.mlst.net), showing that clone ST228-I, or 
related STs, are relatively common in Europe. 
After being isolated in northern European countries (4), ST5 was detected 
in Hungary soon after its double-locus variant, ST228. ST228 seems to have 
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evolved from ST5 (38). However, the appearance of these two clones in Hungary 
probably represents independent events, since ST228 was the first to be detected 
(Figure 2). ST5 appeared almost simultaneously in 11 counties, whereas ST228 
was first isolated in the restricted area of Budapest, and only spread later through-
out the country. Interestingly, to our knowledge, the New York/ Japan clone has 
never been described in countries bordering Hungary, and was therefore probably 
imported from countries in which it is highly prevalent, i.e., the USA, Japan, Korea 
and Mexico (5, 17, 42). Nevertheless, clone ST5-II has been reported recently in 
some Belgium hospitals, as was the ST45-IV clone, which was predominant 
among 251 isolates recovered from 95 hospitals during 2003 (15). ST45-IV was 
also isolated in Hungarian hospitals, but with a very low prevalence (three 
isolates). Other epidemic clones have been described in central Europe, e.g., 
EMRSA-15 (ST22-IV), which has been detected in hospitals throughout all regions 
of the Czech Republic, replacing both the Brazilian (ST239) and related clones, 
and the Iberian clone (ST247) (30). Interestingly, one of the minor clones 
described in Hungary, PFGE pattern V (Table 1), belonged to ST22-IV and was 
represented by two isolates from a single county. Thus, ST5 and related clones, 
such as ST228 and ST111, as well as the non-multiresistant EMRSA-15 (ST22) 
clone, are becoming the major clones circulating in eastern European countries, in 
addition to the Iberian and the Brazilian or ST239-related clones. 
Concerning the 2001-2004 MRSA collection, with the exception of phage 
groups 80 and 83A, which belonged only to PFGE pattern A, the other phage 
groups (I and III) included more than one PFGE pattern. In the two major PFGE 
patterns, A and B, most isolates belonged to phage group III. Phage typing is still 
used to characterise S. aureus (47), but this collection showed low typeability, with 
35.4%of the isolates not being assigned to any group (i.e., belonging to mixed 
phage groups or not typeable). There was poor concordance between phage 
typing and the DNA-based approaches used, as has been observed previously 
(7). 
Although the PVL determinant, a bicomponent leukotoxin virulence factor 
linked to severe necrotising fasciitis and necrotising pneumonia, has been 
detected previously in the hospital setting (1, 36), it is associated more commonly 
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with community-acquired MRSA strains harbouring SCCmec types IV or V (22); it 
was not detected in any of the nosocomial Hungarian isolates in the present study. 
Voyich et al. (46) recently reported that strains lacking PVL were as virulent in 
mouse sepsis and abscess models as those that produce the leukotoxin, and 
therefore concluded that PVL is not the major virulence determinant of community-
acquired MRSA. 
In summary, the present results indicate that a temporal recycling of the 
prevalent clones circulating in Hungary occurred between 1994 and 2004. 
Although ST239-related clones are still isolated in central Europe, e.g., in Poland 
(26) and Romania (12), the prevalence of ST239-related clones is currently almost 
null in Hungary. A progressive replacement of the Hungarian clone by the 
Southern German and New York/ Japan epidemic clones was observed in the 
hospital setting between 2001 and 2004, and the co-dominance and massive 
spread of the New York/ Japan clone in a European country was observed for the 
first time. 
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ABSTRACT 
 
The present study evaluates the performance of the staphylococcal 
interspersed repeat unit (SIRU) method applied to a diverse collection of 104 
Staphylococcus aureus isolates previously characterized by pulsed-field gel 
electrophoresis (PFGE), spa typing, multilocus sequence typing (MLST), and 
staphylococcal cassette chromosome mec typing for methicillin-resistant S. 
aureus. The SIRU method distributed the 104 strains into 81 SIRU profiles that 
could be clustered into 12 groups and 29 singletons. The discriminatory power of 
the method at the profile level, translated by Simpson’s index of diversity (SID), 
was similar to that of PFGE subtyping (SID = 99.23% versus 99.85%) and slightly 
higher than that of spa typing (SID = 97.61%). At the group level, the SIRU SID 
(93.24%) was lower than that of PFGE typing (95.41%) but higher than that of 
MLST (SID = 91.77%). The adjusted Rand (AR) coefficient showed that SIRU 
typing at the group level had the highest congruence with MLST (AR = 0.5736) 
and with clonal complex (CC) (AR = 0.4963) but the lowest congruence with PFGE 
subtype (AR = 0.0242). The Wallace coefficient indicated that in the present 
collection, two strains with the same SIRU profile have a 100% probability of 
belonging to the same CC, a 90% probability of sharing the same spa type, and an 
83% probability of being classified in the same sequence type. The high 
discriminatory power of the SIRU method, along with its apparent concordance 
with MLST results, makes it potentially valuable for S. aureus short-term 
epidemiological investigations and population dynamics as well.  
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INTRODUCTION 
 
Staphylococcus aureus, especially methicillin-resistant S. aureus (MRSA), 
continues to be a major cause of health care-associated and, more recently, 
community-associated infections (40, 62). It is critical to have access to an 
accurate typing method to design cost-effective intervention and prevention 
strategies (45, 48, 61). A large number of molecular typing methods have been 
developed to assess strain relatedness for outbreak control, surveillance 
programs, and population structure and evolution studies (58, 61). The three most 
used typing methods for S. aureus have advantages and disadvantages, as 
follows: (i) Pulsed-field gel electrophoresis (PFGE), which is the “gold standard” 
typing method, has high discriminatory power and accuracy, but it is time-
consuming and expensive, and the interlaboratory exchange of results is 
challenging; (ii) Sequence-based multilocus sequence typing (MLST) is easy to 
perform, and the results, given as an allelic profile, are portable and easy to 
exchange due to a public database available on the Internet (http://www.mlst.net), 
but it is expensive and not useful for local outbreak investigations. MLST is 
frequently combined with staphylococcal cassette chromosome mec (SCCmec) 
typing in order to define clonal types of MRSA (24); (iii) spa typing, a single-locus 
sequence typing method, is being used more frequently for S. aureus typing, and 
the development of a public database on the Internet (http://spaserver.ridom.de), 
as with MLST, ensured an international typing nomenclature and thus a great 
facility in exchanging typing data. By calculation of Simpson’s index of diversity 
(SID), it was shown that spa typing is nearly as discriminatory as PFGE (1, 25), 
although it takes into account a single variable region of the protein A gene. 
In choosing a new method, it is worth taking into consideration that PCR-
based methods are commonly used in typing laboratories because of their 
accuracy, ease of use, low cost, and speed in retrieving results (in a few hours). 
Many bacterial genomes carry loci of repetitive DNA, which may contain 
variable repeated units among strains (43, 60). Systems based on a multilocus 
variable-number tandem-repeat (VNTR) analysis (MLVA) have been used 
extensively for typing of clinical isolates of several bacterial species and were 
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shown to perform well compared to other genotyping methods (43, 61). S. aureus 
harbors a diverse population of DNA repeats, which allowed the design of various 
MLVA schemes (28, 30, 39, 54, 60). Hardy et al. (36, 38) developed a MLVA 
scheme for S. aureus where seven novel multiple tandem repeats with a high 
degree of similarity in the flanking regions were identified based on the alignment 
of seven S. aureus sequenced genomes (strains N315, MW2, Mu50, MSSA476, 
MRSA252, NCTC8325, and COL). Six of these seven loci were located on 
intergenic regions scattered around the S. aureus genome; the remaining locus 
corresponds to the protein A gene, spa. The method, designated staphylococcal 
interspersed repeat unit (SIRU) typing, relies on PCR amplification of the seven 
loci of repetitive DNA, using primers specific for the flanking regions of each locus, 
and on the determination of the size of each amplicon, which reflects the number 
of repeated units present on the targeted SIRU. To each of the seven loci is 
attributed the respective number of DNA repeats, generating a combination of 
seven numbers that characterizes each strain and corresponds to the allelic 
profile. This allelic profile makes the SIRU method amenable to interlaboratory 
comparisons and database management, comparable to MLST. So far, the SIRU 
method has been applied to S. aureus isolates from nosocomial outbreaks in the 
United Kingdom and Germany, mainly MRSA isolates, and therefore to highly 
related strains (29, 35-37). Very recently, a single study evaluated a MLVA 
scheme including the SIRU typing loci and the sspA gene, using a European 
collection of contemporary S. aureus isolates (39). 
The aim of the present study was to evaluate the SIRU method with a more 
diverse collection of S. aureus isolates, including MRSA and methicillin-
susceptible S. aureus (MSSA) isolates, from different continents, isolated 
throughout several decades and previously characterized by well-established 
typing methods (PFGE, spa typing, MLST, and SCCmec for MRSA). 
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MATERIAL and METHODS 
 
Bacterial isolates 
A collection of 104 strains (78 MRSA and 26 MSSA strains), previously 
characterized by PFGE (16), spa typing (1, 56), MLST (9), and SCCmec typing 
(for MRSA strains) (46), was selected from the Laboratory of Molecular Genetics 
collection at Instituto de Tecnologia Química e Biológica, Oeiras, Portugal (Table 
1). The selected collection included hospital- and community-related strains 
isolated during a period of over 50 years (from 1943 to 2006) from 17 countries 
distributed over four continents. Efforts were made to select strains with various 
degrees of genetic relatedness. Therefore, the collection included (i) strains 
belonging to the five main clonal complexes (CCs) of S. aureus - CC5 (n = 23), 
CC8 (n = 32), CC22 (n = 4), CC30 (n = 7), and CC45 (n = 9); (ii) isolates belonging 
to minor CCs - CC1 (n = 7), CC509 (n = 3), CC50, CC59, CC97, CC101, CC228, 
CC398, and CC1021 (one isolate of each); (iii) two isolates belonging to CC80, 
ST80, and SCCmec type IV, identified as community-acquired MRSA; (iv) six 
single CC isolates, referred to as singletons (S1, sequence type 157 [ST157]; S2, 
ST447; S3, ST668; S4, ST707; S5, ST580; S6, ST445); and (v) four strains 
belonging to nondefined CC groups (CC assignments assessed by eBURST v3) 
and designated ND1 to ND4. 
Strains N315, NCTC8325, COL, and MW2 were included for reproducibility 
and methodology control, since their genomes are fully sequenced and were used 
in the theoretical design of the SIRU method (38). 
 
PFGE analysis 
PFGE patterns were analyzed in BioNumerics, version 4.61, software 
(Applied Maths, Sint-Martens-Latem, Belgium) as previously described (25), with 
minor modifications, including an optimization setting of 1.0% for band pattern 
comparisons and a 98% Dice coefficient similarity cutoff for PFGE subtypes. 
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spa typing and MLST analysis 
spa types were assigned through the Ridom web server 
(http://spaserver.ridom.de). Additionally, for one isolate previously characterized 
as nontypeable, the spa type was determined through sequencing of SIRU21 (see 
below). MLST alleles and STs were identified through the MLST database 
(http://www.mlst.net), and CCs were defined using the eBURST v3 algorithm 
(http://eburst.mlst.net). 
 
SIRU typing 
DNA was extracted as previously reported (9). The SIRU method was 
performed as previously described (36, 38), with the following minor modifications: 
(i) 0.5 U of AmpliTaq DNA polymerase (Applied Biosystems, CA) was used per 
PCR in a final volume of 25 l, (ii) an annealing temperature of 59°C was used 
with primer SIRU05R2 (see below), and (iii) PCR products (10 l) were resolved in 
a 2.5% Seakem LE (Cambrex, Rockland, ME) agarose gel in 0.5% Tris-borate-
EDTA buffer (Bio-Rad, Hercules, CA) at 5 V/cm for 2.5 h. The size of each 
amplicon was determined by visual inspection by comparison with a 50-bp ladder 
size marker and by computer analysis using Bionumerics, version 4.61, software, 
which facilitates marker-based normalization of the migration distances and 
therefore guarantees accurate length measurements. The number of repeats was 
calculated, taking into account the combined size of the repeat unit and the 
flanking regions of each locus, as follows: (i) for SIRU01, repeat unit of 55 bp + 
flanking regions of 184 bp = 239 bp for one-repeat-length amplicon; (ii) for 
SIRU05, 60 bp + 146 bp = 206 bp; for SIRU05 with primer SIRU05R2, 60 bp + 156 
bp = 216 bp; (iii) for SIRU07, 56 bp + 191 bp = 247 bp; (iv) for SIRU13, 64 bp + 
148 bp = 212 bp; (v) for SIRU15 131 bp + 212 bp = 343 bp; (vi) for SIRU16, 159 
bp + 162 bp = 321 bp; and (vii) for SIRU21, 24 bp + 96 bp = 120 bp. 
The primers used to amplify each of the seven loci were previously 
published (36), except for those for locus 16 (SIRU16) and an additional reverse 
primer for locus 5 (SIRU05). New SIRU16 primers, SIRU16_2F (5’-
TGGTGTTAATTTAGCTTGC-3’) and SIRU16_2R (5’-
AAACGCAACTTGAAGAAACG-3’), were designed through sequence alignments 
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of the SIRU16 loci of the seven S. aureus genomes previously considered for the 
design of the primers for the remaining loci (38). The new SIRU05 locus reverse 
primer was designed specifically for strains for which there was no amplification 
with the previously published primers (SIRU05L and SIRU05R), namely, for strains 
belonging to STs 1, 22, 45, and 80. Therefore, primer SIRU05R2 (5’-
AGTTGTAGTCATCTTACTGC-3’) was designed through sequence alignments of 
the available SIRU05 loci of MW2, MSSA476 (both ST1), and EMRSA-15 (ST22) 
(sequence from the EMRSA-15 genome sequencing project at the Wellcome Trust 
Sanger Institute 
[http://www.sanger.ac.uk/sequencing/Staphylococcus/aureus/EMRSA15]). All 
sequence alignments were performed using ClustalW2 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html), with default parameters.  
eBURST v3 software was used to cluster SIRU profiles. Isolates sharing 
six of seven loci with at least one isolate (single-locus variants) were included in 
the same SIRU group. Singletons represent profiles that appear once and have no 
related profiles in the collection. 
 
Comparison of typing methods 
SID and the respective confidence intervals were calculated as described 
previously (33, 57). The quantitative level of congruence between typing methods 
was assessed by a framework proposed by Carriço et al. (15), based on the 
adjusted Rand (AR) and Wallace (W) coefficients, available at 
http://www.comparingpartitions.info/. The AR coefficient quantifies the global 
agreement between two methods, whereas the W coefficient indicates the 
probability that two isolates classified as the same type by one method are also 
classified as the same type by another method (15). 
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RESULTS 
 
SIRU typeability 
In a first approach, we tested the method with four completely sequenced 
strains (N315 [ST5-SCCmec II], NCTC8325 [ST8-MSSA], COL [ST250-SCCmec 
I], and MW2 [ST1-SCCmec IV]) for which theoretical SIRU profiles had previously 
been published (36, 38). Five of the seven loci were amplified from the four tested 
strains; SIRU16 was amplified from strain MW2 only, whereas SIRU05 was 
amplified from all strains except MW2. A BLAST search showed that the published 
SIRU16 forward primer (SIRU16_L) (36) has similarity with strain MW2 but not 
with the three remaining tested strains. The SIRU16_L primer was found to have 
similarity with strain MSSA476, which belongs to ST1, like MW2, and with strain 
MRSA252 (ST36-SCCmec II). The primer was tested on additional ST36 isolates, 
and it performed well. These preliminary results led us to design a new SIRU16 
primer that anneals with all available genomes of S. aureus strains (see Materials 
and Methods). The SIRU typing method using the new SIRU16 primers was 
applied to the whole collection. A seven digit profile was obtained for only 70 of 
104 strains, indicating a typeability of 67% when isolates with at least one 
nonamplified locus were considered nontypeable. 
Considering the typeability of each locus separately, SIRU07 was the 
unique locus that showed 100% typeability. SIRU05 showed the lowest typeability 
(72%), followed by SIRU15 (95%), while the remaining SIRUs showed a typeability 
of 99% (one isolate was nontypeable). The consistent nonamplification of SIRU05 
from all strains belonging to particular CCs, i.e., CC22, CC45, and CC80, led us to 
perform a BLAST search with different S. aureus genomes which showed that the 
published SIRU05 reverse primer (SIRU05_R) (36) has no similarity with strains 
MW2, MSSA476, EMRSA-15 (ST22), and RF122 (ST151). Therefore, a new 
SIRU05R2 reverse primer was designed considering these particular strains (see 
Materials and Methods), and a new PCR was performed on all isolates for which 
this locus was not amplified with the previously published SIRU05R primer. 
The sequential use of the SIRU05R2 reverse primer increased the 
typeability from 67% to 89.4%. Moreover, the typeability of the SIRU05 locus alone 
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rose to 95%. Among the 11 nontypeable isolates, 9 isolates showed no 
amplification for a single locus, 1 isolate showed no amplification for two loci 
(SIRU05 and SIRU15), and another isolate showed no amplification for three loci 
(SIRUs 1, 15, and 16).  
For further evaluation of the method, an arbitrarily chosen neutral number 
of repeats (99) was attributed to all non-amplified loci. However, this artifact 
creates a limitation because two isolates showing no amplification at the same 
locus are considered identical in this allele. 
 
SIRU locus discriminatory power 
Considering the discriminatory power of each locus, SIRU07 showed four 
different allele numbers, SIRU16 showed five, SIRU01 and SIRU13 showed six, 
and SIRU15 showed eight. Loci 5 and 21 showed the highest variability among the 
seven loci, with 14 and 13 different allele numbers, respectively. The SIRU21 
locus, the only one located in a coding region, the spa gene, had a direct 
correlation with the spa type. However, an identical number of repeat units may 
contain sequence variations which are not detected by SIRU typing. 
 
SIRU typing clonal assignment 
The 104 strains were distributed into 81 SIRU profiles (differing in at least 
one of the seven loci) that could be clustered into 12 groups and 29 singletons 
(Table 1). Figure 1 shows the assignment of groups when the eBURST v3 
algorithm was applied to the collection. The largest SIRU group, G2 (n = 20), 
included the majority (19 of 23) of the strains belonging to CC5 (ST5, ST85, and 
ST100) and the related strain CC228-ST228. SIRU group G9 included the nine 
strains belonging to CC45 (ST45 and ST508). Similarly, G7 included the four 
CC22 strains (ST22 and ST79), and G10 included the two CC80-ST80 strains. 
SIRU group G8 included only three (ST30 and ST36) of the seven CC30 strains. 
The remaining four strains (ST30 and ST34) were classified as singletons. CC8 
strains were divided into four SIRU groups (G3, G4, G5, and G6) and four 
singletons. Curiously, ST247 and ST250 strains were found in G5 only, while 
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ST239 strains were distributed over G3, G4, and G6 but not in G5. SIRU group G1 
included four of the seven CC1 strains. 
 
 
Figure 1. Schematic representation of the SIRU groups identified by eBURST v3 analysis. The size 
of the dots is proportional to the number of isolates of each SIRU profile. Single-locus variants are 
linked by lines; CCs are highlighted in gray. 
 
Unexpectedly, two isolates which were totally different by all other typing 
methods were grouped in the same SIRU group, G12. In the same way, one CC8 
strain appeared to be a single-locus variant of a CC45 strain and was therefore 
included in the same G9 SIRU group, and a single CC5 strain was clustered with a 
CC509 strain in G11. 
Three of the 12 SIRU groups included a single PFGE type, as follows: G7, 
PFGE J; G8, PFGE K; and G10, PFGE L. Eleven of the 13 singletons defined by 
PFGE were also defined as singletons by SIRU typing. 
Concerning spa typing, all SIRU groups contained related spa types, 
except for (i) one G4 strain (TAW166, t036), (ii) one G9 strain (HU109, t984), (iii) 
two G11 strains (CHL5, t535; and JP82, t375), and (iv) the two G12 strains. 
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Moreover, each spa type was associated with a single SIRU group, with the 
exception of t037, found in SIRU groups G4 and G6 belonging to the same CC, 
and t375, found in a G11 isolate and in singleton S20 (Table 1). Among the 10 
different SCCmec types that characterized the MRSA collection (n = 78), with a 
few exceptions (Table 1), each SIRU profile was associated with a single SCCmec 
type. 
 
Comparison of the discriminatory power of SIRU typing with that of other 
typing methods 
The SID values obtained for the different typing methods are presented in 
Table 2. Considering the 104 isolates, the SIRU method showed a very high 
discriminatory power at the profile level (SID = 99.23%), similar to that observed 
for PFGE at the subtype level (SID = 99.85%) and higher than that observed for 
spa typing, considering both the length and sequence variation (SID = 97.61%). 
Considering discrimination of the SIRU method at the group level (SID = 93.24%), 
it was higher than that of MLST (SID = 91.77%) but lower than that of PFGE at the 
type level (SID = 95.41%). However, since the confidence intervals of the methods 
overlap (Table 2), we cannot exclude the hypothesis that they have similar 
discriminatory powers at a 95% confidence level. 
 
TABLE 2. Number of types identified and Simpson Index of Diversity (SID) of 
each typing method for the 104 S. aureus isolates. 
Typing method No. of types identified SID 95% CI
a 
PFGE subtype 97 99.85 (99.69-100.00) 
SIRU profile 81 99.23 (98.66-99.81) 
spa type 61 97.61 (96.36-98.86) 
PFGE type 33 95.41 (94.11-96.70) 
SIRU group 41 93.24 (90.62-95.87) 
MLST - STb 42 91.77 (88.52-95.01) 
MLST - CCc 25 84.37 (79.68-89.06) 
a CI, confidence interval 
b multilocus sequence type - sequence type 
c multilocus sequence type - clonal complex 
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Clustering concordance and directional agreement between SIRU typing and 
other typing methods 
The clustering concordance between SIRU typing and the remaining 
methods (PFGE, spa typing, MLST, and SCCmec typing) could be traced based 
on the calculation of AR coefficients for the whole collection (Table 3). The AR 
values obtained for the SIRU typing method indicated that the highest level of 
congruence was at the group level for the ST (ARSIRU group-ST = 0.5736), followed by 
the CC (ARSIRU group-CC = 0.4963). At the profile level, the highest congruence was 
with spa type (ARSIRU profile-spa type = 0.4313). Congruence between PFGE (type 
and subtype levels) and SIRU typing was shown to be particularly low (ARSIRU profile-
PFGE type = 0.1067; ARSIRU profile-PFGE subtype = -0.0025). 
 
TABLE 3. Adjusted Rand and Wallace values for the entire collection (n = 104). 
Adjusted Rand   Wallace 
Typing 
method SIRU 
group 
SIRU 
profile    
SIRU 
group 
SIRU 
profile 
PFGE 
type 
PFGE 
subtype spa type 
MLST -
STa 
MLST - 
CCb 
SIRU group   0.1914    0.1113 0.2983 0.0138 0.2928 0.6713 0.9006 
SIRU profile  0.1914    1.0000   0.4146 0.0000 0.9024 0.8293 1.0000 
PFGE type 0.3180 0.1067  0.4390 0.0691   0.0325 0.1870 0.4959 0.7724 
PFGE 
subtype 0.0242 -0.0025  0.6250 0.0000 1.0000   0.3750 1.0000 1.0000 
spa type 0.4119 0.4313  0.8281 0.2891 0.3594 0.0234   0.8047 0.9453 
MLST - STa 0.5736 0.1289  0.5510 0.0771 0.2766 0.0181 0.2336   1.0000 
MLST - CCb 0.4963 0.0800   0.3895 0.0490 0.2270 0.0096 0.1446 0.5269   
a multilocus sequence type - sequence type 
b multilocus sequence type - clonal complex 
 
The W coefficient was calculated to determine the capacity of SIRU typing 
to predict the classification achieved by other methods (Table 3). The results 
obtained showed that in this collection, two strains with the same SIRU profile 
have a 100% probability of belonging to the same CC, a 90% probability of sharing 
the same spa type, and an 83% probability of being classified in the same ST. The 
capacity of SIRU typing at the profile level to predict the PFGE type was low 
(WSIRU profile-PFGE type = 0.4146), and there was no correlation with the PFGE subtype 
(WSIRU profile-PFGE subtype = 0). On the other hand, the SIRU group showed a high 
correlation with the CC (WSIRU group-CC = 0.9006). 
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DISCUSSION 
 
In the present study, we evaluated the performance of the SIRU typing 
method applied to a diverse collection of S. aureus isolates previously 
characterized by well-established typing methods. The SIRU method’s typeability, 
i.e., the method’s ability to assign a type to all isolates tested, was 89.4% when 
new primers designed for SIRU05 and SIRU16 locus amplification were used. The 
consistent nonamplification of SIRU05 from all strains belonging to ST1, CC22, 
CC45, and CC80 observed with our collection when we used the previously 
published SIRU05 primers is in agreement not only with previous studies focusing 
on SIRU typing of EMRSA-15 (CC22) isolates (29, 35-37) but also with the work of 
Ikawaty et al., who reported a reduced typeability for this specific locus on CC1, 
CC5, CC8, CC97, and CC228 isolates as well (39). 
The ability of SIRU typing to assign a different type to two unrelated strains 
randomly sampled from the collection, i.e., its discriminatory power, was found to 
be very high (>99%) and was due mainly to the individual high levels of variability 
of SIRU05 and SIRU21 loci. High variability in SIRU21 is not surprising, since it is 
located in the known highly variable polymorphic region of the spa gene. The 
discriminatory power of SIRU typing at the profile level (SID = 99.23%) is similar to 
that of PFGE subtyping (SID = 99.85%) and spa typing (SID = 97.61%), 
considering the overlapping of the confidence intervals at 95%. Our results are 
concordant with a recent study, besides the fact that only six of the seven SIRU 
loci were taken into account (39). The observed high discriminatory power makes 
SIRU typing suitable for outbreak investigations, as also shown in studies by 
Hardy et al. where strains belonging to an outbreak or consecutively isolated from 
the same ward had the same or highly related SIRU profiles (35, 37). Moreover, in 
a study involving seven different outbreaks, variations in the number of SIRU 
repeats in strains belonging to the same outbreak were found to be rare (39). 
The concordance between SIRU typing and well-established typing 
methods was measured by the calculation of the AR coefficient. We demonstrated 
that at the group level, SIRU typing showed the highest congruence with MLST 
(ST and CC), whereas at the profile level it showed the highest congruence with 
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spa typing. The correspondence with PFGE was low, in contrast to the study of 
Ikawaty et al. on 50 S. aureus isolates, where the AR coefficient between the 
MLVA method and PFGE (AR = 0.599) was higher than that for spa typing (AR = 
0.435) (39). 
The major CCs defined by MLST (CC5, CC8, CC22, CC30, and CC45) 
were maintained when the eBURST v3 algorithm was applied to our SIRU profile 
data. The exception was CC8, known to include a high degree of variability in STs, 
which was divided into four well-distinguished groups. Moreover, a single CC8 
strain was surprisingly clustered with CC45 isolates (G9). Considering that MLST 
is based on the variation in housekeeping genes that have a slow evolutionary 
clock and that the SIRU method looks into variable repeat regions that could 
evolve more rapidly by an introduction or deletion of a single repeat, clonal types 
might be affected by genomic rearrangements to different extents in the two 
methods. The SIRU loci in noncoding regions are less likely to be subject to 
natural selection that affects some VNTRs located on coding regions or promoters 
(43). Interestingly, among the seven SIRU loci, different evolutionary clocks could 
be observed, since SIRU01, SIRU07, SIRU13, SIRU15, and SIRU16 appeared to 
be generally monomorphic between strains from the same group and therefore 
more conserved during evolution. SIRU05 and SIRU21 add high levels of 
variability to the method and could be especially informative for recent levels of 
evolutionary divergence. Therefore, the SIRU typing method includes different 
scales of evolutionary divergence within the same system, making it suitable for 
studies with different purposes. 
The predictive power between SIRU typing and other methods, translated 
by the W index, was maximum for CC and very high for spa typing and MLST in 
our collection. In opposition, the prediction of the PFGE results was low, as SIRU 
typing was able to distinguish among isolates with the same PFGE subtype and 
vice versa. Noller et al. (49) showed that during an investigation of an Escherichia 
coli O157:H7 outbreak, MLVA appeared to have a sensitivity equal to that of 
PFGE and a specificity that was even superior to that of PFGE. On another hand, 
SIRU typing showed the highest congruence with MLST results, i.e., ST and CC 
results. It is noteworthy that the predictive power of a method seems to be linked 
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to the variability in the collection studied, as in a recent study involving two 
collections of S. aureus isolates, where for the first collection the MLVA method 
predicted the spa typing results but the reverse was not observed, while for the 
second collection both methods proved to be mutually predictive (39). 
Our results show that SIRU typing analysis adds to the knowledge of the 
variability of the S. aureus genome and contributes to the understanding of genetic 
relationships among MRSA clones, as seen by Malachowa et al. (44). 
In terms of convenience, the SIRU method was shown to be easy to 
perform, since it is based on single-locus PCRs, which could minimize the 
drawback of band size determination and even reduce the total time required for 
practical procedures if allied to the use of automated systems. Automated MLVA 
approaches were already proposed for S. aureus and Staphylococcus epidermidis 
genotyping through different PCR schemes (27, 28). In terms of cost, SIRU typing 
(11.2€/strain) is comparable to PFGE (13.2€/strain), but it is faster and technically 
easier to perform and much cheaper than spa typing (15.5€/strain) or MLST 
(80€/strain). Additionally, SIRU typing could be combined with spa typing, since 
the spa type may be determined by sequencing of the SIRU21 amplicons of 
nontypeable strains with conventional primers (1, 56). 
In summary, as a PCR-based method, the SIRU typing method is relatively 
fast, accessible, and not expensive, which combined with its high discriminatory 
power makes it useful and reliable for short-term epidemiological investigations of 
S. aureus. In addition, its congruence with MLST results (at the CC and ST levels) 
makes it potentially valuable for evolutionary studies. In order for SIRU typing to 
be considered a useful tool in terms of epidemiological surveillance networks and 
evolutionary purposes, a public database similar to the databases available for 
other bacterial MLVA schemes (34) may be created for SIRU typing, allowing 
harmonization of S. aureus MLVA schemes and the interlaboratory exchange of 
data. 
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Since the introduction of methicillin into clinical practice MRSA has 
emerged as a major human pathogen, initially exclusively in hospitals, and more 
recently in the community as well. However, MSSA, left for a second place facing 
the burden of MRSA, is now recognized not only as a colonizer, but as a virulent 
infectious agent as well. The present work described the genetic background of 
MSSA and MRSA populations from colonization and infection and in both hospital 
and community settings, giving new insights into: (i) the coexistence of MSSA and 
MRSA populations with different genetic backgrounds; (ii) the enhanced virulence 
and infectious potential of MSSA; and (iii) the clonal evolution and geographic 
spread of MRSA in national and international environments.  
The validation of a new MLVA methodology constituted a major contribute 
of the present work on the continuous updating and validation of typing methods 
required for the characterization of S. aureus populations that are in permanent 
evolution. 
 
 
MSSA: A COLONIZER BUT A CLINICAL THREAT 
 
S. aureus carriage in different populations showed that the overwhelming 
majority of the isolates found in the anterior nares (ranging from 97% to 100%) are 
MSSA (7, 13, 17, 50, 72, 85) and several studies evidenced the endogenous 
source in many invasive infections. Moreover, successive reports of severe 
invasive disease due to MSSA, namely in children and neonates and otherwise 
healthy individuals are increasing (20, 34, 53, 58, 67, 68, 76); 
Although the CDC is promoting a new national MRSA education initiative in 
the United States: ”Preventing MRSA skin infections” 
(http://www.cdc.gov/mrsa/mrsa_initiative/skin_infection/index.html#), 25% to 45% 
of the total community acquired S. aureus infections in two pediatric hospitals were 
due to MSSA associated to invasive infections (43, 54, 57). 
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MSSA as a virulent pathogen 
MSSA infections are frequently associated to highly virulent strains 
producing several superantigens, hemolysins and leukocidins, namely PVL (73). 
Rasigade et al. reported a global distribution of PVL-positive MSSA pandemic 
lineages, responsible for a wide variety of diseases comprising SSTI, bone and 
joint infections, and necrotizing pneumonia (73). An unusually high (35%) 
prevalence of PVL-positive MSSA isolates was described in Cape Verde hospitals, 
in Chapter IV, compared to other studies on MSSA from nasal carriage and 
infection that reported a prevalence lower than 1.7% (44, 48, 52, 91).  
In the Cape Verde MSSA collection, with the exception of four isolates 
recovered from skin wounds, all the remaining PVL-positive isolates were 
recovered from nasal colonization, which anticipates that infections would also be 
caused by these high virulent strains. Although the Portuguese MSSA population 
characterized in Chapter II showed some clonal overlapping with the MSSA 
population in Cape Verde, only two ST121 isolates from the former collection 
produced PVL, which suggests that hospitals in Cape Verde may represent a 
reservoir of PVL-positive clones. In addition, the acquisition of virulence 
determinants seems to confer a greater advantage to S. aureus than antibiotic 
resistance genes in a country and temporal period in which the antibiotic pressure 
was low due to the very limited use of antibiotics. 
MSSA are also responsible for the majority of SSTI infections, namely 
cutaneous abscesses and cellulitis in Portuguese children attending a pediatric 
emergency unit, described in Chapter III. ST121 was the prevalent clonal type, but 
the strains were PVL negative in opposition to the Cape Verde isolates recovered 
10 years earlier.  
The ST121 MSSA lineage has been isolated in geographic distinct 
locations associated to both nasal carriage and disease, namely in children (10, 
73, 92), and was already present among the early MSSA isolates from Denmark 
(32, 56), which demonstrates that it is a dynamic and evolving lineage. Of major 
concern was the recent report of methicillin resistance in ST121 isolates causing 
invasive disease in pediatric communities (16, 28).  
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Retrospectively, all genetic backgrounds found in Chapter III, among the 
Portuguese CA-MSSA causing disease (with the exception of ST152), had been 
previously described in carriage in the community between 1992 and 2001 
(Chapter II), suggesting that although a high clonal diversity, MSSA lineages are 
more stable over time than MRSA (2). Moreover, the major CA-MSSA clones 
described in Europe (35) were also found in the pediatric Portuguese community 
(Chapter III) showing clonal spread similar to MRSA (53, 73).  
A regular surveillance of SSTI, namely in children, is critical to predict and 
control the emergence of methicillin resistance and spread of staphylococcal 
infections in the community. 
 
MSSA as a precursor of MRSA 
The origin and evolution of MRSA is still a subject of study. Previous 
studies on the origins of MRSA support the multi-clone theory proposed by Musser 
and Kapur (62), suggesting a polyclonal nature of MRSA and the introduction of 
SCCmec several times into diverse MSSA lineages (25, 30, 32). Robinson and 
Enright (74) and Gomes et al. (32) proposed evolutionary models for the 
emergence of the five major MRSA clonal lineages currently spread worldwide: 
CC5, 8, 22, 30 and 45, based on multiple acquisitions of the SCCmec element by 
various MSSA backgrounds and in various occasions. Oliveira et al. designed an 
evolutionary pathway for the contemporary pandemic MRSA based on multiple 
and independent acquisition of the SCCmec by four distinct genetic backgrounds 
(65).  
Molecular studies of the earliest MSSA isolates available from the Danish 
surveillance system from 1957 to 1972 showed that the genetic backgrounds of 
each of the actual major MRSA clones were already present in this Danish 
disease-causing isolates. However, the mecA gene was firstly aquired by only one 
of these genetic backgrounds, the Archaic clone (ST250) followed by a clonal 
expansion in hospitals (23, 32), rather than the multiple SCCmec acquisition.  
 
In Chapters II and IV we characterized the population structure of MSSA 
from Portugal and Cape Verde, isolated from clinical and carriage sources. While 
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the Cape Verde collection included nosocomial isolates only, the Portuguese 
collection included isolates from both hospital and community. The two studies 
confirmed the high genetic diversity among MSSA populations (14, 24, 35, 36). 
However, despite the variability, 67% of the Portuguese MSSA and 46% of the 
Cape Verde isolates fell into four major clonal complexes (CC30, CC5, CC45 and 
CC8), overlapping with the major international pandemic MRSA lineages (25, 35). 
In Cape Verde islands, no MRSA were found coexisting with the MSSA 
population. In Portugal, the major MSSA clones ST30, ST34, ST5 and ST45 
showed some similarities with MRSA pandemic clones, i.e. EMRSA-16 (ST36), the 
New York/ Japan and Pediatric clones (ST5) and the Berlin clone (ST45) (Figure 
1). However, none of these clones, with the exception of the Pediatric clone had 
been reported among nosocomial Portuguese MRSA isolates recovered during the 
same period, i.e. between 1992 and 2001 (3, 78). On the other hand, the genetic 
backgrounds corresponding to the three dominant MRSA clones in Portuguese 
hospitals until 2001 (Iberian-ST247, Brazilian-ST239, and EMRSA-15-ST22), or 
their ancestral genotypes (ST8 [ancestral of ST239 and ST247] and ST22), were 
not detected or only scarcely found among the co-existing MSSA collection. These 
observations resemble the early Danish scenario, where MSSA isolates belonged 
to genetic backgrounds that were later identified in different countries as major 
MRSA lineages, yet in Denmark only one of these backgrounds was represented 
at the time as the Archaic MRSA clone (19, 23, 32). 
The Pediatric clone is the single MRSA clonal lineage that could have 
originated in Portugal through the acquisition of SCCmec type VI by the MSSA 
genetic background ST5. Therefore, our results suggest that the Iberian, Brazilian, 
and EMRSA-15 MRSA clones have not originated from the introduction of 
SCCmec into dominant MSSA backgrounds present in the Portuguese nosocomial 
or community environment but were more probably imported from abroad (Figure 
1).  
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The non-coexistence of MRSA in Cape Verde islands and the non-
congruence between the genetic backgrounds of the major MSSA and MRSA 
clones within a population indicates that the presence of a successful MSSA 
lineage is not the sole factor necessary for SCCmec acquisition or for the success 
of an MRSA clone, which also supports the hypothesis that some genetic 
backgrounds may be more “receptive” of SCCmec than others (46). A “barrier” 
phenomenon was proposed to prevent the maintenance of the mecA in certain 
MSSA backgrounds limiting its evolution to a successful MRSA lineage (46). In 
fact, some genetic lineages with high virulent and epidemic potential such as 
ST121, associated to PVL, were already present in the 1960s and become a 
prevalent lineage maintaining the MSSA genetic background (32, 46, 73). 
Therefore, the introduction of SCCmec into sensitive clones seems to be a 
relatively infrequent and localized event compared to the geographical spread of 
MRSA clones. A recent study on HA-MRSA surveillance revealed that the New 
York/ Japan clone (ST5-II) emerged in Portuguese hospitals in 2006 (2). In 
Chapter V we described an MRSA isolate belonging to the Berlin clone (ST45) in 
the Portuguese Atlantic Azores islands as well as the Pediatric clone (ST5) as the 
MRSA clone
MSSA clone
Brazilian
ST239-III
NY/Japan
ST5-II
Berlin
ST45-IV
EMRSA-16
ST36-II
EMRSA-15
ST22-IV
Iberian
ST247-I
Pediatric
ST5-VI
SCCmec
Figure 1. Schematic representation of the origin of the major MRSA clones in Portugal and 
similarities of the MSSA genetic background with foreign MRSA clonal lineages. Courtesy of M. 
Aires de Sousa, adapted. 
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second most prevalent clone in the hospital in 2007-2008. These observations 
suggest that the introduction of SCCmec elements into local MSSA lineages could 
not be excluded. 
The report of the ST5 background with different SCCmec cassettes (IVc 
and VI) in the Azores isolates suggests different acquisitions of SCCmec in the 
same MSSA ST5 background, which is in agreement with Nbel et al. description 
of the CC5 lineage evolution of temporal and geographic independent SCCmec 
acquisitions (63). 
 
 
MRSA: STILL THE MOST FREQUENT RESISTANT PATHOGEN IN THE 
NOSOCOMIAL SETTING 
 
The “Public consultation on strategies for improving patients’ safety by 
prevention and control of health-care associated infections”, by the European 
Commission in 2006 stated that “Health-care associated infections affect an 
estimated one in ten patients and lead to considerable increase of illness, mortality 
and costs. These infections are not constrained by national boundaries and can 
rapidly spread between countries as evidenced by international spread of MRSA” 
(27). In 2008, the European Antimicrobial Resistance Surveillance System 
reported for the first time a decreasing trend in the MRSA proportion in several 
European countries, and a global stabilization in MRSA prevalence. However, in 
contrast to the overall improvement, MRSA remains a serious problem in the 
Mediterranean region with Malta and Portugal showing MRSA proportions over 
50% (26).  
In the United States, the CDC reported that in 2006-2007, MRSA was 
responsible for 8% of all hospital acquired infections (42), while in Japan, 45.5% of 
all S. aureus recovered during 2004-2008 within a single hospital were MRSA 
(49), which requires a continuous nosocomial surveillance. 
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MRSA: filling the gap of Portuguese islands 
With the exception of Malta, Portugal shows the higher invasive MRSA 
prevalence in Europe, which reaches 53% in 2008, and continues facing an 
increasing trend (26). Surveillance studies have been conducted in Portugal since 
the early 1990s, defining the clonal nature of the MRSA population over time. 
Successive waves of five major MRSA clones were described in Portuguese 
hospitals for a period of 16 years (2). The Portuguese clone (ST239-III variant) 
found in over 80% of the isolates in 1990-91 was almost completely replaced by 
the Iberian clone (ST247-I) during 1992-93. In 1999-2000, the Brazilian clone 
(ST239-III) was the prevalent clonal type being replaced by EMRSA-15 (ST22-IV) 
in 2003-2005. In 2006 emerged the first isolates belonging to the New York/ Japan 
clone (ST5-II) (2, 3, 9). These previous studies covered all the continental 
Portuguese territory, but the picture in the insular region was unknown. The MRSA 
collection described in Chapter V, recovered between 2007 and 2008 in the 
largest hospital of the Portuguese Azores archipelago, intends to fill this gap.  
The clear dominance of the non-multiresistent EMRSA-15 clone (ST22-IV) 
in the Azorean hospital is, in part, in agreement with the situation in continental 
Portugal (2, 9). EMRSA-15 is also dominant in other European countries, namely 
the United Kingdom where it has been endemic for several years, but also in Asia 
and Australia (2, 9, 33, 45, 59). In fact, in a study involving isolates recovered in 
the same period from 11 hospitals scattered over continental Portugal, EMRSA-15 
was found to be the most prevalent clone. However, and in contrast with the 
Azorean picture, the New York/ Japan clone (ST5-II) was shown to represent a 
new wave of MRSA in the country becoming the prevalent clone (2). Interestingly, 
in the neighbor Spanish islands of Majorca and Canarias EMRSA-15 was also 
found as a major clone, but not in the continental territory as in our country (8, 69, 
90). 
The clonal dissemination of S. aureus is mainly due to travel of human 
populations, as evidenced by the intercontinental spread of MRSA clones (4, 6). 
Hence, the frequent touristic flux from the United Kingdom, hypothesized as the 
cause of the importation of EMRSA-15 to the Mediterranean island of Malta (81), 
could also support, in part, the emergence of this clone in the most touristic 
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Azorean island. In parallel, the regular exchange of inhabitants between the 
islands and the continent seem to be an important vehicle of clonal importation.  
The Pediatric clone (ST5-VI) was described for the first time in a 
Portuguese pediatric hospital in 1992, where it was dominant, but in the last 
national survey it was exceedingly rare (2, 78). Therefore, the hypothesis of a 
recent introduction of this clone in Azores from continental Portugal seems quite 
remote. On the other hand, the Azores islands have a high emigrant community in 
the United States, who frequently travel to the national territory, constituting also 
possible vehicles of dissemination of the Pediatric clone, frequently reported in the 
American continent (5, 31, 51, 78). Emergence of this clone locally is also 
plausible, since SCCmec types VI and IVc were found in the ST5 genetic 
background. There is evidence that ST5-MRSA emerged in numerous 
circumstances and in distinct locations, through multiple and independent 
acquisitions of SCCmec within ST5-MSSA lineage (63). 
Interesting, the isolation of a single MRSA ST45 isolate carrying SCCmec 
IVa suggests another de novo SCCmec acquisition, probably in an already 
established MSSA ST45 background. 
The exclusively detection of small SCCmec types (IV, V and VI) in the 
MRSA Azorean population reflects the actual tendency for the dominance of low 
resistant and fitness cost clones within the hospital setting, which parallels the 
community environment (15). Although the introduction of well-established 
community isolates into the hospital setting is not new, as reported for ST59 clonal 
type in Taiwan, no conclusions can be drawn for the flow direction in the Azores 
environment. 
Additional insights into the MSSA and CA-MRSA populations co-existing in 
the geographic restricted Azores islands will be fundamental to support the 
proposed S. aureus localized evolution, as well as to understand the actual links 
between the hospital and the community. 
 
MRSA population dynamics: clonal shifts over time 
The massive geographic spread of MRSA results from the dissemination of 
a few highly epidemic clones (25, 35). Whereas cross-sectional studies showed 
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the predominance of one or two clones in a defined setting during the 1990’s, 
several longitudinal studies showed a replacement of the predominant clones by 
others within a short temporal space, evidencing that the molecular epidemiology 
of HA-MRSA is dynamic (2, 12, 69, 94, 95). 
Chapter VI describes the MRSA clonal evolution in Hungary, where the 
Hungarian MRSA clonal lineage (ST239-III) was massively spread in the 
nosocomial setting between 1993 and 1998 (22, 64). Soon after, the Hungarian 
clone decreased, and was progressively replaced by two other clones, both 
belonging to CC5, the Southern German (ST228-I) and the New York/ Japan 
(ST5-II), which became the prevalent clones in Hungarian hospitals.  
The Southern German clone, first described in Germany in 1992, was soon 
detected in Budapest and then spread throughout the country. It was later 
frequently detected in other European countries, representing 86% of the MRSA 
isolates in Slovenia in 2004, and showing a similar increasing trend from 6% in 
2002 to 28% in 2004 of the total MRSA in Finland (47, 61).  
The New York/ Japan clone was first detected in the early 1990s as the 
dominant clone in Japan and soon after was reported as prevalent in the New 
York metropolitan hospitals evidencing a transcontinental spread. The highly 
epidemic potential of this ST5 clonal lineage was confirmed by the continuous 
reports of its prevalence in several hospitals in the United States and Canada, 
South America, eastern Asia and Australia (4, 18, 75, 83). The New York/ Japan 
clone had never been described in other European countries at the time of its 
emergence in Hungary, in 2001. Therefore, it was probably imported from another 
continent, suggesting a second transcontinental spread of this lineage.  
We described for the first time the co-dominance and extensive spread of 
the New York/ Japan clone in a European country. Recent studies have reported 
the emergence of this clone in other European countries, such as Spain (70) and 
Portugal, where it started a new epidemic wave of MRSA in 2006 (2). Interestingly, 
in Portuguese hospitals, the New York/ Japan clone emergence was preceded by 
the massive spread of EMRSA-15 clone, which was only found as a minor clone in 
Hungary. 
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Clonal shifts were also observed in small geographic regions within a 
country, for instance in a small region of Switzerland, where within eight years, 
four distinct MRSA clones showed different relative proportions over time (12). 
Several studies from China, Mexico, Spain and Portugal described clonal evolution 
within single hospitals (9, 69, 89).  
Local evolution of variants of well established clonal lineages as CC5 and 
CC8 were already reported, namely a new evolutionary MRSA lineage in 
Gregorian hospitals which resulted from an advantageous variable of the ST239 
Brazilian clone (11). Additional evidence for a local evolution was the referred 
emergence of the Pediatric clone described in Chapter V, by the de novo 
introduction of a different type of SCCmec (type IVc) and the acquisition of PVL. 
Noteworthy, this is the first report of PVL among isolates belonging to the SCCmec 
type VI Pediatric clone.  
In a recent report from a Portuguese hospital, changes in the antimicrobial 
policy were found to be related to the clonal nature of the MRSA population (9). 
However, neither the fundamental driving force promoting these clonal 
replacements nor the factors that lead to the high epidemic potential of specific 
clones is well understood. 
 
MRSA in the Portuguese community: still not a problem? 
Since the early 1990’s that the emergence of specific MRSA clonal 
lineages causing infection in the community, in children and young otherwise 
healthy individuals without risk factors for hospital associated MRSA infection, 
makes a worrisome change in the MRSA epidemiology. CA-MRSA accounts for 
the overwhelming proportion of the MRSA infections in the United States and are 
responsible for the increasing trends in MRSA prevalence in The Netherlands and 
Northern European countries, were the HA-MRSA prevalence is contained by 
strict “search and destroy” policies. Major CA-MRSA PVL-positive pandemic 
lineages such as USA300 (ST8-IV), USA400 (ST1-IV), USA1000 (ST59-IV), the 
European clone (ST80-IV) and the Southwest Pacific clone (ST30-IV), are 
currently spread worldwide (86).  
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CA-MRSA is considered a serious and common public-health problem, 
translated by the increasing prevalence of SSTI due to MRSA. A report from the 
SENTRY Antimicrobial Surveillance Program in 1998-2004, identified S. aureus as 
a first cause of SSTI in North and Latin America and in Europe (55). In the United 
States the prevalence of SSTI infections increased dramatically since 1997 and a 
single CA-MRSA lineage, the USA 300, was found to be the predominant cause of 
SSTI in patients presenting at 11 emergency departments (41, 60). Similar 
increasing trends of CA-MRSA have been reported worldwide (21, 66).  
Previous studies on the CA-MRSA prevalence in Portugal including 
isolates from nasal swabs of young healthy individuals and nasopharyngeal swabs 
of children attending day care centres, reported a very low MRSA prevalence in 
the Portuguese healthy community (0.24% in 1996-1998 and 0.13% in 2006-
2009), suggesting that there is no CA-MRSA reservoir in these populations (77, 
85). Since the nasopharynx is not the preferential niche of S. aureus, the true 
prevalence of MRSA was probably underestimated. Therefore, an alternative 
screening was carried out in Chapter III, including isolates from SSTI and swabs of 
the anterior nares of children attending a pediatric urgency unit in a Portuguese 
hospital. Although the prevalence of MRSA was still low in this population (3 
MRSA out of 38 S. aureus), we reported the first European CA-MRSA isolate 
(ST80-IV PVL positive) in Portugal, which in contrast to what was described in 
several other European countries is not widely spread in this country (2, 29, 88). It 
is conceivable that the prevalence of CA-MRSA in Portugal is underestimated 
partially because skin infection samples are not routinely cultured.  
 
 
TYPING METHODS: A CONSTANT NEED OF IMPROVEMENT 
 
Typing is one of the most important tools to understand and control S. 
aureus infections. A panoply of typing strategies has been used in S. aureus 
studies, however no single typing method has proven to be exclusively sufficient to 
characterize a collection of isolates (84, 93). The choice of the most appropriate 
typing strategy largely depends on the study design and purpose, namely short-
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term or long term surveillance, local or global epidemiology, routine surveillance or 
outbreak investigations. The currently most used typing methods for S. aureus 
characterization include PFGE, spa typing, MLST and SCCmec typing (for MRSA). 
Although regular updates have been introduced in these typing strategies, some 
drawbacks concerning ease of performance, portability of the results and 
associated costs, led to the improvement of new typing schemes such as MLVA 
(40, 71, 79, 80).  
The staphylococcal interspersed repeat unit (SIRU) was the first MLVA 
scheme for S. aureus producing a string of numbers that characterizes each 
strain, which made the results amenable for interlaboratory comparisons similar to 
MLST (38, 40). Some of the performance criteria required for a typing method (87) 
were evaluated in Chapter VII, by the application of the SIRU methodology to a 
diverse collection of S. aureus isolates previously characterized by the most used 
typing methods. The high discriminatory power, similar to PFGE, made the SIRU 
method suitable for outbreak investigations, as also shown in studies by Hardy et 
al. where strains belonging to an outbreak or consecutively isolated from the same 
ward had the same or highly related SIRU profiles (37, 39). Moreover, the 
predictive power between the SIRU typing and the other typing methods, 
translated by the Wallace index, was maximum for clonal complex groupings and 
very high for spa typing and MLST.  
SIRU typing includes different scales of evolutionary divergence within the 
same system, making it suitable for studies with different purposes, since some 
loci appeared to be generally monomorphic between strains from the same group 
and therefore more conserved during evolution, other loci add high levels of 
variability to the method and could be especially informative for recent levels of 
evolutionary divergence. One of these loci is SIRU21, which high variability was 
not surprising since it is located in the known highly variable polymorphic region of 
the spa gene. Therefore, SIRU typing could be easily combined with spa typing, 
since the later may be determined by sequencing of the SIRU21 amplicons in 
previously nontypeable strains (1, 82). 
As a PCR-based method, the SIRU typing is relatively fast, accessible, and 
not expensive, which combined with its high discriminatory power and congruence 
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with MLST results (at the CC and ST levels) makes it useful and reliable for both 
short-term epidemiological investigations and long-term evolutionary studies.  
Two additional MLVA schemes were recently proposed to overcome 
persistent drawbacks in terms of typeability, accuracy in amplicon sizing and 
harmonization of results. While Pourcel et al. (71) designed a more fastidious 
scheme including the amplification of 14 loci resolved by agarose gels, Schouls et 
al. (80) proposed a scheme of eight loci based in two PCR multiplex assays 
followed by an automated fragment sizing in a DNA sequencer apparatus. 
Both schemes included some SIRU loci, namely SIRU21. In agreement 
with our results on SIRU typing, Schouls et al. found a high degree of concordance 
between MLVA groups and MLST clonal complexes, and a straightforward 
clustering of MLVA profiles compared to that of spa types. spa typing focuses on a 
single locus in the genome, and a small change, even a single mutation yields a 
different type, which sometimes is difficult to interpret in an evolutionary context. 
The use of multiple genome loci such as MLST or MLVA provides a more robust 
approach given that the relationship between two isolates that differ in one of the 
several loci tested is more trustful. Therefore, it is proposed that MLVA could 
outperform the currently well-established spa typing method for outbreak 
investigations, especially in hospital laboratories. 
However, there is no consensus about a harmonized S. aureus MLVA 
scheme, which is mandatory for the construction of an online database to easily 
promote the interlaboratory exchange of data and make the MLVA method a 
promising tool in terms of epidemiological surveillance networks and evolutionary 
purposes. 
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CONCLUDING REMARKS 
 
S. aureus has been showing an amazing capacity of adaptation to diverse 
environments and selective pressures. The study of different populations 
concerning methicillin resistance, colonization or infection status, both in the 
nosocomial and in the community settings, led us to reach new insights on the 
actual S. aureus epidemiological scenario.  
Evolutionary trends were drawn in Chapter II, evidencing a most probable 
foreign origin of the nosocomial MRSA in Portugal, rather than the emergence in 
the co-existing MSSA population. The recent report in the hospital of CC5 and 
CC45 lineages (2), previously referred on the MSSA background, raises the 
question about the introduction of the SCCmec cassette into these MSSA 
lineages. 
Although not all MSSA backgrounds seem permissive for SCCmec 
introduction (46), a few major well-adapted lineages become pandemic. Moreover, 
a worrisome scenario was painted in Chapters III and IV, describing well-armed 
MSSA lineages, carrying a panoply of virulence factors including PVL. Moreover, 
the amazing capacity of MSSA to promote disease in the pediatric community is of 
major concern, anticipating the birth of a new branch in the S. aureus 
pathogenesis: virulence instead of resistance. The increasing virulence of MSSA 
lineages is in line with the European and global scenario, warranting a new 
surveillance target.  
In Portugal, in contrast to most European countries and the Unites States, 
despite the extraordinary high HA-MRSA prevalence, CA-MRSA seems to be still 
uncommon, even when the focus of the study was SSTI in the pediatric 
community, as described in Chapter III. The emergence and spread of MRSA in 
the community, where the antibiotic pressure is almost null, raises the question: 
“What manages the emergence of resistance outside the healthcare 
environment?” 
The prevalence of the non-multiresistant EMRSA-15 in an Azorean 
hospital, described in Chapter V, highlights the epidemic potential of the clone in 
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detriment of high resistance. However, what drives the major epidemic potential of 
a S. aureus clone remains unclear. 
Another unanswered question, regards the mechanisms driving the MRSA 
clonal replacement. In Chapter VI the 10-year surveillance study of MRSA in 
Hungarian hospitals clearly illustrates this phenomenon, which is in line with a 
plethora of clonal shift reports from all over the world. An intriguing point in the 
clonal evolution in Portuguese hospitals is the replacement of the previously 
prevalent EMRSA-15 by the New York/ Japan clone whereas in other European 
countries, namely the United Kingdom, this clone has been endemic in the 
hospitals in co-existence with the EMRSA-16, for a long time. The reasons 
underlying the distinct behavior of the same clonal lineage in different countries 
are not known and are certainly intriguing. 
Although many questions are still unanswered and many other are 
emerging every day, the work developed and presented in this Thesis, filled some 
dark spaces on the knowledge of a spectacular “super bug” that constantly 
surprises us. 
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